WO2022007809A1 - 新型多肽制剂及其治疗用途 - Google Patents

新型多肽制剂及其治疗用途 Download PDF

Info

Publication number
WO2022007809A1
WO2022007809A1 PCT/CN2021/104822 CN2021104822W WO2022007809A1 WO 2022007809 A1 WO2022007809 A1 WO 2022007809A1 CN 2021104822 W CN2021104822 W CN 2021104822W WO 2022007809 A1 WO2022007809 A1 WO 2022007809A1
Authority
WO
WIPO (PCT)
Prior art keywords
aib
compound
amino acid
group
pharmaceutical formulation
Prior art date
Application number
PCT/CN2021/104822
Other languages
English (en)
French (fr)
Inventor
韩捷
沈志超
Original Assignee
鸿绪生物医药科技（北京）有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 鸿绪生物医药科技（北京）有限公司 filed Critical 鸿绪生物医药科技（北京）有限公司
Priority to CN202180048688.9A priority Critical patent/CN116133677A/zh
Publication of WO2022007809A1 publication Critical patent/WO2022007809A1/zh

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/605—Glucagons
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Definitions

  • the present invention relates to a preparation of a polypeptide compound and its use in medicine.
  • Metabolic syndrome is a combination of medical conditions that increase the risk of developing type 2 diabetes, atherosclerotic vascular disease, heart disease, and stroke.
  • the medical parameters that define metabolic syndrome include diabetes mellitus, impaired glucose tolerance, elevated fasting blood glucose, insulin resistance, central obesity, hypertension, elevated total cholesterol and triglycerides, elevated LDL cholesterol, and decreased HDL cholesterol.
  • Diabetes includes type 1 diabetes, type 2 diabetes, and gestational diabetes. According to the World Health Organization (WHO), the prevalence of diabetes in developed countries is 5% to 10%. By 2030, the number of diabetic patients in the world will double from 2000. More than 50% of people with undiagnosed diabetes worldwide are prediabetic, and there are even more people with prediabetes than with diabetes.
  • WHO World Health Organization
  • the number of people with diabetes in China has reached 114 million, and another 500 million people have low glucose tolerance and impaired glucose regulation, and are about to become diabetics. More than half of patients do not know they have the disease.
  • the great harm of diabetes mainly lies in serious complications and high mortality. Data show that diabetes is the leading cause of lower extremity amputation and new blindness in adults.
  • Obesity is a medical condition in which excess fat accumulation in the body can adversely affect health and life expectancy, and due to its increasing prevalence among adults and children, it has become one of the modern preventable causes of death. It increases the likelihood of various other diseases, including heart disease, type 2 diabetes, obstructive sleep apnea, certain types of cancer, and osteoarthritis, and is often caused by excess food intake, reduced energy A combination of consumption and genetic susceptibility.
  • Asians have higher levels of visceral fat than Caucasians for the same body mass index (BMI), so Asians are more insulin resistant than Caucasians, and Asians with normal weight type 2 diabetes are more likely than non-diabetics The patient's insulin sensitivity decreased significantly.
  • GLP-1 receptor agonists can control blood sugar by promoting insulin secretion, improving insulin sensitivity, and reducing glucagon release. Therefore, GLP-1 drugs are suitable for the treatment of metabolic diseases, especially diabetes.
  • GLP-1 receptor agonists exenatide, liraglutide, etc. have all shown the effect of reducing body weight in animal tests and clinical trials, with relatively few side effects. Liraglutide is already approved in the U.S. for diabetes and obesity, making it the only drug available for both conditions.
  • GLP-1 drugs all have the side effects of large gastrointestinal reactions. These side effects affect the patient's medication compliance and reduce the drug usage and user base. According to the physiological mechanism of GLP-1 receptors, GLP-1 drugs have a slow effect on weight loss, and the clinical treatment of obesity requires a higher dose than that of diabetes treatment, resulting in more prominent side effects of gastrointestinal reactions. Most patients lost an average of no more than 5% of their body weight, and their weight rebounded significantly after drug withdrawal.
  • the polypeptides of the present invention may provide new options for the treatment of these diseases.
  • the polypeptide of the present invention is suitable for various diseases caused by abnormal lipid metabolism, including hyperlipidemia, non-alcoholic fatty liver and the like.
  • the polypeptides of the present invention can also be used for diseases such as hypertension, arteriosclerosis, coronary heart disease, peripheral arterial disease, stroke, or any combination of these diseases.
  • the polypeptide of the present invention is not only beneficial to enhance the curative effect, reduce the toxic and side effects, but also facilitate the patient, thereby improving the therapeutic effect.
  • the polypeptides of the present invention can also be used for diabetes treatment like GLP-1 drugs. Since these polypeptides reduce body weight and body fat and improve insulin resistance, they not only have excellent hypoglycemic effects, but also have special effects on a high proportion of diabetic patients who are ill due to overweight. Although many overweight or obese people in the population are not medically classified as diabetics, they have pre-diabetic symptoms such as glucose intolerance and excessive postprandial blood glucose. The polypeptide of the present invention is also suitable for pre-diabetic people.
  • the present invention relates to a pharmaceutical formulation comprising a peptide compound of formula (VII) or a pharmaceutically acceptable salt or solvate thereof,
  • X1 represents an amino acid selected from L or Y
  • X2 represents an amino acid selected from Q, A, aib or Y
  • X3 represents an amino acid selected from D or E
  • X4 represents an amino acid selected from E or K
  • X5 represents an amino acid selected from An amino acid of V or A
  • X6 represents an amino acid selected from K, R or Q
  • X7 represents an amino acid selected from I or V
  • X8 represents an amino acid selected from E, Q, N or A
  • X9 represents an amino acid selected from I or L Amino acid, X10 for absent or GPSSGAPPP, GPPSGAPPP, GPSSGKPPP, GPSSGEPPP, GPSSaibAPPP, GPSSGAPP, GPSSGAP, GPSSGA, GPSSG, GPSS, GPS, GP, G
  • X13 represents the amino acid of L, E or D
  • X11 represents T or I
  • one or two amino acids selected from the group consisting of S or a side chain containing an amino group or a sulfhydryl group are added, and the carboxyl group of the C-terminal amino acid is optionally amidated to a C-terminal amide, the amino acid having the formula
  • n1 is an integer of 1-7, when II or III is a C-terminal amino acid, its carboxyl moiety is COOH or CONH 2 , preferably, an amino acid containing a side chain amino acid is lysine, the amino acid containing a thiol group in the side chain is cysteine,
  • the amino acid containing a side chain amino group added at the C-terminus of X10 is modified with a long-acting group at its side chain amino group, preferably, the long-acting group has the structure of formula (IV):
  • O1 represents the structure of formula (V) or (VI):
  • n2 is an integer of 6-24, preferably 10-24, more preferably 16-22;
  • O2 to O8 is independently composed of the following amino acid residues or Any of the long chain structures represents: ⁇ -Glu, ⁇ -Glu, ⁇ -Asp, ⁇ -Asp, ⁇ -hGlu, ⁇ -hGlu, Gly, Ala, ⁇ -Ala, GABA or PEG2, or in O2 to O8 One or more of are absent, provided that at least two of O2 to O8 are present, preferably, O2 to O8 contain at least one negatively charged moiety.
  • the present invention relates to a pharmaceutical formulation
  • a pharmaceutical formulation comprising a peptide compound of formula (I), or a salt or solvate thereof, and a pharmaceutically acceptable carrier or excipient.
  • X1 represents an amino acid selected from L or Y
  • X2 represents an amino acid selected from Q
  • X3 represents an amino acid selected from D or E
  • X4 represents an amino acid selected from E or K
  • X5 represents an amino acid selected from An amino acid of V or A
  • X6 represents an amino acid selected from K or R
  • X7 represents an amino acid selected from I or V
  • X8 represents an amino acid selected from E, A, Q or N
  • X9 represents an amino acid selected from I or L
  • X10 stands for absence or GPSSGAPPP, GPPSGAPPP, GPSSGKPPP, GPSSGEPPP, GPSSaibAPPP, GPSSGAPP, GPSSGAP, GPSSGA, GPSSG, GPSS, GPS, GP, G;
  • one or two amino acids selected from the group consisting of S or a side chain containing an amino group or a sulfhydryl group are added, and the carboxyl group of the C-terminal amino acid is optionally amidated to a C-terminal amide, the amino acid having the formula
  • n1 is an integer of 1-7; when II or III is a C-terminal amino acid, its carboxyl moiety is COOH or CONH 2 ;
  • the amino acid containing a side chain amino group added at the C-terminus of X10 is modified with a long-acting group at its side chain amino group, preferably, the long-acting group has the structure of formula (IV):
  • O1 represents the structure of formula (V) or (VI):
  • n2 is an integer of 6-24, preferably 10-24, more preferably 16-22;
  • O2 to O8 is independently composed of the following amino acid residues or Any of the long chain structures represents: ⁇ -Glu, ⁇ -Glu, ⁇ -Asp, ⁇ -Asp, ⁇ -hGlu, ⁇ -hGlu, Gly, Ala, ⁇ -Ala, GABA or PEG2, or in O2 to O8 One or more of are absent, provided that at least two of O2 to O8 are present, preferably, O2 to O8 contain at least one negatively charged moiety.
  • O2-O3-O4-O5-O6-O7-O8- represents a linker selected from the group consisting of ⁇ Glu-PEG2- ⁇ Glu-, ⁇ Glu-PEG2-2 ⁇ Glu-, ⁇ Glu- PEG2-, ⁇ Glu-2 ⁇ PEG2-, ⁇ Glu-3 ⁇ PEG2-, ⁇ Glu-PEG2- ⁇ Glu-PEG2-, ⁇ Glu-2 ⁇ PEG2- ⁇ Glu-, ⁇ Glu-2 ⁇ PEG2-2 ⁇ Glu-, 2 ⁇ Glu- , 2 ⁇ Glu-PEG2-, 2 ⁇ Glu-PEG2- ⁇ Glu-, 2 ⁇ Glu-PEG2- ⁇ Glu-PEG2-, 2 ⁇ Glu-2 ⁇ PEG2- ⁇ Glu-, 2 ⁇ ⁇ Glu-2 ⁇ PEG2-2 ⁇ Glu-.
  • O2-O3-O4-O5-O6-O7-O8- represents a linker selected from the group consisting of ⁇ Glu-PEG2-, ⁇ Glu-2 ⁇ PEG2-, ⁇ Glu-3 ⁇ PEG2-, O1 represents the structure of formula (V) or (VI).
  • O2-O3-O4-O5-O6-O7-O8- represents a linker selected from the group consisting of ⁇ Glu-PEG2-, ⁇ Glu-2 ⁇ PEG2-, ⁇ Glu-3 ⁇ PEG2-, O1 represents the structure of formula (V).
  • O2-O3-O4-O5-O6-O7-O8- represents a linker selected from the group consisting of ⁇ Glu-2 ⁇ PEG2-, ⁇ Glu-3 ⁇ PEG2 -, O1 represents the structure of formula (V).
  • O2-O3-O4-O5-O6-O7-O8- represents the linker ⁇ Glu-2 ⁇ PEG2- and O1 represents the structure of formula (V).
  • O2-O3-O4-O5-O6-O7-O8- represents the linker ⁇ Glu-2 ⁇ PEG2-
  • O1 represents the structure of formula (V), wherein n2 is an integer of 16-22;
  • the amino acid containing a side chain sulfhydryl group added at the C-terminal of X10 is modified at its side chain sulfhydryl group by the long-acting group of formula (IV), optionally, the side chain sulfhydryl group and the long-acting group of the C-terminal amino acid are A reactive group that can react with a sulfhydryl group to form a covalent bond can be added as required.
  • connection relationship between the side chain sulfhydryl group of the side chain sulfhydryl group-containing amino acid and the long-acting group is: the side chain sulfhydryl group of the side chain sulfhydryl group-containing amino acid-sulfhydryl reactive group-optional linking group L-long-acting group.
  • the side-chain sulfhydryl group of the side-chain sulfhydryl-containing amino acid is reacted with a Michael-reactive acceptor (eg, maleimide or vinyl sulfone) or a thiol-reactive group (eg, iodoacetic acid or bromoacetic acid) ) is connected with one end of the connecting group L after the reaction, preferably, the other end of the connecting group L is further connected with the long-acting group of formula IV to form a covalent bond.
  • a Michael-reactive acceptor eg, maleimide or vinyl sulfone
  • a thiol-reactive group eg, iodoacetic acid or bromoacetic acid
  • L is -NH-CH 2 - (CH 2 CH 2 O) 3 - (CH 2) 3 -NH-.
  • non-limiting illustrative examples of Michael reaction acceptors or thiol reactive groups attached to the linking group L include
  • the wavy line is the point of attachment to the long-acting group of formula (IV), eg, to O8. * is the point of attachment of the side chain sulfhydryl group of the amino acid containing the side chain sulfhydryl group to other parts of the amino acid.
  • any amino acid in the polypeptide fragment represented by X10 can be substituted with an amino acid whose side chain contains an amino group or a sulfhydryl group, and the amino acid has the structure of formula (II) or formula (III).
  • the amino acid containing a side chain amino group is modified by a long-acting group in its side chain amino group, preferably, the long-acting group has the structure of formula (IV);
  • the amino acid containing a side chain sulfhydryl group is in Its side chain sulfhydryl group is modified by a long-acting group, preferably, the long-acting group has the structure of formula (IV), optionally, between the side chain sulfhydryl group and the long-acting group can be added as required, which can react with the sulfhydryl group.
  • a reactive group that forms a covalent bond is optionally, between the side chain sulfhydryl group and the long-acting group can be added as required, which can react
  • polypeptide fragments GPPSGAPPP, GPSSGKPPP, GPSSGEPPP, GPSSaibAPPP represented by X10 can be reduced by 1, 2, 3, 4, 5, 6, 7, 8 amino acids from the C-terminus of the fragment to the N-terminus of the fragment.
  • X1 is L. According to the pharmaceutical formulation of any of the preceding aspects, in some embodiments, X1 is Y. According to the pharmaceutical formulation of any of the preceding aspects, in some embodiments, X1 is I. According to the pharmaceutical formulation of any of the preceding aspects, in some embodiments, X1 is V.
  • X2 is Q. According to the pharmaceutical formulation of any of the preceding aspects, in some embodiments, X2 is Y. According to the pharmaceutical formulation of any of the preceding aspects, in some embodiments, X2 is A. According to the pharmaceutical formulation of any of the preceding aspects, in some embodiments, X2 is Aib.
  • X3 is D. According to the pharmaceutical formulation of any of the preceding aspects, in some embodiments, X3 is E.
  • X4 is E. According to the pharmaceutical formulation of any of the preceding aspects, in some embodiments, X4 is K.
  • X5 is V. According to the pharmaceutical formulation of any of the preceding aspects, in some embodiments, X5 is A.
  • X6 is K. According to the pharmaceutical formulation of any of the preceding aspects, in some embodiments, X6 is R.
  • X7 is I. According to the pharmaceutical formulation of any of the preceding aspects, in some embodiments, X7 is V.
  • X8 is E. According to the pharmaceutical formulation of any of the preceding aspects, in some embodiments, X8 is N. According to the pharmaceutical formulation of any of the preceding aspects, in some embodiments, X8 is Q. According to the pharmaceutical formulation of any of the preceding aspects, in some embodiments, X8 is A.
  • X9 is I. According to the pharmaceutical formulation of any of the preceding aspects, in some embodiments, X9 is L. According to the pharmaceutical formulation of any of the preceding aspects, in some embodiments, X9 is Aib. According to the pharmaceutical formulation of any of the preceding aspects, in some embodiments, X9 is V.
  • X10 is absent.
  • X10 is GPSSGAPPPSK.
  • X10 is GPSSGAPPPSC.
  • X10 is GPSSGAPPPS.
  • the pharmaceutical formulation according to any of the preceding aspects, in some embodiments, X10 is GPSSGAPPPK.
  • X10 is GPSSGAPPPC.
  • X10 is GPSSGAPPP.
  • X10 is GPSSGAPP. According to the pharmaceutical formulation of any of the preceding aspects, in some embodiments, X10 is GPSSGAP. According to the pharmaceutical formulation of any of the preceding aspects, in some embodiments, X10 is GPSSGA. According to the pharmaceutical formulation of any of the preceding aspects, in some embodiments, X10 is GPSSG. According to the pharmaceutical formulation of any of the preceding aspects, in some embodiments, X10 is GPSS. According to the pharmaceutical formulation of any of the preceding aspects, in some embodiments, X10 is GPS. According to the pharmaceutical formulation of any of the preceding aspects, in some embodiments, X10 is GP. According to the pharmaceutical formulation of any of the preceding aspects, in some embodiments, X10 is G.
  • X1 is L and X10 is GPSSGAPPPS.
  • the pharmaceutical formulation according to any of the preceding aspects, in some embodiments, X1 is L and X10 is GPSSGAPPPK.
  • the pharmaceutical formulation according to any of the preceding aspects, in some embodiments, X1 is L and X10 is GPSSGAPPPC.
  • the pharmaceutical formulation according to any of the preceding aspects, in some embodiments, X1 is L and X10 is GPSSGAPPP.
  • X1 is L and X10 is GPSSGAPP.
  • the pharmaceutical formulation according to any of the preceding aspects, in some embodiments, X1 is L and X10 is GPSSGAPP.
  • the pharmaceutical formulation according to any of the preceding aspects, in some embodiments, X1 is L and X10 is GPSSGAP.
  • X1 is L and X10 is GPSSGA.
  • the pharmaceutical formulation according to any of the preceding aspects, in some embodiments, X1 is L and X10 is GPSSG.
  • the pharmaceutical formulation according to any of the preceding aspects, in some embodiments, X1 is L and X10 is GPSS.
  • the pharmaceutical formulation according to any of the preceding aspects, in some embodiments, X1 is L and X10 is GPS.
  • the pharmaceutical formulation according to any of the preceding aspects, in some embodiments, X1 is L and X10 is GP. According to the pharmaceutical formulation of any of the preceding aspects, in some embodiments, X1 is L and X10 is G.
  • X2 is Q and X10 is GPSSGAPPPK.
  • X2 is Q and X10 is GPSSGAPPPC.
  • X2 is A and X10 is GPSSGAPPPS.
  • X2 is A and X10 is GPSSGAPPPK.
  • X2 is A and X10 is GPSSGAPPPC.
  • X2 is aib and X10 is GPSSGAPPPS.
  • X2 is aib and X10 is GPSSGAPPPK.
  • X2 is aib and X10 is GPSSGAPPPC.
  • X2 is Q and X10 is GPS.
  • X2 is Q and X10 is GP.
  • X2 is Q and X10 is G.
  • X2 is A and X10 is GPSSGAPPP.
  • the pharmaceutical formulation according to any of the preceding aspects, in some embodiments, X2 is A and X10 is GPSSGAPP.
  • the pharmaceutical formulation according to any of the preceding aspects, in some embodiments, X2 is A and X10 is GPSSGAP.
  • the pharmaceutical formulation according to any of the preceding aspects, in some embodiments, X2 is A and X10 is GPSSGA.
  • the pharmaceutical formulation according to any of the preceding aspects, in some embodiments, X2 is A and X10 is GPSSG. According to the pharmaceutical formulation of any of the preceding aspects, in some embodiments, X2 is A and X10 is GPSS.
  • X2 is A and X10 is GPS.
  • X2 is A and X10 is G.
  • X2 is aib and X10 is GPSSGAPPP.
  • the pharmaceutical formulation according to any of the preceding aspects, in some embodiments, X2 is aib and X10 is GPSSGAPP.
  • the pharmaceutical formulation according to any of the preceding aspects, in some embodiments, X2 is aib and X10 is GPSSGAP.
  • the pharmaceutical formulation according to any of the preceding aspects, in some embodiments, X2 is aib and X10 is GPSSGA.
  • X2 is aib and X10 is GPSSG.
  • X2 is aib and X10 is GPSS.
  • X2 is aib and X10 is GPS.
  • X2 is aib and X10 is GP.
  • X2 is aib and X10 is G.
  • X1 is L and X2 is Q.
  • X1 is L and X2 is A.
  • X1 is L, X2 is Q, and X10 is GPSSGAPPPS.
  • X1 is L, X2 is Q, and X10 is GPSSGAPPPK.
  • X1 is L, X2 is Q, and X10 is GPSSGAPPPC.
  • X1 is L, X2 is Q, and X10 is GPSSGAPPP.
  • X1 is L, X2 is Q, and X10 is GPSSGAPP.
  • X1 is L, X2 is Q, and X10 is GPSSGAP.
  • X1 is L, X2 is Q, and X10 is GPSSGA.
  • X1 is L, X2 is Q, and X10 is GPSSG.
  • X1 is L, X2 is Q, and X10 is GPSS.
  • X1 is L, X2 is Q, and X10 is GPS.
  • X1 is L, X2 is Q, and X10 is GP.
  • X1 is L, X2 is Q, and X10 is G.
  • X1 is L, X2 is A, and X10 is GPSSGAPPPS.
  • X1 is L, X2 is A, and X10 is GPSSGAPPPK.
  • X1 is L, X2 is A, and X10 is GPSSGAPPPC.
  • X1 is L, X2 is A, and X10 is GPSSGAPPP.
  • X1 is L, X2 is A, and X10 is GPSSGAPP.
  • X1 is L, X2 is A, and X10 is GPSSGAP.
  • X1 is L, X2 is A, and X10 is GPSSGA.
  • X1 is L, X2 is A, and X10 is GPSSG.
  • X1 is L, X2 is A, and X10 is GPSS.
  • X1 is L
  • X2 is A
  • X10 is GPS
  • X1 is L
  • X2 is A
  • X10 is GP
  • X1 is L
  • X2 is A
  • X10 is G.
  • X1 is L, X2 is aib, and X10 is GPSSGAPPPS.
  • X1 is L, X2 is aib, and X10 is GPSSGAPPPK.
  • X1 is L, X2 is aib, and X10 is GPSSGAPPPC.
  • X1 is L, X2 is aib, and X10 is GPSSGAPPP.
  • X1 is L, X2 is aib, and X10 is GPSSGAPP.
  • X1 is L, X2 is aib, and X10 is GPSSGAP.
  • X1 is L, X2 is aib, and X10 is GPSSGA.
  • X1 is L, X2 is aib, and X10 is GPSSG.
  • X1 is L, X2 is aib, and X10 is GPSS.
  • X1 is L, X2 is aib, and X10 is GPS.
  • X1 is L, X2 is aib, and X10 is GP.
  • X1 is L, X2 is aib, and X10 is G.
  • X1 is L, X2 is Q, X5 is V, and X10 is GPSSGAPPPS.
  • X1 is L
  • X2 is Q
  • X5 is V
  • X10 is GPSSGAPPPK.
  • X1 is L
  • X2 is Q
  • X5 is V
  • X10 is GPSSGAPPPC.
  • X1 is L
  • X2 is aib
  • X5 is V
  • X10 is GPSSGAPPPS.
  • X1 is L
  • X2 is aib
  • X5 is V
  • X10 is GPSSGAPPPK.
  • X1 is L
  • X2 is aib
  • X5 is V
  • X10 is GPSSGAPPPC.
  • X1 is L
  • X2 is A
  • X3 is E
  • X5 is V
  • X10 is GPSSGAPPPS.
  • X1 is L
  • X2 is A
  • X3 is E
  • X5 is V
  • X10 is GPSSGAPPPK.
  • X1 is L
  • X2 is A
  • X3 is E
  • X5 is V
  • X10 is GPSSGAPPPC.
  • X1 is L
  • X2 is aib
  • X3 is E
  • X5 is V
  • X10 is GPSSGAPPPS.
  • X1 is L
  • X2 is aib
  • X3 is E
  • X5 is V
  • X10 is GPSSGAPPPK.
  • X1 is L
  • X2 is aib
  • X3 is E
  • X5 is V
  • X10 is GPSSGAPPPC.
  • X1 is L, X2 is Q, X3 is E, X4 is K, X5 is V, and X10 is GPSSGAPPPS.
  • X1 is L, X2 is Q, X3 is E, X4 is K, X5 is V, and X10 is GPSSGAPPPK.
  • X1 is L, X2 is Q, X3 is E, X4 is K, X5 is V, and X10 is GPSSGAPPPC.
  • X1 is L
  • X2 is A
  • X3 is E
  • X4 is K
  • X5 is V
  • X10 is GPSSGAPPPS.
  • X1 is L
  • X2 is A
  • X3 is E
  • X4 is K
  • X5 is V
  • X10 is GPSSGAPPPK.
  • X1 is L
  • X2 is A
  • X3 is E
  • X4 K
  • X5 is V
  • X10 is GPSSGAPPPK
  • X1 is L
  • X2 is A
  • X3 is E
  • X4 is K
  • X5 is V
  • X10 is GPSSGAPPPC.
  • X1 is L, X2 is aib, X3 is E, X4 is K, X5 is V, and X10 is GPSSGAPPPS.
  • X1 is L, X2 is aib, X3 is E, X4 is K, X5 is V, and X10 is GPSSGAPPPK.
  • X1 is L, X2 is aib, X3 is E, X4 is K, X5 is V, and X10 is GPSSGAPPPC.
  • X1 is L, X2 is Q, X3 is E, X4 is K, X5 is V, X7 is I, and X10 is GPSSGAPPPS.
  • X1 is L, X2 is Q, X3 is E, X4 is K, X5 is V, X7 is I, and X10 is GPSSGAPPPK.
  • X1 is L, X2 is Q, X3 is E, X4 is K, X5 is V, X7 is I, and X10 is GPSSGAPPPC.
  • X1 is L, X2 is A, X3 is E, X4 is K, X5 is V, X7 is I, and X10 is GPSSGAPPPS.
  • X1 is L, X2 is A, X3 is E, X4 is K, X5 is V, X7 is I, and X10 is GPSSGAPPPK.
  • X1 is L, X2 is A, X3 is E, X4 is K, X5 is V, X7 is I, and X10 is GPSSGAPPPC.
  • X1 is L
  • X2 is aib
  • X3 is E
  • X4 is K
  • X5 is V
  • X7 is I
  • X10 is GPSSGAPPPS.
  • X1 is L
  • X2 is aib
  • X3 is E
  • X4 is K
  • X5 is V
  • X7 is I
  • X10 is GPSSGAPPPK.
  • X1 is L
  • X2 is aib
  • X3 is E
  • X4 is K
  • X5 is V
  • X7 is I
  • X10 is GPSSGAPPPC.
  • X2 is A and X5 is V.
  • X2 is aib and X5 is V.
  • X1 is L
  • X2 is A
  • X5 is V
  • X1 is L
  • X2 is aib
  • X5 is V
  • X1 is L
  • X2 is A
  • X3 is E
  • X5 is V
  • X1 is L
  • X2 is aib
  • X3 is E
  • X5 is V.
  • X1 is L
  • X2 is A
  • X3 is E
  • X4 is K
  • X5 is V
  • X7 is I
  • X1 is L
  • X2 is aib
  • X3 is E
  • X4 is K
  • X5 is V
  • X7 is I.
  • X2 is Q and X9 is L.
  • X2 is Q, X9 is L, and X10 is GPSSGAPPPS.
  • X2 is Q, X9 is L, and X10 is GPSSGAPPPK.
  • X2 is Q, X9 is L, and X10 is GPSSGAPPPC.
  • X2 is A and X9 is L.
  • X2 is A, X9 is L, and X10 is GPSSGAPPPS.
  • X2 is A, X9 is L, and X10 is GPSSGAPPPK.
  • X2 is A, X9 is L, and X10 is GPSSGAPPPC.
  • X2 is aib and X9 is L.
  • X2 is aib, X9 is L, and X10 is GPSSGAPPPS.
  • X2 is aib, X9 is L, and X10 is GPSSGAPPPK.
  • X2 is aib, X9 is L, and X10 is GPSSGAPPPC.
  • X1 is L, X2 is Q, X9 is L, and X10 is GPSSGAPPPS.
  • X1 is L
  • X2 is Q
  • X9 is L
  • X10 is GPSSGAPPPK.
  • X1 is L
  • X2 is Q
  • X9 is L
  • X10 is GPSSGAPPPC.
  • X1 is L
  • X2 is A
  • X9 is L
  • X10 is GPSSGAPPPS.
  • X1 is L
  • X2 is A
  • X9 is L
  • X10 is GPSSGAPPPK.
  • X1 is L
  • X2 is A
  • X9 is L
  • X10 is GPSSGAPPPC.
  • X1 is L
  • X2 is aib
  • X9 is L
  • X10 is GPSSGAPPPS.
  • X1 is L
  • X2 is aib
  • X9 is L
  • X10 is GPSSGAPPPK.
  • X1 is L
  • X2 is aib
  • X9 is L
  • X10 is GPSSGAPPPC.
  • X1 is L
  • X2 is Q
  • X5 is V
  • X9 is L
  • X10 is GPSSGAPPPS.
  • X1 is L
  • X2 is Q
  • X5 is V
  • X9 is L
  • X10 is GPSSGAPPPK.
  • X1 is L
  • X2 is Q
  • X5 is V
  • X9 is L
  • X10 is GPSSGAPPPC.
  • X1 is L
  • X2 is A
  • X5 is V
  • X9 is L
  • X10 is GPSSGAPPPS.
  • X1 is L
  • X2 is A
  • X5 is V
  • X9 is L
  • X10 is GPSSGAPPPK.
  • X1 is L
  • X2 is A
  • X5 is V
  • X9 is L
  • X10 is GPSSGAPPPC.
  • X1 is L
  • X2 is aib
  • X5 is V
  • X9 is L
  • X10 is GPSSGAPPPS.
  • X1 is L
  • X2 is aib
  • X5 is V
  • X9 is L
  • X10 is GPSSGAPPPK.
  • X1 is L
  • X2 is aib
  • X5 is V
  • X9 is L
  • X10 is GPSSGAPPPC.
  • X1 is L, X2 is Q, X3 is E, X5 is V, X9 is L, and X10 is GPSSGAPPPS.
  • X1 is L, X2 is Q, X3 is E, X5 is V, X9 is L, and X10 is GPSSGAPPPK.
  • X1 is L, X2 is Q, X3 is E, X5 is V, X9 is L, and X10 is GPSSGAPPPC.
  • X1 is L
  • X2 is A
  • X3 is E
  • X5 is V
  • X9 is L
  • X10 is GPSSGAPPPS.
  • X1 is L
  • X2 is A
  • X3 is E
  • X5 is V
  • X9 is L
  • X10 is GPSSGAPPPK.
  • X1 is L
  • X2 is A
  • X3 is E
  • X5 is V
  • X9 is L
  • X10 is GPSSGAPPPC.
  • X1 is L
  • X2 is aib
  • X3 is E
  • X5 is V
  • X9 is L
  • X10 is GPSSGAPPPS.
  • X1 is L
  • X2 is aib
  • X3 is E
  • X5 is V
  • X9 is L
  • X10 is GPSSGAPPPK.
  • X1 is L
  • X2 is aib
  • X3 is E
  • X5 is V
  • X9 is L
  • X10 is GPSSGAPPPC.
  • X1 is L, X2 is Q, X3 is E, X4 is K, X5 is V, X9 is L, and X10 is GPSSGAPPPS.
  • X1 is L, X2 is Q, X3 is E, X4 is K, X5 is V, X9 is L, and X10 is GPSSGAPPPK.
  • X1 is L, X2 is Q, X3 is E, X4 is K, X5 is V, X9 is L, and X10 is GPSSGAPPPC.
  • X1 is L
  • X2 is A
  • X3 is E
  • X4 is K
  • X5 is V
  • X9 is L
  • X10 is GPSSGAPPPS.
  • X1 is L
  • X2 is A
  • X3 is E
  • X4 is K
  • X5 is V
  • X9 is L
  • X10 is GPSSGAPPPK.
  • X1 is L
  • X2 is A
  • X3 is E
  • X4 is K
  • X5 is V
  • X9 is L
  • X10 is GPSSGAPPPC.
  • X1 is L
  • X2 is aib
  • X3 is E
  • X4 is K
  • X5 is V
  • X9 is L
  • X10 is GPSSGAPPPS.
  • X1 is L
  • X2 is aib
  • X3 is E
  • X4 is K
  • X5 is V
  • X9 is L
  • X10 is GPSSGAPPPK.
  • X1 is L
  • X2 is aib
  • X3 is E
  • X4 is K
  • X5 is V
  • X9 is L
  • X10 is GPSSGAPPPC.
  • X1 is L
  • X2 is Q
  • X3 is E
  • X4 is K
  • X5 is V
  • X7 is I
  • X9 is L
  • X10 is GPSSGAPPPS.
  • X1 is L
  • X2 is Q
  • X3 is E
  • X4 is K
  • X5 is V
  • X7 is I
  • X9 is L
  • X10 is GPSSGAPPPK.
  • X1 is L
  • X2 is Q
  • X3 is E
  • X4 is K
  • X5 is V
  • X7 is I
  • X9 is L
  • X10 is GPSSGAPPPC.
  • X1 is L
  • X2 is A
  • X3 is E
  • X4 is K
  • X5 is V
  • X7 is I
  • X9 is L
  • X10 is GPSSGAPPPS.
  • X1 is L
  • X2 is A
  • X3 is E
  • X4 is K
  • X5 is V
  • X7 is I
  • X9 is L
  • X10 is GPSSGAPPPK.
  • X1 is L
  • X2 is A
  • X3 is E
  • X4 is K
  • X5 is V
  • X7 is I
  • X9 is L
  • X10 is GPSSGAPPPC.
  • X1 is L
  • X2 is aib
  • X3 is E
  • X4 is K
  • X5 is V
  • X7 is I
  • X9 is L
  • X10 is GPSSGAPPPS.
  • X1 is L
  • X2 is aib
  • X3 is E
  • X4 is K
  • X5 is V
  • X7 is I
  • X9 is L
  • X10 is GPSSGAPPPK.
  • X1 is L
  • X2 is aib
  • X3 is E
  • X4 is K
  • X5 is V
  • X7 is I
  • X9 is L
  • X10 is GPSSGAPPPC.
  • X1 is L
  • X2 is Q
  • X3 is E
  • X4 is K
  • X5 is V
  • X7 is V
  • X9 is L
  • X10 is GPSSGAPPPS.
  • X1 is L
  • X2 is Q
  • X3 is E
  • X4 is K
  • X5 is V
  • X7 is V
  • X9 is L
  • X10 is GPSSGAPPPK.
  • X1 is L
  • X2 is A
  • X3 is E
  • X4 is K
  • X5 is V
  • X7 is V
  • X9 is L
  • X10 is GPSSGAPPPS.
  • X1 is L
  • X2 is A
  • X3 is E
  • X4 is K
  • X5 is V
  • X7 is V
  • X9 is L
  • X10 is GPSSGAPPPK.
  • X1 is L
  • X2 is A
  • X3 is E
  • X4 is K
  • X5 is V
  • X7 is V
  • X9 is L
  • X10 is GPSSGAPPPC.
  • X1 is L
  • X2 is aib
  • X3 is E
  • X4 is K
  • X5 is V
  • X7 is I
  • X9 is L
  • X10 is GPSSGAPPPS.
  • X1 is L
  • X2 is aib
  • X3 is E
  • X4 is K
  • X5 is V
  • X7 is V
  • X9 is L
  • X10 is GPSSGAPPPK.
  • X1 is L
  • X2 is aib
  • X3 is E
  • X4 is K
  • X5 is V
  • X7 is V
  • X9 is L
  • X10 is GPSSGAPPPC.
  • X3 is E and X10 is GPSSGAPPPK.
  • X1 is L
  • X3 is E
  • X10 is GPSSGAPPPK.
  • X1 is L
  • X3 is E
  • X9 is L
  • X10 is GPSSGAPPPK.
  • X1 is L
  • X3 is E
  • X5 is V
  • X9 is L
  • X10 is GPSSGAPPPK.
  • X1 is L, X3 is E, X4 is K, X5 is V, X9 is L, and X10 is GPSSGAPPPK.
  • X1 is L, X3 is E, X4 is K, X5 is V, X7 is I, X9 is L, and X10 is GPSSGAPPPK.
  • X1 is L, X3 is E, X4 is K, X5 is V, X7 is I, X9 is L, and X10 is GPSSGAPPPK.
  • X1 is L, X3 is E, X4 is K, X5 is V, X7 is I, X8 is E, X9 is L, and X10 is GPSSGAPPPK.
  • X1 is L
  • X3 is E
  • X4 is K
  • X5 is V
  • X6 is R
  • X7 is I
  • X8 is E
  • X9 is L
  • X10 is GPSSGAPPPK .
  • X1 is L
  • X3 is E
  • X4 is K
  • X5 is V
  • X6 is R
  • X7 is I
  • X8 E
  • X9 L
  • X10 is GPSSGAPPPK , in which the C-terminal lysine side chain amino group of X10 is conjugated with a long-acting group.
  • the C-terminal lysine side chain amino-conjugated long-acting group of X10 has the structure of formula (VIII) or formula (IX).
  • the pharmaceutical formulation according to any of the preceding aspects in some embodiments, X1 is L, X2 is A or aib, X3 is E, X4 is K, X5 is V, X6 is R, X7 is I, X8 is E, X9 is L, X10 is GPSSGAPPPK.
  • the C-terminal lysine side chain amino group of X10 is conjugated to a long-acting group.
  • the C-terminal lysine side chain amino-conjugated long-acting group of X10 has the structure of formula (VIII) or formula (IX).
  • the pharmaceutical formulation according to any of the preceding aspects in some embodiments, X1 is L, X2 is A, X3 is E, X4 is K, X5 is V, X6 is R, X7 is I, X8 is E, and X9 is L , X10 is GPSSGAPPPK.
  • the C-terminal lysine side chain amino group of X10 is conjugated to a long-acting group.
  • X1 is Y and X2 is Q.
  • X1 is Y and X2 is A.
  • the pharmaceutical formulation according to any of the preceding aspects in some embodiments, X1 is Y and X2 is Aib.
  • X1 is Y and X2 is Y.
  • X4 is K and X9 is L.
  • X1 is Y, X4 is K, and X9 is L.
  • X1 is Y, X2 is Y, X4 is K, and X9 is L.
  • X1 is Y, X2 is Y, X4 is K, and X9 is L.
  • X1 is Y, X2 is Y, X4 is K, and X9 is L.
  • X1 is Y, X2 is Y, X4 is K, X5 is V, and X9 is L.
  • X1 is Y, X2 is Y, X3 is E, X4 is K, X5 is V, and X9 is L.
  • X1 is Y, X2 is Y, X3 is E, X4 is K, X5 is V, X7 is V, and X9 is L.
  • X1 is Y, X2 is Y, X3 is E, X4 is K, X5 is V, X7 is V, X8 is N, and X9 is L.
  • X1 is Y, X2 is Y, X3 is E, X4 is K, X5 is V, X7 is V, X8 is N, and X9 is I.
  • X1 is Y, X2 is Y, X3 is E, X4 is K, X5 is V, X7 is I, X8 is E, and X9 is L.
  • X1 is L
  • X2 is Q
  • X3 is E
  • X4 is K
  • X5 is V
  • X9 is L
  • X1 is L
  • X2 is Q
  • X3 is E
  • X4 is K
  • X5 is V
  • X7 is I
  • X8 is E
  • X9 is L.
  • X1 is L and X2 is A.
  • X1 is L, X2 is A, and X9 is L.
  • X1 is L, X2 is A, X5 is V, and X9 is L.
  • X1 is L, X2 is A, X3 is E, X5 is V, and X9 is L.
  • X1 is L
  • X2 is A
  • X3 is E
  • X4 is K
  • X5 is V
  • X9 is L
  • X1 is L
  • X2 is A
  • X3 is E
  • X4 is K
  • X5 is V
  • X7 is I
  • X8 is E
  • X9 is L.
  • X1 is L
  • X2 is aib
  • X3 is E
  • X4 is K
  • X5 is V
  • X9 is L
  • X1 is L
  • X2 is aib
  • X3 is E
  • X4 is K
  • X5 is V
  • X7 is I
  • X8 is E
  • X9 is L.
  • X1 is L and X2 is Y.
  • X1 is L
  • X2 is Y
  • X5 is V
  • X1 is L
  • X2 is Y
  • X3 is E
  • X5 is V
  • X1 is L
  • X2 is Y
  • X3 is E
  • X4 is K
  • X5 is V.
  • the pharmaceutical preparations can be prepared, for example, as tablets, coated tablets, dragees, hard and soft gelatine capsules, solutions, emulsions or suspensions for oral administration. However, it can also be formulated as a suppository for rectal administration, or as an injectable solution for parenteral administration. Commonly used parenteral administration methods include subcutaneous injection, intravenous injection, transdermal administration, inhalation administration and the like.
  • the carrier or excipient is selected from one or more of buffers, preservatives, isotonic agents, solubilizers, stabilizers, surfactants, and chelating agents.
  • the buffer is one or more of disodium hydrogen phosphate, dipotassium hydrogen phosphate, sodium dihydrogen phosphate, potassium dihydrogen phosphate, and sodium acetate solution .
  • the buffer is a disodium hydrogen phosphate solution.
  • the preservative is selected from the group consisting of phenol, m-cresol, p-cresol, o-cresol, chlorocresol, benzyl alcohol, phenylmercuric nitrite, phenoxyethanol, formaldehyde, chlorine Butanol, magnesium chloride (such as magnesium chloride hexahydrate), alkyl parabens (methyl, ethyl, propyl, butyl, etc.), benzalkonium chloride, benzethonium chloride, sodium methylpyrone and one or more of thimerosal.
  • the preservative is selected from the group consisting of phenol, m-cresol, p-cresol, o-cresol, chlorocresol, benzyl alcohol, phenylmercuric nitrite, phenoxyethanol, formaldehyde, chlorine Butanol, magnesium chloride (such as magnesium chloride hexahydrate), alkyl parabens (methyl, ethyl,
  • the preservative is phenol
  • the isotonicity agent is an osmotic pressure regulator commonly used in the art, such as carbohydrates, polyols or salts.
  • the isotonicity agent is selected from one or more of glycerol, propylene glycol, monosaccharide, disaccharide, polysaccharide, alditol and sodium chloride; preferably, the monosaccharide is selected from fructose, maltose, galactose, glucose, D -Mannose, sorbose, etc.; preferably, the disaccharide is selected from lactose, sucrose, trehalose, cellobiose, etc.; Glycosides, starch, etc.; preferably, the alditol is selected from mannitol, xylitol, maltitol, lactitol, xylitol, sorbitol (glucitol) and the like.
  • the osmotic pressure regulator commonly used in the art,
  • the isotonicity agent is glycerol.
  • the isotonicity agent is propylene glycol.
  • the excipient is a sugar excipient; the sugar excipient is selected from the group consisting of: one of monosaccharides, disaccharides, polysaccharides, and alditols or variety.
  • the surfactant is selected from polysorbates (eg, eg, Tween (polyoxyethylene (20) sorbitan monolaurate), Tween (polyoxyethylene (20) sorbitan monopalmitate), Tween (polyoxyethylene (20) sorbitan monooleate)), Poloxamer 184 or 188, Pluronic F68 (polyoxyethylene-polyoxypropylene block copolymer) and PEG (polyethylene glycol alcohol) or surfactants such as polysorbate 20 or 80 or one or more of poloxamers 184 or 188, pluronic, other block copolymers.
  • polysorbates eg, eg, Tween (polyoxyethylene (20) sorbitan monolaurate), Tween (polyoxyethylene (20) sorbitan monopalmitate), Tween (polyoxyethylene (20) sorbitan monooleate)
  • Poloxamer 184 or 188 Poloxamer 184 or 188
  • the concentration of the peptide compound is at least 0.1 mg/ml, preferably 0.5-20 mg/ml, 0.5-10 mg/ml, 1-8 mg/ml, 1-6 mg/ml ml, 1-5 mg/ml, 1.5-4 mg/ml; more preferably 1.5 mg/ml.
  • the concentration of disodium hydrogen phosphate is at least 0.1 mg/ml, preferably 0.1-10 mg/ml, 0.3-10 mg/ml, 0.5-10 mg/ml, 0.5-5 mg /ml, 0.5-3mg/ml, 0.7-2mg/ml.
  • the disodium hydrogen phosphate used in the preparation of the present invention can be anhydrous disodium hydrogen phosphate or disodium hydrogen phosphate hydrate, such as disodium hydrogen phosphate dihydrate, disodium hydrogen phosphate heptahydrate, disodium hydrogen phosphate dodecahydrate, etc. .
  • Preferred pharmaceutical excipients disodium hydrogen phosphate dodecahydrate.
  • the concentration of glycerol is at least 12 mg/ml, preferably 15-25 mg/ml, 17-22 mg/ml, 17-20 mg/ml.
  • the concentration of propylene glycol is at least 8 mg/ml, preferably 10-20 mg/ml, 10-18 mg/ml, 10-16 mg/ml, 12-16 mg/ml, 13 -15mg/ml.
  • the pH of the pharmaceutical formulation is between 3-9, preferably 4-8.8, 5-8.6, 6-8.5, 6.5-8.5, 7.0-8.5, 7.2 -8.5, 7.2-8.0, 7.4-8.0, 7.5-8.0, 7.4-7.6, 7.5-7.6.
  • the preservative is phenol, preferably at a concentration of not more than 5.5 mg./ml, preferably not more than 5.0 mg/ml.
  • the peptide compound in the pharmaceutical formulation is compound 27, 29, 220 or 221.
  • the present invention relates to methods of treating or preventing the following diseases or conditions: impaired glucose tolerance (IGT), hyperglycemia, type 1 diabetes, type 2 diabetes, obesity, metabolic syndrome and neurodegenerative diseases, in particular For delaying or preventing disease progression in type 2 diabetes, delaying progression from impaired glucose tolerance to type 2 diabetes; delaying progression from type 2 diabetes to insulin-requiring diabetes; treating metabolic syndrome, for regulating appetite, inducing Satiety, reducing food intake, increasing energy expenditure, treating obesity or preventing overweight; preventing weight regain after successful weight loss; treating a disease or condition associated with overweight or obesity; treating bulimia; treating binge eating; treating lipids Abnormalities, atherosclerosis, hypertension, coronary heart disease, ⁇ -blocker poisoning; non-alcoholic fatty liver disease (NAFLD, non-alcoholic fatty liver disease) (can be divided into simple fatty liver (SFL), non-alcoholic fatty liver disease steatohepatitis (NASH) and its associated cirrhosis); for suppressing motility of the gastrointestinal disorders
  • the invention relates to the use of a pharmaceutical formulation of any of the preceding aspects in the manufacture of a medicament for lowering blood sugar or treating diabetes.
  • the invention relates to the use of a pharmaceutical formulation of any of the preceding aspects in the manufacture of a medicament for weight loss.
  • the present invention relates to a method for the preparation of a pharmaceutical formulation according to any of the preceding aspects, wherein the method of preparation comprises the steps of:
  • the preparation solution was sterile filtered with a 0.22-micron filter.
  • Figure 2 Tests for compounds 31, 35, 38, 44 and 49 of the invention to lower blood glucose in db/db mice.
  • FIG. 3 Intraperitoneal glucose tolerance test (IPGTT) of compounds 6, 13, 14 and 26 of the present invention.
  • Figure 8 Fasting blood glucose test for compounds 21, 22, 27, 28, 29 and 30 of the present invention.
  • Figure 9 Tests for compounds of the invention 42, 115 and 178 to lower blood glucose in db/db mice.
  • Figure 10 Compound 27 and Compound 29 of the present invention are effective in reducing body weight.
  • FIG. 11 Compound 27 and Compound 29 of the present invention are effective in reducing food intake.
  • FIG. 12 Compound 27 and Compound 29 of the present invention are effective in lowering low-density lipoprotein cholesterol (LDL-C).
  • LDL-C low-density lipoprotein cholesterol
  • FIG. 13 Compound 35 and Compound 40 of the present invention are effective in reducing adipose tissue mass.
  • Amino acid refers to a molecule that contains both amino and carboxyl functional groups, the amino and carboxyl groups of an alpha-amino acid being attached to the same carbon atom (alpha carbon). The alpha carbon may additionally have 1-2 organic substituents.
  • Amino acids contain L and D isomers and racemic mixtures. Unless otherwise specified, the amino acid residues in the polypeptide sequence of the present invention are all L isomers, namely L-amino acids, and D-amino acids are represented by adding a lowercase letter "d" before the amino acid name or abbreviation, such as dK.
  • amino acid sequences of the present invention contain conventional one-letter or three-letter codes for naturally occurring amino acids, as well as generally recognized three-letter codes for other amino acids, such as Tic(1,2,3,4-tetrahydroisoquinoline -3-carboxylic acid), Aib ( ⁇ -aminoisobutyric acid) or GABA ( ⁇ -aminobutyric acid).
  • Abbreviated codes for common molecular structures include:
  • hGlu is homoglutamic acid
  • ⁇ -hGlu is the L isomer of -HNCH(CO-)CH 2 CH 2 CH 2 COOH;
  • ⁇ -hGlu is the L isomer of -HNCH(COOH)CH 2 CH 2 CH 2 CO-;
  • ⁇ -Glu is the L isomer of -HNCH(CO-)CH 2 CH 2 COOH;
  • ⁇ -Glu or gGlu is the L isomer of -HNCH(COOH)CH 2 CH 2 CO-;
  • ⁇ -Asp is the L isomer of -HNCH(COOH)CH 2 CO-;
  • ⁇ -Ala is -HN-CH 2 -CH 2 -COOH
  • PEG2 is 2-(2-(2-aminoethoxy)ethoxy)acetic acid (CAS No. 134978-97-5).
  • amino acid composition of the polypeptides of the present invention can be altered without substantially affecting its biological activity.
  • a polypeptide sequence can contain one or more conservative amino acid substitutions.
  • Conservative amino acid substitutions are the replacement of one amino acid residue by another amino acid residue with a similar side chain.
  • Amino acid residues are classified in the literature according to the properties of their side chains.
  • Amino acid residues containing basic side chains include lysine, arginine, histidine; amino acid residues containing acidic side chains and their amide side chains include aspartic acid, glutamic acid, asparagine, glutamine ; small aliphatic, non-polar or weakly polar side chain amino acid residues include glycine, alanine, threonine, serine, proline; large aliphatic, non-polar side chain amino acid residues include leucine , isoleucine, valine; aromatic amino acid residues include phenylalanine, tryptophan, tyrosine; sulfur-containing side chain amino acid residues include cysteine, methionine.
  • the derivative comprises a substituent comprising a lipophilic moiety and optionally 1-3 negatively charged moieties, wherein one of the negatively charged moieties is distal to the lipophilic moiety .
  • the substituent is attached to the side chain of the amino acid at the C-terminus of the sequence. If the C-terminus of the sequence is lysine, it is attached to the epsilon amino group of the lysine residue.
  • treating includes inhibiting, slowing, stopping or reversing the progression or severity of an existing symptom or condition.
  • treatment includes prevention, treatment and/or cure.
  • Prevention refers to preventing an underlying disease and/or preventing the worsening of symptoms or the development of a disease.
  • therapeutic effect refers to an effect resulting from treatment of an individual that alters, generally ameliorates or ameliorates the symptoms of a disease or condition, or cures the disease or condition.
  • a “therapeutically effective amount” or “therapeutically effective dose” refers to an amount of a substance, compound, material, or composition comprising a compound that is at least sufficient to produce a therapeutic effect after administration to a subject. Thus, it is an amount necessary to prevent, cure, ameliorate, retard or partially retard the symptoms of a disease or disorder.
  • a prophylactically effective amount or “prophylactically effective dose” refers to an amount of a substance, compound, material or composition comprising a compound that, when administered to a subject, will have the desired prophylactic effect, eg, prevent or delay a disease or symptom occurrence or recurrence, and reduce the likelihood of occurrence or recurrence of disease or symptoms.
  • a fully prophylactically effective dose need not occur by administering one dose, and may occur only after administering a series of doses. Thus, a prophylactically effective amount can be administered in one or more administrations.
  • the term "patient” refers to a mammal, such as a human.
  • GLP-1 receptor agonists such as GLP-1, Lira Glutide and Exendin-4.
  • Certain compounds of the present invention are generally effective over a wide dosage range. For example, a dose administered once a week may range from about 0.05 to about 30 mg per person per week. Certain compounds of the present invention may be administered daily. Additionally, certain compounds of the present invention may be administered once a week.
  • the therapeutic agents according to the described embodiments will be administered with suitable pharmaceutically acceptable carriers, excipients, and other agents that are incorporated into the formulation to provide improved transfer, delivery, tolerability, and the like.
  • suitable pharmaceutically acceptable carriers, excipients, and other agents that are incorporated into the formulation to provide improved transfer, delivery, tolerability, and the like.
  • suitable formulations can be found in pharmacopeias known to all medicinal chemists: Remington's Pharmaceutical Sciences (15th edition, Mack Publishing Company, Easton, Pa. (1975)), especially chapter 87 of Blaug, Seymour therein .
  • Such formulations include, for example, powders, pastes, ointments, gels, waxes, oils, lipids, lipid-containing (cationic or anionic) carriers (eg, LipofectinTM), DNA conjugates, anhydrous slurries, oil-in-water and Water-in-oil emulsions, emulsion polyethylene glycols (polyethylene glycols of various molecular weights), semisolid gels, and semisolid mixtures containing polyethylene glycols. Any of the foregoing mixtures may be suitable for use in treatment or therapy according to the present invention, provided that the active ingredient in the formulation is not inactivated by the formulation and that the formulation is physiologically compatible and tolerated by the route of administration.
  • the term "pharmaceutically acceptable carrier” is intended to include any and all solvents, dispersion media, coatings, antibacterial and antifungal agents, isotonic and absorption delaying agents, and the like, compatible with pharmaceutical administration .
  • Suitable carriers are described in the latest edition of Remington's Pharmaceutical Sciences, a standard bibliography in the field, which is incorporated herein by reference.
  • Preferred examples of such carriers or diluents include, but are not limited to, water, saline, Ringer's solution, dextrose solution, and 5% human serum albumin.
  • Liposomes and non-aqueous vehicles, such as fixed oils, can also be used. The use of such media and agents for pharmaceutically active substances is well known in the art.
  • Formulations to be used for clinical in vivo administration must be sterile. This can be easily achieved by filtration through sterile membranes.
  • the compounds of the present invention can react with any of a variety of inorganic or organic acids to form pharmaceutically acceptable acid addition salts.
  • Pharmaceutically acceptable salts and common methods of preparing them are well known in the art. See, eg, Handbook of Pharmaceutical Salts: Properties, Selection and Use. Second Revised Edition (Wiley-VCH, 2011); SM Berge et al. "Pharmaceutical Salts", Journal of Pharmaceutical Sciences, Vol. 66, No. 1, 1 1977 moon.
  • Commonly used pharmaceutically acceptable salts include trifluoroacetate, acetate, citrate, hydrochloride, phosphate and the like.
  • the compounds of the present invention can react with one or more inorganic or organic bases to form pharmaceutically acceptable salts.
  • pharmaceutically acceptable salts include sodium salts, potassium salts, ammonium salts and the like.
  • compositions of the embodiments are formulated to be compatible with their intended route of administration.
  • routes of administration include parenteral, eg, intravenous, intradermal, subcutaneous, oral (eg, inhalation), transdermal (Ptopical), transmucosal, and rectal administration.
  • Solutions or suspensions for parenteral, intradermal or subcutaneous administration may include the following components: sterile injectable diluents such as water, saline solutions, fixed oils, polyethylene glycols, glycerol, propylene glycol or other synthetic solvents; Antibacterial agents such as benzyl alcohol, methylparaben, phenol or m-cresol; antioxidants such as ascorbic acid or sodium bisulfite; chelating agents such as ethylenediaminetetraacetic acid (EDTA); buffers such as ethyl acetate salts, citrates or phosphates, and agents to adjust osmotic pressure, such as sodium chloride or dextrose.
  • sterile injectable diluents such as water, saline solutions, fixed oils, polyethylene glycols, glycerol, propylene glycol or other synthetic solvents
  • Antibacterial agents such as benzyl alcohol, methylparaben, phenol or m-cresol
  • the pH can be adjusted with acids or bases, such as hydrochloric acid or sodium hydroxide.
  • the parenteral preparation can be packaged in ampoules, vials, disposable syringes, multiple dose vials made of glass or plastic, or injection pens.
  • injection pens There are two main types of injection pens, one is a one-time pre-filled pen, which contains medicines, no need to replace the medicine refill, and can be thrown away after use; the other is a more commonly used durable injection pen. It is composed of an injection pen and a drug refill, and the refill can be replaced after use.
  • the carrier can be a solvent or dispersion medium containing, for example, water, ethanol, polyol (for example, glycerol, propylene glycol, and liquid polyethylene glycol, and the like), and suitable mixtures thereof.
  • Proper fluidity can be maintained, for example, by the use of coatings such as lecithin to maintain the desired particle size in the case of dispersions, and by the use of surfactants.
  • Prevention of the action of microorganisms can be achieved by various antibacterial and antifungal agents such as parabens, chlorobutanol, phenol, m-cresol, ascorbic acid, thimerosal, and the like.
  • isotonic agents such as sugars, polyols (such as mannitol, sorbitol), sodium chloride in the composition.
  • Prolonged absorption of the injectable compositions can be brought about by including in the composition an agent which delays absorption, for example, aluminum monostearate and gelatin.
  • Sterile injectable solutions can be prepared by incorporating the compounds of this invention in the required amount in an appropriate solvent with one or a combination of ingredients enumerated above, as required, followed by filter sterilization.
  • dispersions are prepared by incorporating a compound of the present invention into a sterile vehicle that contains a dispersion medium and the required other ingredients from those enumerated above.
  • the methods of preparation are vacuum drying and freeze-drying to obtain a powder containing the active ingredient and any additional desired ingredient from a sterile-filtered solution of those previously enumerated. .
  • the compounds are delivered as an aerosol spray from a pressurized container or dispenser containing a gas of a suitable propellant, such as carbon dioxide, or a nebulizer.
  • a gas of a suitable propellant such as carbon dioxide, or a nebulizer.
  • Systemic administration can also be by transmucosal or transdermal means.
  • penetrants appropriate to the permeation barrier are used in the formulation.
  • penetrants are generally known in the art and include, for example, detergents, bile salts and fusidic acid derivatives for transmucosal administration.
  • Transmucosal administration can be accomplished through the use of nasal sprays or suppositories.
  • one or more of the compounds of the present invention may be formulated into an ointment, ointment, gel, or cream as generally known in the art.
  • the compounds can also be prepared for rectal delivery in the form of suppositories (eg, with conventional suppository bases such as cocoa butter or other glycerides) or retention enemas.
  • suppositories eg, with conventional suppository bases such as cocoa butter or other glycerides
  • retention enemas e.g., retention enemas.
  • the compounds of the present invention may be prepared with carriers that will protect them against rapid elimination from the body, such as sustained/controlled release formulations, including implants and microencapsulated delivery systems.
  • sustained/controlled release formulations including implants and microencapsulated delivery systems.
  • Biodegradable, biocompatible polymers can be used, such as ethylene vinyl acetate, polyanhydrides, polyglycolic acid, collagen, polyorthoesters, and polylactic acid. Methods for preparing such formulations will be apparent to those skilled in the art.
  • these active ingredients can be encapsulated in microcapsules prepared, for example, by coacervation techniques or by interfacial polymerization, such as in colloidal drug delivery systems (eg, liposomes, albumin microspheres, microemulsions, nanoparticles, and nanocapsules) or hydroxymethylcellulose or gelatin microcapsules and poly(methyl methacrylate) microcapsules in macroemulsions.
  • colloidal drug delivery systems eg, liposomes, albumin microspheres, microemulsions, nanoparticles, and nanocapsules
  • hydroxymethylcellulose or gelatin microcapsules hydroxymethylcellulose or gelatin microcapsules and poly(methyl methacrylate) microcapsules in macroemulsions.
  • Sustained release formulations can be prepared.
  • suitable sustained release formulations include semipermeable matrices of solid hydrophobic polymers containing the compounds of the present invention in the form of shaped articles such as films or microcapsules.
  • sustained-release matrices include polyesters, hydrogels (eg, poly(2-hydroxyethyl-methylpropionate), or poly(vinyl alcohol)), polylactides (US Pat. No.
  • Polylactic acid (PLA) and poly(lactic-co-glycolic acid) (PLGA) are the research hotspots in recent years.
  • albumin microspheres chitosan microspheres, gelatin microspheres, etc.
  • Liposomal suspensions can also be used as pharmaceutically acceptable carriers. These can be prepared according to methods known to those skilled in the art, for example as described in US Pat. No. 4,522,811.
  • Dosage unit form refers to physically discrete units suitable as unitary dosages for the subjects to be treated; each unit containing a predetermined quantity calculated to produce the desired therapeutic effect in association with the required pharmaceutical carrier one or more of said compounds of the invention.
  • the specifications for the dosage unit forms of the embodiments are indicated by and are directly dependent on the unique characteristics of the compounds of the present invention and the particular therapeutic effect to be achieved, and the limitations inherent in the art of formulation of such compounds of the present invention for the treatment of individuals sex.
  • the present invention provides a method for treating type 2 diabetes in a patient comprising administering to a patient in need of such treatment an effective amount of a compound of the present invention or a pharmaceutically acceptable salt thereof.
  • the present invention also provides a method for treating type 2 diabetes in a patient comprising administering to a patient in need of such treatment an effective amount of a compound of the present invention or a pharmaceutically acceptable salt thereof, wherein the administration is subcutaneous.
  • the present invention also provides a method of treating type 2 diabetes in a patient, comprising administering to a patient in need of such treatment an effective amount of a compound of the present invention, or a pharmaceutically acceptable salt thereof, and concurrently, separately, or sequentially administering the effective amount of one or more other active ingredients.
  • the other active ingredient(s) are currently available oral glucose-lowering drugs from a class of drugs that are considered standard of care prior to administration (such as those from the American Diabetes Association). Association) industry guidelines).
  • the present invention also provides methods of treating or preventing the following diseases or conditions: impaired glucose tolerance (IGT), hyperglycemia, type 1 diabetes, type 2 diabetes, obesity, metabolic syndrome and neurodegenerative diseases, particularly with For delaying or preventing disease progression in type 2 diabetes, delaying progression from impaired glucose tolerance to type 2 diabetes; delaying progression from type 2 diabetes to insulin-requiring diabetes; treating metabolic syndrome, for regulating appetite, inducing satiety Foot sensation, reduce food intake, increase energy expenditure, treat obesity or prevent overweight; prevent weight regain after successful weight loss; treat diseases or conditions associated with overweight or obesity; treat bulimia; treat binge eating; treat dyslipidemia , atherosclerosis, hypertension, coronary heart disease, ⁇ -blocker poisoning; non-alcoholic fatty liver disease (NAFLD, non-alcoholic fatty liver disease) (can be divided into simple fatty liver (SFL), non-alcoholic fatty liver disease Steatohepatitis (NASH) and its associated cirrhosis); for the inhibition of motility of the gastrointestinal tract, for use in conjunction
  • Further preferred medicinal uses include the treatment or prevention of degenerative diseases, especially neurodegenerative diseases such as Alzheimer's disease, Parkinson's disease, Huntington's disease s disease), ataxias (eg, spinocerebellar ataxia), Kennedy disease, myotonic dystrophy, Lewy body dementia, multi-system atrophy, Amyotrophic lateral sclerosis, primary lateral sclerosis, spinal muscular atrophy, prion-related diseases (eg, Creutzfeldt-Jacob disease), multiple sclerosis, telangiectasia, Baytown Batten disease, corticobasal degeneration, subacute combined degeneration of the spinal cord, tuberculosis, Tay-Sachs disease, toxic encephalopathy, infantile Lefsum disease Refsum disease, Refsum disease, neuroacanthocytosis, Niemann-Pick disease, Lyme disease, Machado-Joseph disease, Sander Sandhoff disease, Shy-Drager syndrome, wobbly hedgehog syndrome, prote
  • ACN acetonitrile: acetonitrile
  • BOP benzotriazol-1-yloxytris(dimethylamino)phosphonium hexafluorophosphate: benzotriazole-1-tris(trimethylamino)-hexafluorophosphate (Carter condensate);
  • DCC N,N'-Dicyclohexylcarbodiimide : dicyclohexylcarbodiimide; DCM: dichloromethane;
  • DEPBT 3-(Diethoxyphosphoryloxy)-1,2,3-benzotriazin-4(3H)-one: 3-(diethoxyphosphoryloxy) -1,2,3-Benzotriazin-4-one;
  • DIC N,N'-Diisopropylcarbodiimide: N,N'-diisopropylcarbodiimide
  • DIPEA or DIEA
  • diisopropylethylamine diisopropyl
  • the commonly used cleavage reagent is TFA.
  • TFA Trifluoroacetic acid:triisopropylsilane:1,2-ethanedithiol:water:benzene
  • Methyl sulfide cutting solution (10-25mL/g resin)
  • cover with lid cover with lid
  • 8-10 times the volume of glacial ether dropwise After 2 hours, filter the resin with suction, wash the resin 2-3 times with new TFA, combine the filtrates, and add 8-10 times the volume of glacial ether dropwise. Finally, the precipitated crude polypeptide was collected by centrifugation.
  • Boc-Cys(4-MeBzl)-OH Boc-Asp(OcHx)-OH, Boc-Glu(OcHx)-OH, Boc-His(Bom )-OH, Boc-Lys(2-Cl-Z)-OH, Boc-Asn(Xan)-OH, Boc-Arg(Tos)-OH, Boc-Ser(Bzl)-OH, Boc-Thr(Bzl) -OH, Boc-Trp(CHO)-OH and Boc-Tyr(2-Br-Z)-OH
  • the side chain amino group of lysine can be protected with allyloxycarbonyl (aloc) or Fmoc protection. If the side chain carboxyl group of aspartic acid or glutamic acid is used for lactam synthesis or acylation reaction, the carboxyl group should be converted to allyl ester or 9-fluorenyl methyl protection, such as Boc-Glu(OAllyl)-OH, Boc -Glu(Ofm)-OH.
  • HF is usually used to cut, add 5 ml of HF per 0.1 mmol of resin, and add reagents such as p-cresol, p-mercaptophenol or anisole at the same time, and the mixture is cooled in an ice bath. under stirring for 1 hour. After vacuum drying HF, the polypeptide was precipitated with ice ether, and the precipitate was collected by centrifugation, separated and purified by HPLC, and freeze-dried to obtain the final product.
  • reagents such as p-cresol, p-mercaptophenol or anisole
  • a ZORBAX 300 SB-C18 (4.6X250 mm, 5 ⁇ M) column was used, buffer A was 0.1% TFA in water and buffer B was 0.1% TFA in acetonitrile. Flow rate 1 ml/min, detection at 210 nm wavelength. The fractions containing the pure target peptide were pooled and lyophilized to obtain the peptide product in aliquots and stored in glass vials.
  • Some compounds of the present invention are conjugated with long-acting groups or modified groups through the side chain amino group or thiol group of an amino acid whose side chain contains an amino group or a thiol group.
  • Step A Coupling Lys(PG) and resin to obtain Lys(PG)-resin, PG is the protecting group of amino group of lysine side chain;
  • Step B Lys(PG)-resin is coupled with amino acids or amino acid derivatives step by step to obtain the first peptide resin whose sequence is shown in the main peptide chain of compound 27;
  • Step C Remove the side chain protecting group PG of Lys in the first peptide resin whose sequence is shown in the main peptide chain of compound 27, and then couple 2-(2-(2-aminoethoxy)ethoxy) step by step through the second step.
  • yl)acetic acid, 2-(2-(2-aminoethoxy)ethoxy)acetic acid, ⁇ -Glu and octadecanedioic acid to obtain a second peptide resin
  • the coupling agent used in the first stepwise coupling in step B and the second stepwise coupling in step C includes a condensing agent and a reaction solvent
  • the condensing agent can be a mixture of DIC and HOBt, a mixture of PyBOP, HOBt and DIEA, or The mixed solution of HATU, HOAt and DIEA, or the mixed solution of DEPBT and DIEA, or the mixed solution of HBTU and DIEA
  • the reaction solvent is one or more of DMF, DCM, NMP or DMSO.
  • the reagents used for the removal in step C are 1-20 equivalents of morpholine (or 1-20 equivalents of phenylsilane instead of morpholine) and 0.05-3 equivalents of Pd(PPh 3 ) 4 removal.
  • aloc protection group with 5-10 equivalents of morpholine (5-10 equivalents or alternative morpholin phenyl silane) and 0.1 to 0.3 equivalents of Pd (PPh 3) 4 removed.
  • the protecting group removal reaction can be carried out twice, each time for 10-30 minutes, preferably CH 2 Cl 2 is used as the solvent.
  • Another method to remove the Aloc protecting group is to use a catalytic amount of tetrakis(triphenylphosphine)palladium(0) and a 37:2:1 ratio of DCM, glacial acetic acid and NMM (15 mL/g resin) under argon atmosphere, Stir at room temperature for 2 hours. After reaction each gram resin was washed with 0.5% DIPEA/DMF (10 mL), 0.5% sodium diethyldithiocarbamate/DMF (3 ⁇ 10 mL), 1:1 DCM:DMF (5 ⁇ 10 mL).
  • the reagent used to remove the protecting group in step C is a hydrazine hydrate/DMF mixture.
  • a 2% (w/v) solution of hydrazine hydrate in DMF (25 mL/g resin) was prepared, added to the resin, drained after 5 minutes, and the resin was washed with DMF. The process of deprotection with 2% hydrazine hydrate/DMF and washing with DMF was repeated 3 times.
  • stepwise coupling of Fmoc-8-amino-3,6-dioxaoctanoic acid (CAS No. 166108-71-0), Fmoc-Glu-OtBu (CAS No. 166108-71-0) No. 84793-07-7) and mono-tert-butyl octadecanedioate HOOC-(CH2)16-COOtBu.
  • the reagents used in the cleavage in step D include TFA and one, two or more compounds selected from PhSMe, PhOMe, EDT, H 2 O, TIS, and PhOH.
  • the reagent used for cleavage is a mixture of TFA, anisole, methyl sulfide and EDT, and the volume ratio of TFA, anisole, methyl sulfide and EDT is 90:5:3:2.
  • the reagent used for lysis is a mixed solution of TFA, H 2 O and TIS, and the volume ratio is 95:2.5:2.5.
  • the present invention also includes novel intermediates and methods useful in the synthesis of the compounds of the present invention or pharmaceutically acceptable salts thereof.
  • the intermediates and compounds of the present invention can be prepared by a variety of methods known in the art. In particular, methods using chemical synthesis are exemplified in the examples below. The specific synthetic steps described for each route can be combined in various ways to prepare compounds of the invention or salts thereof. Reagents and starting materials are readily available to those of ordinary skill in the art.
  • Amino acid raw materials, condensation reagents, etc. were purchased from Gill Biochemical (Shanghai) Co., Ltd.
  • Rink Amide resin was purchased from Shangyu Poole Company and Tianjin Nankai Hecheng Technology Co., Ltd.
  • a pre-loaded low loading Fmoc-Lys(Aloc)-Rink Amide resin (eg 0.29 mmole/g) was chosen.
  • Each synthetic unit from the C-terminal to the N-terminal of the polypeptide adopts the coupling method of Example 1, and the amino acid residues other than the C-terminal lysine use the Fmoc solid-phase synthesis listed in the "polypeptide solid-phase chemical synthesis method" section. Commonly used the protecting group.
  • the C-terminal lysine side chain allyloxycarbonyl group can be removed with tetrakis(triphenylphosphine)palladium(0) and 37:2:1 ratio of DCM, glacial acetic acid and NMM (15mL/g resin) ) was stirred under argon atmosphere at room temperature for 2 hours. Tetrakis(triphenylphosphine)palladium(0) can be used in a catalytic amount to 1 equivalent. After reaction each gram resin was washed with 0.5% DIPEA/DMF (10 mL), 0.5% sodium diethyldithiocarbamate/DMF (3 ⁇ 10 mL), 1:1 DCM:DMF (5 ⁇ 10 mL).
  • Aloc protecting groups can also use 5-10 equivalents of morpholine (phenyl silane or 5-10 equivalents) and 0.1-0.3 equivalents of Pd (PPh 3) 4 removed.
  • the deprotection reaction can be carried out twice for 30 minutes each time, and CH 2 Cl 2 is selected as the solvent.
  • the synthesis of this lysine side chain substituent uses the building blocks Fmoc-8-amino-3,6-dioxoctanoic acid (CAS No.
  • Another method is to choose a preloaded low-load Fmoc-Lys(ivDde)-Rink Amide resin.
  • the synthesis method of the main peptide chain is the same as that in the previous paragraph using Fmoc-Lys(Aloc)-RinkAmide resin.
  • the C-terminal lysine side chain ivDde protecting group was removed with 2% hydrazine hydrate/DMF.
  • a 2% (w/v) solution of hydrazine hydrate in DMF 25 mL/g resin was prepared, added to the resin, drained after 5 minutes, and the resin was washed with DMF.
  • the C-terminus is lysine and the side chain amino group is connected to the long-acting group, such as compounds 4, 6, 11, 13, 14, 17, 21-23, 27-30, 220 and 221. Synthesized by the method of Example 3, or using the method for the synthesis of compound 27 in the "Preparation Methods" section.
  • Table 1 lists the calculated and measured molecular weights of some compounds of the present invention.
  • the polypeptide was dissolved in physiological saline (pH 7.4) to prepare a stock solution.
  • the polypeptide concentration in the stock solution was quantified by conventional methods such as Bradford method and UV spectrophotometric detection method.
  • PBS buffered physiological saline
  • a more suitable injection volume for each animal is 5ml/kg body weight. The volume of injection solution that needs to be prepared can be calculated from this.
  • the in vivo efficacy of the polypeptides of the invention can be determined in any suitable animal model known in the art as well as in clinical trials.
  • db/db mouse is a more suitable animal model of diabetes.
  • the db/db mice were kept in the animal house with strictly controlled environmental conditions, the temperature of the house was maintained at 20-24°C, and the humidity was maintained at 40-70%.
  • the temperature and humidity in the breeding room were monitored in real time by a thermo-hygrometer, and the temperature and humidity were recorded twice a day (once in the morning and once in the afternoon).
  • the lighting in the animal breeding room is controlled by an electronic timed light-on system, with the lights on for 12 hours a day and off for 12 hours (on at 7:00 am and off at 19:00 pm).
  • the animals were housed in single cages, and the mice in each cage were provided with toys. During the experiment, animals had free access to water.
  • mice (6 weeks old) were acclimated to the experimental environment for one week. Three days before the test (-3 days -1 day) Baseline blood glucose and body weight were recorded. Mice were randomized into groups of 6 based on three-day blood glucose and body weight. Mice were injected subcutaneously with normal saline (5 ml/kg, control group) or polypeptide compounds 1, 2, 8, 16, 18, 19, 24 and 36 (30 nmol/kg) at 10:00 am, 0 hours before administration and Blood was collected at 1, 2, 4, 6, 8, and 10 hours after administration, and blood glucose was detected using the Johnson & Johnson Wenhao blood glucose meter and supporting test strips. Taking the time as the abscissa and the blood glucose value at different time points as the ordinate, draw the blood glucose curve, calculate the area under the curve (AUC), and compare the time and effect of the hypoglycemic effect of the polypeptide compound.
  • AUC area under the curve
  • mice were the same as in Example 7.
  • db/db male mice (8 weeks old) were acclimated to the experimental environment for one week.
  • Three days before the test (-3 days -1 day) Baseline blood glucose and body weight were recorded.
  • Mice were randomized into groups of 6 based on three-day blood glucose and body weight. Mice were injected subcutaneously with normal saline (5ml/kg, control group) or polypeptide compounds 31, 35, 38, 44 and 49 (30nmol/kg) at 10:00 in the morning, 0 hours before administration and 1, 2 after administration , 4, 6, 8 and 10 hours to collect blood, and use Johnson &Johnson's Wenhao blood glucose meter and supporting test strips to detect blood sugar. Taking the time as the abscissa and the blood glucose values at different time points as the ordinate, the time-effect curve of the hypoglycemic effect was established, and the area under the curve (AUC) of the hypoglycemic effect was calculated.
  • AUC area under the curve
  • mice were the same as in Example 7. Three days before the test (-3 days -1 day) Baseline blood glucose and body weight were recorded in db/db male mice (6 weeks old). Mice were randomized into groups of 6 based on three-day blood glucose and body weight. At 18:00 on the day before the test (-1 day), the experimental animals were subcutaneously injected with normal saline (5 ml/kg, control group) or compounds 6, 13, 14 and 26 (3 nmol/kg). The animals were fasted for 6 hours (8:00-14:00) on the day of the experiment, and an intraperitoneal glucose tolerance test (IPGTT) was performed.
  • IPGTT intraperitoneal glucose tolerance test
  • the in vivo efficacy of the polypeptides of the invention can be determined in any suitable animal model known in the art as well as in clinical trials.
  • Diet-induced obesity (DIO) mice are animal models of obesity, insulin resistance, and hyperlipidemia.
  • 5-week-old male C57BL/6 mice were housed in an animal house with strictly controlled environmental conditions.
  • the temperature of the house was maintained at 20-24°C and the humidity was maintained at 30-70%.
  • the temperature and humidity in the breeding room were monitored in real time by a thermo-hygrometer, and the temperature and humidity were recorded twice a day (once in the morning and once in the afternoon).
  • the lighting in the animal breeding room is controlled by an electronic timed light-on system, with the lights on for 12 hours a day and off for 12 hours (on at 6:00 am and off at 18:00 pm).
  • the animals were housed in single cages, and the mice in each cage were provided with toys.
  • Animals were fed with high-fat diet from 6 weeks of age (the weight ratio of each nutrient component was protein 26.2%, carbohydrate 26.3%, fat 36.9%, and the percentages of calories provided were 20%, 20% and 60%, respectively). During the feeding process, the animals had free access to water. 25-week-old male DIO mice with an average weight of about 49 grams were selected for the experiment. Animals were acclimated to grasping and subcutaneous injection for 1 week. The body weight and food intake were measured 3 consecutive days before the experiment, and the blood glucose of the animals was measured 1 day before the experiment, and the animals were grouped according to their blood glucose and body weight, with 6 animals in each group.
  • mice in the control group and liraglutide group were subcutaneously injected with saline or liraglutide (100 nmol/kg) once a day.
  • the other 5 groups of animals were subcutaneously injected with polypeptides 4, 11, 17, 20 and 23 (25 nmol/kg) on days 1, 3, 5, 7, 9, 11, and 13, respectively.
  • the body weight and food intake of the animals were weighed daily. The percent change in body weight is [(final body weight - starting body weight)/starting body weight]*100%.
  • the fasting blood glucose level of the animals was detected by a blood glucose meter one day before the start of the experiment and on the 15th day.
  • the fasting time of animals was from 9:00 am to 15:00 pm, and the detection time was 15:00 pm.
  • TG triglyceride
  • TC cholesterol
  • Biochemical indicators were analyzed using a Hitachi series automatic biochemical analyzer (HITACHI 7180). In addition, animal livers were collected, and liver triglycerides and cholesterol were measured.
  • db/db male mice (Jiangsu JiCui Yaokang Biotechnology, 6 weeks old) were kept in the animal breeding room with strictly controlled environmental conditions after arriving at the facility.
  • the temperature in the breeding room was maintained at 20-24 °C and the humidity was maintained at 40-70% .
  • the temperature and humidity in the breeding room were monitored in real time by a thermo-hygrometer, and the temperature and humidity were recorded twice a day (once in the morning and once in the afternoon).
  • the lighting in the animal breeding room is controlled by an electronic timed light-on system, with the lights on for 12 hours a day and off for 12 hours (on at 7:00 am and off at 19:00 pm).
  • the animals were housed in single cages, and the mice in each cage were provided with toys.
  • mice had free access to water. Animals were acclimated for two weeks. Three days before the test (-3 days -1 day) Fasting blood glucose was measured at 15:00 after the animals were fasted for 6 hours at 9:00 in the morning. Mice were randomized into groups of 6 based on three-day fasting blood glucose and body weight. The goal of the test was to measure the ability of the compounds to reduce fasting blood sugar in mice. Animals were fasted from 9:00 am to 21:00 pm during the experiment.
  • mice On the first day of the experiment, mice were pre-fasted for 6 hours ((9:00-15:00), and then subcutaneously injected with normal saline (5 ml/kg) or compounds 21, 22, 27, 28, 29 and 30 (5 nmol/kg) , blood was collected at 0 hours before administration and 1, 3, 6, 24, 30, and 48 hours after administration, and blood glucose was detected using Johnson &Johnson's Wenhao blood glucose meter and supporting test strips. The blood glucose value is on the ordinate, and the time-effect curve of the hypoglycemic effect is established.
  • compounds 21, 22, 27, 28, 29 and 30 can significantly reduce the blood glucose of db/db mice, and there is a statistically significant difference with the control group. These compounds have potential as long-acting diabetes treatments.
  • three pairs of compounds 21 and 22, 27 and 28, 29 and 30 showed that when the C-terminal lysine side chain of the compound was connected to a long-acting group, the deletion of the ortho-serine significantly improved the efficacy of the compound, resulting in unexpected Effect.
  • mice The feeding conditions of db/db mice were the same as in Example 7.
  • db/db male mice (Jiangsu JiCui Yaokang Biotechnology, 7 weeks old) were acclimated to the experimental environment for one week. Three days before the test (-3 days -1 day) Baseline blood glucose and body weight were recorded. Mice were randomized into groups of 6 based on three-day blood glucose and body weight. Mice were injected subcutaneously with normal saline (5ml/kg, control group) or polypeptide compounds 42, 115, 178 (35nmol/kg) at 10:00 in the morning, 0 hours before administration and 1.5, 4, 7, 10 after administration Blood was collected every hour, and blood glucose was detected using the Johnson & Johnson Wenhao blood glucose meter and supporting test strips. Taking the time as the abscissa and the blood glucose values at different time points as the ordinate, draw the blood glucose curve, calculate the area under the curve (AUC), and compare the time and effect of the hypoglycemic effect of the poly
  • the DIO obese mouse experiment was completed by Shanghai WuXi AppTec New Drug Development Co., Ltd.
  • Male C57BL/6 mice were fed a high-fat diet (Cat. No. D12492i, Research Diets, Inc) for 25 weeks starting at 5 weeks of age. Animals were acclimated to grasping and subcutaneous injection for 1 week at 30 weeks of age. The body weight and food intake were weighed for 3 consecutive days before the experiment, and the fasting blood glucose of the animals was measured 1 day before the experiment, and the animals with excessive blood sugar were removed, and the animals were grouped according to their random blood sugar and body weight (with body weight as the main reference index), with 5 animals in each group .
  • the animals were subcutaneously injected with physiological saline, compound 27 and compound 29 (3 nmol/kg) once a day by group, and the administration period was 10 days. During the experiment, the body weight and food intake of the animals were measured every day. After the experiment, the animals were fasted for 6 hours, euthanized, and the animals were dissected, blood was collected from the heart, and centrifuged into plasma for the detection of biochemical levels.
  • the body weight of the animals in the administration group was significantly decreased compared with the control group.
  • the body weight of the animals in the administration group was significantly decreased compared with the control group.
  • P ⁇ 0.0001 the body weight of the animals in the administration group
  • LDL-C low-density lipoprotein cholesterol
  • the DIO obese mouse experiment was completed by Shanghai WuXi AppTec New Drug Development Co., Ltd. Animal feeding conditions were the same as in Example 13. Animals were acclimated to grasping and subcutaneous injection for 1 week at 40 weeks of age. The body weight and food intake were measured for 3 consecutive days before the experiment, and the fasting blood sugar of the animals was measured 1 day before the experiment, and the animals with excessive blood sugar were excluded, and the animals were grouped according to their random blood sugar and body weight (with body weight as the main reference index), with an average body weight of 47 grams , 6 in each group.
  • the animals were subcutaneously injected with physiological saline once a day or each animal was subcutaneously injected with 1.5 nmole compound 35 or compound 40, and the dosing cycle was 14 days.
  • the body fat content of the animals was detected by the EchoMRI body fat meter.
  • Figure 13 shows the results of changes in the amount of adipose tissue and lean muscle tissue before the start of the DIO obese mouse experiment (day 0) and after the end of the experiment (day 15).
  • the amount of adipose tissue of the animals in the administration group decreased significantly, and there was a statistically significant difference with the control group, but the amount of lean muscle tissue remained basically unchanged, indicating that compound 35 and compound 40 can lose weight in an ideal way.
  • Disodium hydrogen phosphate system prepare a phosphate solution with a pH value ranging from 6.2 to 8.5, add APIs to investigate the solubility, and the test results in solutions with different pH values show that: with the increase of pH value, the solubility of compound 27 increases significantly.
  • pH ⁇ 6.5 the solubility is lower than 1mg/ml, and when pH>6.5, the solubility and dissolution rate are greatly improved, and the concentration can reach 2mg/ml or even higher. Therefore, the disodium hydrogen phosphate system with pH>6.5 is suitable to be formulated into the target concentration water injection of the API.
  • Acetate system when the pH is greater than 6.5, the solubility and dissolution rate of the API are relatively low.
  • the solution of the API is prepared according to the concentration of 1 mg/ml, and the dissolution time is more than 30 minutes, which is not suitable for scale-up production, and it should be placed under refrigeration conditions. Drug precipitation was found when the physical stability was investigated. When pH ⁇ 6.5, dissolution is difficult.
  • the phosphate solution of compound 27 bulk drug was prepared, the concentration of compound 27 was 1 mg/ml, and each milliliter contained: 20 mg of glycerol, 5.5 mg of phenol, 2.86 mg of disodium hydrogen phosphate (dodecahydrate) and water for injection.
  • the pH was adjusted with 1N hydrochloric acid or aqueous sodium hydroxide. Under the conditions of room temperature (25-30°C) and refrigerated (2-8°C), they were placed for different time respectively for investigation. The specific results are shown in Table 2.
  • the pH value of the injection is generally not higher than 8.5, preferably not higher than 8.2.
  • Compound 220 formulation formulations are shown in Tables 7-9.
  • Compound 221 formulation formulations are shown in Tables 10 and 11.
  • the standard substance is diluted with water for injection into solutions of different concentrations, and the above-mentioned HPLC operation method is used for detection. Different concentrations of the standard substance obtain different peak areas, and then use Excel software to make a standard curve to obtain the calculation formula.
  • the preparation samples were placed under accelerated conditions (25°C ⁇ 2°C, 60% ⁇ 5%) for 6 months, and samples were taken at the end of the first, third, and sixth months for inspection (Table 13).
  • injections of prescription 1 to prescription 7 are all within the compliance range within 6 months under long-term conditions, and the injections of prescription 1 are within the compliance range within 6 months under accelerated conditions of 25°C. within the range.
  • mice were the same as in Example 7.
  • db/db male mice (8 weeks old) were acclimated to the experimental environment for one week.
  • Baseline blood glucose and body weight were recorded three days before the experiment, and mice were randomly divided into 4 groups of 8 mice based on the three-day blood glucose and body weight.
  • Mice were subcutaneously injected with blank injection every 72 hours (each milliliter contained: disodium hydrogen phosphate (dodecahydrate) 2.0 mg, glycerol 18.0 mg, phenol 5.0 mg, sterile water for injection 974.4 mg; control group) or polypeptide compound 27 , 220, 221 (8nmol/kg, respectively according to prescription 2, prescription 3 and prescription 6 to prepare preparations), repeated administration 10 times.

Abstract

涉及多肽化学领域，具体而言涉及一种多肽化合物及其在医疗中的用途。

Description

新型多肽制剂及其治疗用途 技术领域
本发明涉及一种多肽化合物制剂及其在医疗中的用途。
发明背景
代谢综合征是多种医学病症的组合，会增加发生2型糖尿病、动脉粥样硬化性血管疾病、心脏病和中风的风险。定义代谢综合征的医学参数包括糖尿病、葡萄糖耐量降低、空腹血糖升高、胰岛素抵抗、中心性肥胖、高血压、总胆固醇和甘油三酯升高、低密度胆固醇升高和高密度胆固醇降低。糖尿病包括一型糖尿病、二型糖尿病、妊娠糖尿病等。根据世界卫生组织(WHO)的数据，发达国家糖尿病患病率为5％～10％，到2030年，全世界糖尿病患者人数将比2000年翻一番。全球糖尿病未诊断人数超过50％，而且糖尿病前期的人数甚至要多于糖尿病人数。例如，中国糖尿病人数达到1.14亿，另外还有5亿人糖耐量低下、糖调节功能受损，即将成为糖尿病患者。超过半数的患者不知道自己已经得病。糖尿病的巨大危害主要在于严重的并发症和高死亡率。资料显示，糖尿病是造成下肢截肢和成人新发失明的首要病因。
肥胖是一种医学疾病，体内多余的脂肪积聚可能对健康和预期寿命产生不利影响，并且由于其在成人和儿童中的流行程度越来越高，它已经成为现代可预防的死亡原因之一。它增加了各种其它疾病，包括心脏病、2型糖尿病、阻塞性睡眠呼吸暂停、某些类型的癌症，以及骨关节炎的可能性，它通常是由多余的食物摄入量、减少的能量消耗以及遗传易感性等综合导致。在身体质量指数(BMI)相同的情况下，亚洲人比白种人的内脏脂肪含量更高，因此亚洲人比白种人存在更严重的胰岛素抵抗，亚洲体重正常的2型糖尿病患者比非糖尿病患者胰岛素敏感性显著下降。多余脂肪导致胰岛素抵抗和β细胞受损，破坏血糖调节功能。肥胖相关的多种代谢异常显著增加了心血管疾病的风险。根据临床统计，70％以上的2型糖尿病患者患病的原因是体重超标。因此，减轻糖尿病患者的体重和体脂量，是有效控制甚至逆转糖尿病发展的一个重要途径。现有小分子减肥药副作用都非常大。胰高血糖素样肽-1(GLP-1)受体激动剂类药物可以通过促进胰岛素分泌、提高胰岛素敏感度、减少胰高血糖素的释放达到控制血糖的效果。因此，GLP-1类药物适于代谢类疾病治疗，尤其是糖尿病治疗。GLP-1受体激动剂艾塞那肽、利拉鲁肽等都在动物试验和临床上显示出降低体重的效果，副作用相对较少。利拉鲁肽已经在美国被批准用于糖尿病和肥胖症治疗，成为唯一一个可以用于这两个病症的药物。
但是，现有GLP-1类药物都有胃肠道反应大的副作用。这些副作用影响了患者的用药依从度，减小了药品使用量和用户群。根据GLP-1受体的生理学机理，GLP-1药物在减肥方面作用缓慢，临床治疗肥胖症时需要使用高于糖尿病治疗的大剂量，导致胃肠道反应大的副作用更加突出。多数患者体重减轻平均不超过5％，而且停药以后体重反弹明显。
因此，对于能够降低血糖，同时降低血脂和体内脂肪含量，减轻体重的药物存在临床需求。
糖尿病患者发生心血管疾病的风险较高，因此，糖尿病患者需要严格控制血脂指标。临床研究表明，长期使用他汀类药物可能会增加使用者得糖尿病的风险。他汀类和贝特类降脂药物副作用明显，而且都有不耐受人群。非酒精性脂肪肝目前尚无疗效理想的治疗药物。本发明的多肽化合物不仅可以降血糖，而且可以显著降低甘油三脂和总胆固醇，尤其是低密度胆固醇(LDL)，有望同时解决“三高”中高血糖、高血脂两个问题，预计对使用者的心血管健康有明显益处。本发明的多肽比他汀类药物更适合糖尿病患者或糖尿病前期人群。本发明的多肽可以为这些疾病治疗提供新的选择。本发明的多肽适用于脂代谢异常引起的多种疾病，包括高脂血症、非酒精性脂肪肝等。本发明的多肽还可以用于高血压、动脉硬化、冠心病、外周动脉疾病、中风等疾病或者这些疾病的任何组合。
糖尿病患者大多数为中老年人，需要服用多种药物。这必然牵涉到药物之间的兼容和匹配。除药物交叉反应和多种药物可能导致更多的毒副作用之外，不同药物有效时间不同，服用频率不同，也给患者增加困扰。因此，本发明的多肽不仅有利于增强疗效，降低毒副作用，而且方便患者，从而改善治疗效果。
本发明的多肽也可以像GLP-1类药物一样用于糖尿病治疗。由于这些多肽降低体重和体脂量，改善胰岛素抵抗，所以不但降糖疗效优异，对于糖尿病患者中很高比例的由于体重超标而患病的病人应该有特效。人群中很多体重超标或者肥胖的人虽然没有在医学上被定性为糖尿病人，但出现葡萄糖耐受不良、餐后血糖过度升高等糖尿病前期症状，本发明的多肽也适合糖尿病前期人群。
发明内容
在一方面，本发明涉及一种药物制剂，所述药物制剂包含式(VII)的肽化合物或其药学上可接受的盐或溶剂合物，
Y-aib-E-G-T-F-X11-S-D-X1-S-X12-X2-L-X3-X4-E-A-X5-X6-X13-F-X7-X8-W-L-X9-A-G-X10(VII)
其中，X1代表选自L或Y的氨基酸，X2代表选自Q、A、aib或Y的氨基酸，X3代表选自D或E的氨基酸，X4代表选自E或K的氨基酸，X5代表选自V或A的氨基酸，X6代表选自K、R或Q的氨基酸，X7代表选自I或V的氨基酸，X8代表选自E、Q、N或A的氨基酸，X9代表选自I或L的氨基酸，X10代表不存在或GPSSGAPPP，GPPSGAPPP，GPSSGKPPP，GPSSGEPPP，GPSSaibAPPP，GPSSGAPP，GPSSGAP，GPSSGA，GPSSG，GPSS，GPS，GP，G；X11代表T或I的氨基酸；X12代表I、S或K的氨基酸；X13代表L、E或D的氨基酸；
任选地，在X10的C端添加一个或两个选自S或者侧链含有氨基或者巯基的氨基酸，并且C末端氨基酸的羧基任选地被酰胺化为C末端酰胺，所述氨基酸具有式
Figure PCTCN2021104822-appb-000001
其中波浪线代表连接至相邻基团的连接点，n1为1-7的整数，当II或III为C末端氨基酸时，其羧基部分是COOH或CONH 2，优选地，含有侧链氨基的氨基酸是赖氨酸，含有侧链巯基的氨基酸是半胱氨酸，
任选地，X10的C端添加的含有侧链氨基的氨基酸在其侧链氨基被长效基团修饰，优选地，所述长效基团具有式(IV)的结构：
O1-O2-O3-O4-O5-O6-O7-O8-(IV)，
其中O1代表式(V)或(VI)的结构：
Figure PCTCN2021104822-appb-000002
其中n2为6-24的整数，优选10-24，进一步优选16-22；
其中波浪线代表连接至相邻基团的氨基的连接点，O2-O3-O4-O5-O6-O7-O8-代表连接体，其中O2至O8中的每一个独立地由以下氨基酸残基或长链结构中的任一个表示：α-Glu、γ-Glu、α-Asp、β-Asp、α-hGlu、δ-hGlu、Gly、Ala、β-Ala、GABA或PEG2，或者O2至O8中的一个或多个不存在，条件是O2至O8中至少有两个存在，优选地，O2至O8中含有至少一个带负电荷的部分。
在一方面，本发明涉及一种本发明涉及一种药物制剂，其包含式(I)的肽化合物，或其盐或溶剂合物，以及药学上可接受的载体或赋形剂。
Y-aib-E-G-T-F-T-S-D-X1-S-I-X2-L-X3-X4-E-A-X5-X6-L-F-X7-X8-W-L-X9-A-G-X10(I)
其中，X1代表选自L或Y的氨基酸，X2代表选自Q、A、aib或Y的氨基酸，X3代表选自D或E的氨基酸，X4代表选自E或K的氨基酸，X5代表选自V或A的氨基酸，X6代表选自K或R的氨基酸，X7代表选自I或V的氨基酸，X8代表选自E、A、Q或N的氨基酸，X9 代表选自I或L的氨基酸，X10代表不存在或GPSSGAPPP，GPPSGAPPP，GPSSGKPPP，GPSSGEPPP，GPSSaibAPPP，GPSSGAPP，GPSSGAP，GPSSGA，GPSSG，GPSS，GPS，GP，G；
任选地，在X10的C端添加一个或两个选自S或者侧链含有氨基或者巯基的氨基酸，并且C末端氨基酸的羧基任选地被酰胺化为C末端酰胺，所述氨基酸具有式
Figure PCTCN2021104822-appb-000003
其中波浪线代表连接至相邻基团的连接点，n1为1-7的整数；当II或III为C末端氨基酸时，其羧基部分是COOH或CONH 2；
任选地，在X10的C端添加的含有侧链氨基的氨基酸在其侧链氨基被长效基团修饰，优选地，所述长效基团具有式(IV)的结构：
O1-O2-O3-O4-O5-O6-O7-O8-(IV)，
其中O1代表式(V)或(VI)的结构：
Figure PCTCN2021104822-appb-000004
其中n2为6-24的整数，优选10-24，进一步优选16-22；
其中波浪线代表连接至相邻基团的氨基的连接点，O2-O3-O4-O5-O6-O7-O8-代表连接体，其中O2至O8中的每一个独立地由以下氨基酸残基或长链结构中的任一个表示：α-Glu、γ-Glu、α-Asp、β-Asp、α-hGlu、δ-hGlu、Gly、Ala、β-Ala、GABA或PEG2，或者O2至O8中的一个或多个不存在，条件是O2至O8中至少有两个存在，优选地，O2至O8中含有至少一个带负电荷的部分。
根据前述任一方面的药物制剂，其中O2-O3-O4-O5-O6-O7-O8-代表选自下组的连接体γGlu-PEG2-γGlu-、γGlu-PEG2-2×γGlu-、γGlu-PEG2-、γGlu-2×PEG2-、γGlu-3×PEG2-、γGlu-PEG2-γGlu-PEG2-、γGlu-2×PEG2-γGlu-、γGlu-2×PEG2-2×γGlu-、2×γGlu-、2×γGlu-PEG2-、2×γGlu-PEG2-γGlu-、2×γGlu-PEG2-γGlu-PEG2-、2×γGlu-2×PEG2-、2×γGlu-2×PEG2-γGlu-、2×γGlu-2×PEG2-2×γGlu-。
根据前述任一方面的药物制剂，在一些实施方案中，其中O2-O3-O4-O5-O6-O7-O8-代表选自下组的连接体γGlu-PEG2-、γGlu-2×PEG2-、γGlu-3×PEG2-，O1代表式(V)或(VI)的结构。
根据前述任一方面的药物制剂，在一些实施方案中，其中O2-O3-O4-O5-O6-O7-O8-代表选自下组的连接体γGlu-PEG2-、γGlu-2×PEG2-、γGlu-3×PEG2-，O1代表式(V)的结构。
根据前述任一方面的药物制剂，在一些实施方案中，其中O2-O3-O4-O5-O6-O7-O8-代表选自下组的连接体γGlu-2×PEG2-、γGlu-3×PEG2-，O1代表式(V)的结构。
根据前述任一方面的药物制剂，在一些实施方案中，其中O2-O3-O4-O5-O6-O7-O8-代表连接体γGlu-2×PEG2-，O1代表式(V)的结构。
根据前述任一方面的药物制剂，在一些实施方案中，其中O2-O3-O4-O5-O6-O7-O8-代表连接体γGlu-2×PEG2-，O1代表式(V)的结构，其中n2为16-22的整数；
任选地，根据前述任一方面的药物制剂，其中赖氨酸侧链氨基缀合长效基团，具有式(VIII)或式(IX)的结构：
Figure PCTCN2021104822-appb-000005
其中波浪线代表连接至相邻氨基酸残基的连接点。
任选地，X10的C端添加的含有侧链巯基的氨基酸在其侧链巯基被式(IV)的长效基团修饰，任选地，在C端氨基酸的侧链巯基和长效基团之间可以根据需要添加能够与巯基反应生成共价键的反应基团。
在一些实施方案中，含有侧链巯基的氨基酸的侧链巯基与长效基团之间的连接关系是：含有侧链巯基的氨基酸的侧链巯基-巯基反应基团-可选的连接基团L-长效基团。
在一些实施方案中，所述含有侧链巯基的氨基酸的侧链巯基通过与迈克尔反应受体(例如马来酰亚胺或乙烯基砜)或硫醇反应性基团(例如碘乙酸或溴乙酸)反应后与连接基团L一端连接，优选地，所述连接基团L另一端进一步与式IV的长效基团形成共价键连接。
在一些实施方式中，所述连接基团L是-(CH 2) n3-和-(CH 2CH 2O) n4-根据结构需要排列组合，通过共价键连接在一起形成的长链；或者-(CH 2) n3-、-(CH 2CH 2O) n4-的一端或者两端任选地包含氨基或羧基，通过酰胺键连接在一起形成的长链，例如，所述连接基团L选自-NH-(CH 2) n5-(CH 2CH 2O) n6-(CH 2) n7-，-NH-(CH 2) n5-(CH 2CH 2O) n6-(CH 2) n7-NH-，-NH-(CH 2) n5-(CH 2CH 2O) n6-(CH 2) n7-CO-，-NH-(CH 2) n5-(CH 2CH 2O) n6-(CH 2) n7-NHCO-(CH 2) n8-，-NH-(CH 2) n5-(CH 2CH 2O) n6-(CH 2) n7-NHCO-(CH 2) n8-NH-或其任意组合，其中n3、n4、n5、n6、n7、n8各自是0至10的整数，例如0、1、2、3、4、5、6、7、8、9、10。
在一些实施方式中，L是-NH-CH 2-(CH 2CH 2O) 3-(CH 2) 3-NH-。
在一些实施方式中，迈克尔反应受体或硫醇反应性基团与连接基团L连接的非限制性说明性实例包括
Figure PCTCN2021104822-appb-000006
以上示例性迈克尔反应受体或硫醇反应性基团与含有侧链巯基的氨基酸的侧链巯基反应后的结构如下：
Figure PCTCN2021104822-appb-000007
Figure PCTCN2021104822-appb-000008
波浪线为与式(IV)的长效基团的连接点，例如，连接到O8上。*为含有侧链巯基的氨基酸的侧链巯基与氨基酸其它部分的连接点。
任选地，X10代表的多肽片段中的任何一个氨基酸可以被侧链含有氨基或者巯基的氨基酸取代，所述氨基酸具有式(II)或式(III)结构。任选地，含有侧链氨基的氨基酸在其侧链氨基被长效基团修饰，优选地，所述长效基团具有式(IV)的结构；任选地，含有侧链巯基的氨基酸在其侧链巯基被长效基团修饰，优选地，所述长效基团具有式(IV)的结构，任选地，侧链巯基和长效基团之间可以根据需要添加能够与巯基反应生成共价键的反应基团。
任选地，X10代表的多肽片段GPPSGAPPP，GPSSGKPPP，GPSSGEPPP，GPSSaibAPPP可以从片段C末端向片段N末端缩减1，2，3，4，5，6，7，8个氨基酸。
根据前述任一方面的药物制剂，在一些实施方案中，X1是L。根据前述任一方面的药物制剂，在一些实施方案中，X1是Y。根据前述任一方面的药物制剂，在一些实施方案中，X1是I。根据前述任一方面的药物制剂，在一些实施方案中，X1是V。
根据前述任一方面的药物制剂，在一些实施方案中，X2是Q。根据前述任一方面的药物制剂，在一些实施方案中，X2是Y。根据前述任一方面的药物制剂，在一些实施方案中，X2是A。根据前述任一方面的药物制剂，在一些实施方案中，X2是Aib。
根据前述任一方面的药物制剂，在一些实施方案中，X3是D。根据前述任一方面的药物制剂，在一些实施方案中，X3是E。
根据前述任一方面的药物制剂，在一些实施方案中，X4是E。根据前述任一方面的药物制剂，在一些实施方案中，X4是K。
根据前述任一方面的药物制剂，在一些实施方案中，X5是V。根据前述任一方面的药物制剂，在一些实施方案中，X5是A。
根据前述任一方面的药物制剂，在一些实施方案中，X6是K。根据前述任一方面的药物制剂，在一些实施方案中，X6是R。
根据前述任一方面的药物制剂，在一些实施方案中，X7是I。根据前述任一方面的药物制剂，在一些实施方案中，X7是V。
根据前述任一方面的药物制剂，在一些实施方案中，X8是E。根据前述任一方面的药物制剂，在一些实施方案中，X8是N。根据前述任一方面的药物制剂，在一些实施方案中，X8是Q。根据前述任一方面的药物制剂，在一些实施方案中，X8是A。
根据前述任一方面的药物制剂，在一些实施方案中，X9是I。根据前述任一方面的药物制剂，在一些实施方案中，X9是L。根据前述任一方面的药物制剂，在一些实施方案中，X9是Aib。根据前述任一方面的药物制剂，在一些实施方案中，X9是V。
根据前述任一方面的药物制剂，在一些实施方案中，X10不存在。根据前述任一方面的药物制剂，在一些实施方案中，X10是GPSSGAPPPSK。根据前述任一方面的药物制剂，在一些实施方案中，X10是GPSSGAPPPSC。根据前述任一方面的药物制剂，在一些实施方案中，X10是GPSSGAPPPS。根据前述任一方面的药物制剂，在一些实施方案中，X10是GPSSGAPPPK。根据前述任一方面的药物制剂，在一些实施方案中，X10是GPSSGAPPPC。根据前述任一方面的药物制剂，在一些实施方案中，X10是GPSSGAPPP。根据前述任一方面的药物制剂，在一些实施方案中，X10是GPSSGAPP。根据前述任一方面的药物制剂，在一些实施方案中，X10是GPSSGAP。根据前述任一方面的药物制剂，在一些实施方案中，X10是GPSSGA。根据前述任一方面的药物制剂，在一些实施方案中，X10是GPSSG。根据前述任一方面的药物制剂，在一些实施方案中，X10是GPSS。根据前述任一方面的药物制剂，在一些实施方案中，X10是GPS。根据前述任一方面的药物制剂，在一些实施方案中，X10是GP。根据前述任一方面的药物制剂，在一些实施方案中，X10是G。
根据前述任一方面的药物制剂，在一些实施方案中，X1是L，X10是GPSSGAPPPS。根据前述任一方面的药物制剂，在一些实施方案中，X1是L，X10是GPSSGAPPPK。根据前述任一方面的药物制剂，在一些实施方案中，X1是L，X10是GPSSGAPPPC。根据前述任一方面的药物制剂，在一些实施方案中，X1是L，X10是GPSSGAPPP。根据前述任一方面的药物制剂，在一些实施方案中，X1是L，X10是GPSSGAPP。根据前述任一方面的药物制剂，在一些实施方案中，X1是L，X10是GPSSGAP。根据前述任一方面的药物制剂，在一些实施方案中，X1是L，X10是GPSSGA。根据前述任一方面的药物制剂，在一些实施方案中，X1是L，X10是GPSSG。根据前述任一方面的药物制剂，在一些实施方案中，X1是L，X10是GPSS。根据前述任一方面的药物制剂，在一些实施方案中，X1是L，X10是GPS。根据前述任一方面的药物制剂，在一些实施方案中，X1是L，X10是GP。根据前述任一方面的药物制剂，在一些实施方案中，X1是L，X10是G。
根据前述任一方面的药物制剂，在一些实施方案中，X2是Q，X10是GPSSGAPPPS。
根据前述任一方面的药物制剂，在一些实施方案中，X2是Q，X10是GPSSGAPPPK。
根据前述任一方面的药物制剂，在一些实施方案中，X2是Q，X10是GPSSGAPPPC。
根据前述任一方面的药物制剂，在一些实施方案中，X2是A，X10是GPSSGAPPPS。
根据前述任一方面的药物制剂，在一些实施方案中，X2是A，X10是GPSSGAPPPK。
根据前述任一方面的药物制剂，在一些实施方案中，X2是A，X10是GPSSGAPPPC。
根据前述任一方面的药物制剂，在一些实施方案中，X2是aib，X10是GPSSGAPPPS。
根据前述任一方面的药物制剂，在一些实施方案中，X2是aib，X10是GPSSGAPPPK。
根据前述任一方面的药物制剂，在一些实施方案中，X2是aib，X10是GPSSGAPPPC。
根据前述任一方面的药物制剂，在一些实施方案中，X2是Q，X10是GPSSGAPPP。根据前述任一方面的药物制剂，在一些实施方案中，X2是Q，X10是GPSSGAPP。根据前述任一方面的药物制剂，在一些实施方案中，X2是Q，X10是GPSSGAP。根据前述任一方面的药物制剂，在一些实施方案中，X2是Q，X10是GPSSGA。根据前述任一方面的药物制剂，在一些实施方案中，X2是Q，X10是GPSSG。根据前述任一方面的药物制剂，在一些实施方案中，X2是Q，X10是GPSS。根据前述任一方面的药物制剂，在一些实施方案中，X2是Q，X10是GPS。根据前述任一方面的药物制剂，在一些实施方案中，X2是Q，X10是GP。根据前述任一方面的药物制剂，在一些实施方案中，X2是Q，X10是G。
根据前述任一方面的药物制剂，在一些实施方案中，X2是A，X10是GPSSGAPPP。根据前述任一方面的药物制剂，在一些实施方案中，X2是A，X10是GPSSGAPP。根据前述任一方面的药物制剂，在一些实施方案中，X2是A，X10是GPSSGAP。根据前述任一方面的药物制剂，在一些实施方案中，X2是A，X10是GPSSGA。根据前述任一方面的药物制剂，在一些实施方案中，X2是A，X10是GPSSG。根据前述任一方面的药物制剂，在一些实施方案中，X2是A，X10是GPSS。根据前述任一方面的药物制剂，在一些实施方案中，X2是A，X10是GPS。根据前述任一方面的药物制剂，在一些实施方案中，X2是A，X10是GP。根据前述任一方面的药物制剂，在一些实施方案中，X2是A，X10是G。
根据前述任一方面的药物制剂，在一些实施方案中，X2是aib，X10是GPSSGAPPP。根据前述任一方面的药物制剂，在一些实施方案中，X2是aib，X10是GPSSGAPP。根据前述任一方面的药物制剂，在一些实施方案中，X2是aib，X10是GPSSGAP。根据前述任一方面的药物制剂，在一些实施方案中，X2是aib，X10是GPSSGA。根据前述任一方面的药物制剂，在一些实施方案中，X2是aib，X10是GPSSG。根据前述任一方面的药物制剂，在一些实施方案中，X2是aib，X10是GPSS。根据前述任一方面的药物制剂，在一些实施方案中，X2是aib，X10是GPS。根据前述任一方面的药物制剂，在一些实施方案中，X2是aib，X10是GP。根据前述任一方面的药物制剂，在一些实施方案中，X2是aib，X10是G。
根据前述任一方面的药物制剂，在一些实施方案中，X1是L，X2是Q。根据前述任一方面的药物制剂，在一些实施方案中，X1是L，X2是A。根据前述任一方面的药物制剂，在一些实施方案中，X1是L，X2是aib。
根据前述任一方面的药物制剂，在一些实施方案中，X1是L，X2是Q，X10是GPSSGAPPPS。根据前述任一方面的药物制剂，在一些实施方案中，X1是L，X2是Q，X10是GPSSGAPPPK。根据前述任一方面的药物制剂，在一些实施方案中，X1是L，X2是Q，X10是GPSSGAPPPC。根据前述任一方面的药物制剂，在一些实施方案中，X1是L，X2是Q，X10是GPSSGAPPP。根据前述任一方面的药物制剂，在一些实施方案中，X1是L，X2是Q，X10是GPSSGAPP。根据前述任一方面的药物制剂，在一些实施方案中，X1是L，X2是Q，X10是GPSSGAP。根据前述任一方面的药物制剂，在一些实施方案中，X1是L，X2是Q，X10是GPSSGA。根据前述任一方面的药物制剂，在一些实施方案中，X1是L，X2是Q，X10是GPSSG。根据前述任一方面的药物制剂，在一些实施方案中，X1是L，X2是Q，X10是GPSS。根据前述任一方面的药物制剂，在一些实施方案中，X1是L，X2是Q，X10是GPS。根据前述任一方面的药物制剂，在一些实施方案中，X1是L，X2是Q，X10是GP。根据前述任一方面的药物制剂，在一些实施方案中，X1是L，X2是Q，X10是G。
根据前述任一方面的药物制剂，在一些实施方案中，X1是L，X2是A，X10是GPSSGAPPPS。根据前述任一方面的药物制剂，在一些实施方案中，X1是L，X2是A，X10是GPSSGAPPPK。根据前述任一方面的药物制剂，在一些实施方案中，X1是L，X2是A，X10是GPSSGAPPPC。根据前述任一方面的药物制剂，在一些实施方案中，X1是L，X2是A，X10是GPSSGAPPP。根据前述任一方面的药物制剂，在一些实施方案中，X1是L，X2是A，X10是GPSSGAPP。根据前述任一方面的药物制剂，在一些实施方案中，X1是L，X2是A，X10是GPSSGAP。根据前述任一方面的药物制剂，在一些实施方案中，X1是L，X2是A，X10是GPSSGA。根据前述任一方面的药物制剂，在一些实施方案中，X1是L，X2是A，X10是GPSSG。根据前述任一方面的药物制剂，在一些实施方案中，X1是L，X2是A，X10是GPSS。根据前述任一方面的药物制剂，在一些实施方案中，X1是L，X2是A，X10是GPS。根据前述任一方面的药物制剂，在一些实施方案中，X1是L，X2是A，X10是GP。根据前述任一方面的药物制剂，在一些实施方案中，X1是L，X2是A，X10是G。
根据前述任一方面的药物制剂，在一些实施方案中，X1是L，X2是aib，X10是GPSSGAPPPS。根据前述任一方面的药物制剂，在一些实施方案中，X1是L，X2是aib，X10是GPSSGAPPPK。根据前述任一方面的药物制剂，在一些实施方案中，X1是L，X2是aib，X10是GPSSGAPPPC。根据前述任一方面的药物制剂，在一些实施方案中，X1是L，X2是aib，X10是GPSSGAPPP。根据前述任一方面的药物制剂，在一些实施方案中，X1是L，X2是aib，X10是GPSSGAPP。根据前述任一方面的药物制剂，在一些实施方案中，X1是L，X2是aib，X10是GPSSGAP。根据前述任一方面的药物制剂，在一些实施方案中，X1是L，X2是aib，X10是GPSSGA。根据前述任一方面的药物制剂，在一些实施方案中，X1是L，X2是aib，X10是GPSSG。根据前述任一方面的药物制剂，在一些实施方案中，X1是L，X2是aib，X10是GPSS。根据前述任一方面的药物制剂，在一些实施方案中，X1是L，X2是aib，X10是GPS。根据前述任一方面的药物制剂，在一些实施方案中，X1是L，X2是aib，X10是GP。根据前述任一方面的药物制剂，在一些实施方案中，X1是L，X2是aib，X10是G。
根据前述任一方面的药物制剂，在一些实施方案中，X1是L，X2是Q，X5是V，X10是GPSSGAPPPS。根据前述任一方面的药物制剂，在一些实施方案中，X1是L，X2是Q，X5是V，X10是GPSSGAPPPK。根据前述任一方面的药物制剂，在一些实施方案中，X1是L，X2是Q，X5是V，X10是GPSSGAPPPC。
根据前述任一方面的药物制剂，在一些实施方案中，X1是L，X2是A，X5是V，X10是GPSSGAPPPS。根据前述任一方面的药物制剂，在一些实施方案中，X1是L，X2是A，X5是V，X10是GPSSGAPPPK。根据前述任一方面的药物制剂，在一些实施方案中，X1是L，X2是A，X5是V，X10是GPSSGAPPPC。
根据前述任一方面的药物制剂，在一些实施方案中，X1是L，X2是aib，X5是V，X10是GPSSGAPPPS。根据前述任一方面的药物制剂，在一些实施方案中，X1是L，X2是aib，X5 是V，X10是GPSSGAPPPK。根据前述任一方面的药物制剂，在一些实施方案中，X1是L，X2是aib，X5是V，X10是GPSSGAPPPC。
根据前述任一方面的药物制剂，在一些实施方案中，X1是L，X2是Q，X3是E，X5是V，X10是GPSSGAPPPS。根据前述任一方面的药物制剂，在一些实施方案中，X1是L，X2是Q，X3是E，X5是V，X10是GPSSGAPPPK。根据前述任一方面的药物制剂，在一些实施方案中，X1是L，X2是Q，X3是E，X5是V，X10是GPSSGAPPPC。
根据前述任一方面的药物制剂，在一些实施方案中，X1是L，X2是A，X3是E，X5是V，X10是GPSSGAPPPS。根据前述任一方面的药物制剂，在一些实施方案中，X1是L，X2是A，X3是E，X5是V，X10是GPSSGAPPPK。根据前述任一方面的药物制剂，在一些实施方案中，X1是L，X2是A，X3是E，X5是V，X10是GPSSGAPPPC。
根据前述任一方面的药物制剂，在一些实施方案中，X1是L，X2是aib，X3是E，X5是V，X10是GPSSGAPPPS。根据前述任一方面的药物制剂，在一些实施方案中，X1是L，X2是aib，X3是E，X5是V，X10是GPSSGAPPPK。根据前述任一方面的药物制剂，在一些实施方案中，X1是L，X2是aib，X3是E，X5是V，X10是GPSSGAPPPC。
根据前述任一方面的药物制剂，在一些实施方案中，X1是L，X2是Q，X3是E，X4是K，X5是V，X10是GPSSGAPPPS。根据前述任一方面的药物制剂，在一些实施方案中，X1是L，X2是Q，X3是E，X4是K，X5是V，X10是GPSSGAPPPK。根据前述任一方面的药物制剂，在一些实施方案中，X1是L，X2是Q，X3是E，X4是K，X5是V，X10是GPSSGAPPPC。
根据前述任一方面的药物制剂，在一些实施方案中，X1是L，X2是A，X3是E，X4是K，X5是V，X10是GPSSGAPPPS。根据前述任一方面的药物制剂，在一些实施方案中，X1是L，X2是A，X3是E，X4是K，X5是V，X10是GPSSGAPPPK。根据前述任一方面的药物制剂，在一些实施方案中，X1是L，X2是A，X3是E，X4是K，X5是V，X10是GPSSGAPPPC。
根据前述任一方面的药物制剂，在一些实施方案中，X1是L，X2是aib，X3是E，X4是K，X5是V，X10是GPSSGAPPPS。根据前述任一方面的药物制剂，在一些实施方案中，X1是L，X2是aib，X3是E，X4是K，X5是V，X10是GPSSGAPPPK。根据前述任一方面的药物制剂，在一些实施方案中，X1是L，X2是aib，X3是E，X4是K，X5是V，X10是GPSSGAPPPC。
根据前述任一方面的药物制剂，在一些实施方案中，X1是L，X2是Q，X3是E，X4是K，X5是V，X7是I，X10是GPSSGAPPPS。根据前述任一方面的药物制剂，在一些实施方案中，X1是L，X2是Q，X3是E，X4是K，X5是V，X7是I，X10是GPSSGAPPPK。根据前述任一方面的药物制剂，在一些实施方案中，X1是L，X2是Q，X3是E，X4是K，X5是V，X7是I，X10是GPSSGAPPPC。
根据前述任一方面的药物制剂，在一些实施方案中，X1是L，X2是A，X3是E，X4是K，X5是V，X7是I，X10是GPSSGAPPPS。根据前述任一方面的药物制剂，在一些实施方案中，X1是L，X2是A，X3是E，X4是K，X5是V，X7是I，X10是GPSSGAPPPK。根据前述任一方面的药物制剂，在一些实施方案中，X1是L，X2是A，X3是E，X4是K，X5是V，X7是I，X10是GPSSGAPPPC。
根据前述任一方面的药物制剂，在一些实施方案中，X1是L，X2是aib，X3是E，X4是K，X5是V，X7是I，X10是GPSSGAPPPS。根据前述任一方面的药物制剂，在一些实施方案中，X1是L，X2是aib，X3是E，X4是K，X5是V，X7是I，X10是GPSSGAPPPK。根据前述任一方面的药物制剂，在一些实施方案中，X1是L，X2是aib，X3是E，X4是K，X5是V，X7是I，X10是GPSSGAPPPC。
根据前述任一方面的药物制剂，在一些实施方案中，X2是A，X5是V。
根据前述任一方面的药物制剂，在一些实施方案中，X2是aib，X5是V。
根据前述任一方面的药物制剂，在一些实施方案中，X1是L，X2是A，X5是V。
根据前述任一方面的药物制剂，在一些实施方案中，X1是L，X2是aib，X5是V。
根据前述任一方面的药物制剂，在一些实施方案中，X1是L，X2是A，X3是E，X5是V。根据前述任一方面的药物制剂，在一些实施方案中，X1是L，X2是aib，X3是E，X5是V。
根据前述任一方面的药物制剂，在一些实施方案中，X1是L，X2是A，X3是E，X4是K，X5是V。根据前述任一方面的药物制剂，在一些实施方案中，X1是L，X2是aib，X3是E，X4是K，X5是V。
根据前述任一方面的药物制剂，在一些实施方案中，X1是L，X2是A，X3是E，X4是K，X5是V，X7是I。根据前述任一方面的药物制剂，在一些实施方案中，X1是L，X2是aib，X3是E，X4是K，X5是V，X7是I。
根据前述任一方面的药物制剂，在一些实施方案中，X2是Q，X9是L。根据前述任一方面的药物制剂，在一些实施方案中，X2是Q，X9是L，X10是GPSSGAPPPS。根据前述任一方面的药物制剂，在一些实施方案中，X2是Q，X9是L，X10是GPSSGAPPPK。根据前述任一方面的药物制剂，在一些实施方案中，X2是Q，X9是L，X10是GPSSGAPPPC。
根据前述任一方面的药物制剂，在一些实施方案中，X2是A，X9是L。根据前述任一方面的药物制剂，在一些实施方案中，X2是A，X9是L，X10是GPSSGAPPPS。根据前述任一方面的药物制剂，在一些实施方案中，X2是A，X9是L，X10是GPSSGAPPPK。根据前述任一方面的药物制剂，在一些实施方案中，X2是A，X9是L，X10是GPSSGAPPPC。
根据前述任一方面的药物制剂，在一些实施方案中，X2是aib，X9是L。根据前述任一方面的药物制剂，在一些实施方案中，X2是aib，X9是L，X10是GPSSGAPPPS。根据前述任一方面的药物制剂，在一些实施方案中，X2是aib，X9是L，X10是GPSSGAPPPK。根据前述任一方面的药物制剂，在一些实施方案中，X2是aib，X9是L，X10是GPSSGAPPPC。
根据前述任一方面的药物制剂，在一些实施方案中，X1是L，X2是Q，X9是L，X10是GPSSGAPPPS。根据前述任一方面的药物制剂，在一些实施方案中，X1是L，X2是Q，X9是L，X10是GPSSGAPPPK。根据前述任一方面的药物制剂，在一些实施方案中，X1是L，X2是Q，X9是L，X10是GPSSGAPPPC。
根据前述任一方面的药物制剂，在一些实施方案中，X1是L，X2是A，X9是L，X10是GPSSGAPPPS。根据前述任一方面的药物制剂，在一些实施方案中，X1是L，X2是A，X9是L，X10是GPSSGAPPPK。根据前述任一方面的药物制剂，在一些实施方案中，X1是L，X2是A，X9是L，X10是GPSSGAPPPC。
根据前述任一方面的药物制剂，在一些实施方案中，X1是L，X2是aib，X9是L，X10是GPSSGAPPPS。根据前述任一方面的药物制剂，在一些实施方案中，X1是L，X2是aib，X9是L，X10是GPSSGAPPPK。根据前述任一方面的药物制剂，在一些实施方案中，X1是L，X2是aib，X9是L，X10是GPSSGAPPPC。
根据前述任一方面的药物制剂，在一些实施方案中，X1是L，X2是Q，X5是V，X9是L，X10是GPSSGAPPPS。根据前述任一方面的药物制剂，在一些实施方案中，X1是L，X2是Q，X5是V，X9是L，X10是GPSSGAPPPK。根据前述任一方面的药物制剂，在一些实施方案中，X1是L，X2是Q，X5是V，X9是L，X10是GPSSGAPPPC。
根据前述任一方面的药物制剂，在一些实施方案中，X1是L，X2是A，X5是V，X9是L，X10是GPSSGAPPPS。根据前述任一方面的药物制剂，在一些实施方案中，X1是L，X2是A，X5是V，X9是L，X10是GPSSGAPPPK。根据前述任一方面的药物制剂，在一些实施方案中，X1是L，X2是A，X5是V，X9是L，X10是GPSSGAPPPC。
根据前述任一方面的药物制剂，在一些实施方案中，X1是L，X2是aib，X5是V，X9是L，X10是GPSSGAPPPS。根据前述任一方面的药物制剂，在一些实施方案中，X1是L，X2是aib，X5是V，X9是L，X10是GPSSGAPPPK。根据前述任一方面的药物制剂，在一些实施方案中，X1是L，X2是aib，X5是V，X9是L，X10是GPSSGAPPPC。
根据前述任一方面的药物制剂，在一些实施方案中，X1是L，X2是Q，X3是E，X5是V，X9是L，X10是GPSSGAPPPS。根据前述任一方面的药物制剂，在一些实施方案中，X1是L，X2是Q，X3是E，X5是V，X9是L，X10是GPSSGAPPPK。根据前述任一方面的药物制剂，在一些实施方案中，X1是L，X2是Q，X3是E，X5是V，X9是L，X10是GPSSGAPPPC。
根据前述任一方面的药物制剂，在一些实施方案中，X1是L，X2是A，X3是E，X5是V，X9是L，X10是GPSSGAPPPS。根据前述任一方面的药物制剂，在一些实施方案中，X1是L，X2是A，X3是E，X5是V，X9是L，X10是GPSSGAPPPK。根据前述任一方面的药物制剂，在一些实施方案中，X1是L，X2是A，X3是E，X5是V，X9是L，X10是GPSSGAPPPC。
根据前述任一方面的药物制剂，在一些实施方案中，X1是L，X2是aib，X3是E，X5是V，X9是L，X10是GPSSGAPPPS。根据前述任一方面的药物制剂，在一些实施方案中，X1是L，X2是aib，X3是E，X5是V，X9是L，X10是GPSSGAPPPK。根据前述任一方面的药物制剂，在一些实施方案中，X1是L，X2是aib，X3是E，X5是V，X9是L，X10是GPSSGAPPPC。
根据前述任一方面的药物制剂，在一些实施方案中，X1是L，X2是Q，X3是E，X4是K，X5是V，X9是L，X10是GPSSGAPPPS。根据前述任一方面的药物制剂，在一些实施方案中，X1是L，X2是Q，X3是E，X4是K，X5是V，X9是L，X10是GPSSGAPPPK。根据前述任一方面的药物制剂，在一些实施方案中，X1是L，X2是Q，X3是E，X4是K，X5是V，X9是L，X10是GPSSGAPPPC。
根据前述任一方面的药物制剂，在一些实施方案中，X1是L，X2是A，X3是E，X4是K，X5是V，X9是L，X10是GPSSGAPPPS。根据前述任一方面的药物制剂，在一些实施方案中，X1是L，X2是A，X3是E，X4是K，X5是V，X9是L，X10是GPSSGAPPPK。根据前述任一方面的药物制剂，在一些实施方案中，X1是L，X2是A，X3是E，X4是K，X5是V，X9是L，X10是GPSSGAPPPC。
根据前述任一方面的药物制剂，在一些实施方案中，X1是L，X2是aib，X3是E，X4是K，X5是V，X9是L，X10是GPSSGAPPPS。根据前述任一方面的药物制剂，在一些实施方案中，X1是L，X2是aib，X3是E，X4是K，X5是V，X9是L，X10是GPSSGAPPPK。根据前述任一方面的药物制剂，在一些实施方案中，X1是L，X2是aib，X3是E，X4是K，X5是V，X9是L，X10是GPSSGAPPPC。
根据前述任一方面的药物制剂，在一些实施方案中，X1是L，X2是Q，X3是E，X4是K，X5是V，X7是I，X9是L，X10是GPSSGAPPPS。根据前述任一方面的药物制剂，在一些实施方案中，X1是L，X2是Q，X3是E，X4是K，X5是V，X7是I，X9是L，X10是GPSSGAPPPK。根据前述任一方面的药物制剂，在一些实施方案中，X1是L，X2是Q，X3是E，X4是K，X5是V，X7是I，X9是L，X10是GPSSGAPPPC。
根据前述任一方面的药物制剂，在一些实施方案中，X1是L，X2是A，X3是E，X4是K，X5是V，X7是I，X9是L，X10是GPSSGAPPPS。根据前述任一方面的药物制剂，在一些实施方案中，X1是L，X2是A，X3是E，X4是K，X5是V，X7是I，X9是L，X10是GPSSGAPPPK。根据前述任一方面的药物制剂，在一些实施方案中，X1是L，X2是A，X3是E，X4是K，X5是V，X7是I，X9是L，X10是GPSSGAPPPC。
根据前述任一方面的药物制剂，在一些实施方案中，X1是L，X2是aib，X3是E，X4是K，X5是V，X7是I，X9是L，X10是GPSSGAPPPS。根据前述任一方面的药物制剂，在一些实施方案中，X1是L，X2是aib，X3是E，X4是K，X5是V，X7是I，X9是L，X10是GPSSGAPPPK。根据前述任一方面的药物制剂，在一些实施方案中，X1是L，X2是aib，X3是E，X4是K，X5是V，X7是I，X9是L，X10是GPSSGAPPPC。
根据前述任一方面的药物制剂，在一些实施方案中，X1是L，X2是Q，X3是E，X4是K，X5是V，X7是V，X9是L，X10是GPSSGAPPPS。根据前述任一方面的药物制剂，在一 些实施方案中，X1是L，X2是Q，X3是E，X4是K，X5是V，X7是V，X9是L，X10是GPSSGAPPPK。根据前述任一方面的药物制剂，在一些实施方案中，X1是L，X2是Q，X3是E，X4是K，X5是V，X7是V，X9是L，X10是GPSSGAPPPC。
根据前述任一方面的药物制剂，在一些实施方案中，X1是L，X2是A，X3是E，X4是K，X5是V，X7是V，X9是L，X10是GPSSGAPPPS。根据前述任一方面的药物制剂，在一些实施方案中，X1是L，X2是A，X3是E，X4是K，X5是V，X7是V，X9是L，X10是GPSSGAPPPK。根据前述任一方面的药物制剂，在一些实施方案中，X1是L，X2是A，X3是E，X4是K，X5是V，X7是V，X9是L，X10是GPSSGAPPPC。
根据前述任一方面的药物制剂，在一些实施方案中，X1是L，X2是aib，X3是E，X4是K，X5是V，X7是I，X9是L，X10是GPSSGAPPPS。根据前述任一方面的药物制剂，在一些实施方案中，X1是L，X2是aib，X3是E，X4是K，X5是V，X7是V，X9是L，X10是GPSSGAPPPK。根据前述任一方面的药物制剂，在一些实施方案中，X1是L，X2是aib，X3是E，X4是K，X5是V，X7是V，X9是L，X10是GPSSGAPPPC。
根据前述任一方面的药物制剂，在一些实施方案中，X3是E，X10是GPSSGAPPPK。根据前述任一方面的药物制剂，在一些实施方案中，X1是L，X3是E，X10是GPSSGAPPPK。根据前述任一方面的药物制剂，在一些实施方案中，X1是L，X3是E，X9是L，X10是GPSSGAPPPK。根据前述任一方面的药物制剂，在一些实施方案中，X1是L，X3是E，X5是V，X9是L，X10是GPSSGAPPPK。根据前述任一方面的药物制剂，在一些实施方案中，X1是L，X3是E，X4是K，X5是V，X9是L，X10是GPSSGAPPPK。根据前述任一方面的药物制剂，在一些实施方案中，X1是L，X3是E，X4是K，X5是V，X7是I，X9是L，X10是GPSSGAPPPK。根据前述任一方面的药物制剂，在一些实施方案中，X1是L，X3是E，X4是K，X5是V，X7是I，X8是E，X9是L，X10是GPSSGAPPPK。根据前述任一方面的药物制剂，在一些实施方案中，X1是L，X3是E，X4是K，X5是V，X6是R，X7是I，X8是E，X9是L，X10是GPSSGAPPPK。根据前述任一方面的药物制剂，在一些实施方案中，X1是L，X3是E，X4是K，X5是V，X6是R，X7是I，X8是E，X9是L，X10是GPSSGAPPPK，其中X10的C末端赖氨酸侧链氨基缀合长效基团。优选地，X10的C末端赖氨酸侧链氨基缀合长效基团具有式(VIII)或式(IX)的结构。根据前述任一方面的药物制剂，在一些实施方案中，X1是L，X2是A或aib，X3是E，X4是K，X5是V，X6是R，X7是I，X8是E，X9是L，X10是GPSSGAPPPK。优选地，X10的C末端赖氨酸侧链氨基缀合长效基团。更优选地，X10的C末端赖氨酸侧链氨基缀合长效基团具有式(VIII)或式(IX)的结构。根据前述任一方面的药物制剂，在一些实施方案中，X1是L，X2是A，X3是E，X4是K，X5是V，X6是R，X7是I，X8是E，X9是L，X10是GPSSGAPPPK。优选地，X10的C末端赖氨酸侧链氨基缀合长效基团。
根据前述任一方面的药物制剂，在一些实施方案中，X1是Y，X2是Q。根据前述任一方面的药物制剂，在一些实施方案中，X1是Y，X2是A。根据前述任一方面的药物制剂，在一些实施方案中，X1是Y，X2是Aib。根据前述任一方面的药物制剂，在一些实施方案中，X1是Y，X2是Y。
根据前述任一方面的药物制剂，在一些实施方案中，X4是K，X9是L。根据前述任一方面的药物制剂，在一些实施方案中，X1是Y，X4是K，X9是L。根据前述任一方面的药物制剂，在一些实施方案中，X1是Y，X2是Y，X4是K，X9是L。根据前述任一方面的药物制剂，在一些实施方案中，X1是Y，X2是Y，X4是K，X5是V，X9是L。根据前述任一方面的药物制剂，在一些实施方案中，X1是Y，X2是Y，X3是E，X4是K，X5是V，X9是L。根据前述任一方面的药物制剂，在一些实施方案中，X1是Y，X2是Y，X3是E，X4是K，X5是V，X7是V，X9是L。根据前述任一方面的药物制剂，在一些实施方案中，X1是Y，X2是Y，X3是E，X4是K，X5是V，X7是V，X8是N，X9是L。根据前述任一方面的药物制剂，在一些实施方案中，X1是Y，X2是Y，X3是E，X4是K，X5是V，X7是V，X8 是N，X9是I。根据前述任一方面的药物制剂，在一些实施方案中，X1是Y，X2是Y，X3是E，X4是K，X5是V，X7是I，X8是E，X9是L。
根据前述任一方面的药物制剂，在一些实施方案中，X1是L，X9是I。根据前述任一方面的药物制剂，在一些实施方案中，X1是L，X9是L。根据前述任一方面的药物制剂，在一些实施方案中，X1是L，X2是Q，X9是L。根据前述任一方面的药物制剂，在一些实施方案中，X1是L，X2是Q，X5是V，X9是L。根据前述任一方面的药物制剂，在一些实施方案中，X1是L，X2是Q，X3是E，X5是V，X9是L。根据前述任一方面的药物制剂，在一些实施方案中，X1是L，X2是Q，X3是E，X4是K，X5是V，X9是L。根据前述任一方面的药物制剂，在一些实施方案中，X1是L，X2是Q，X3是E，X4是K，X5是V，X7是I，X8是E，X9是L。
根据前述任一方面的药物制剂，在一些实施方案中，X1是L，X2是A。根据前述任一方面的药物制剂，在一些实施方案中，X1是L，X2是A，X9是L。根据前述任一方面的药物制剂，在一些实施方案中，X1是L，X2是A，X5是V，X9是L。根据前述任一方面的药物制剂，在一些实施方案中，X1是L，X2是A，X3是E，X5是V，X9是L。根据前述任一方面的药物制剂，在一些实施方案中，X1是L，X2是A，X3是E，X4是K，X5是V，X9是L。根据前述任一方面的药物制剂，在一些实施方案中，X1是L，X2是A，X3是E，X4是K，X5是V，X7是I，X8是E，X9是L。
根据前述任一方面的药物制剂，在一些实施方案中，X1是L，X2是aib。根据前述任一方面的药物制剂，在一些实施方案中，X1是L，X2是aib，X9是L。根据前述任一方面的药物制剂，在一些实施方案中，X1是L，X2是aib，X5是V，X9是L。根据前述任一方面的药物制剂，在一些实施方案中，X1是L，X2是aib，X3是E，X5是V，X9是L。根据前述任一方面的药物制剂，在一些实施方案中，X1是L，X2是aib，X3是E，X4是K，X5是V，X9是L。根据前述任一方面的药物制剂，在一些实施方案中，X1是L，X2是aib，X3是E，X4是K，X5是V，X7是I，X8是E，X9是L。
根据前述任一方面的药物制剂，在一些实施方案中，X1是L，X2是Y。根据前述任一方面的药物制剂，在一些实施方案中，X1是L，X2是Y，X5是V。根据前述任一方面的药物制剂，在一些实施方案中，X1是L，X2是Y，X3是E，X5是V。根据前述任一方面的药物制剂，在一些实施方案中，X1是L，X2是Y，X3是E，X4是K，X5是V。
根据前述任一方面的药物制剂，其中所述肽化合物选自：
化合物1.Y(aib)EGTFTSDYSIYLDEEAVRLFVNWLIAGGPSSGAPPPS-NH 2
化合物2.Y(aib)EGTFTSDYSIYLDEEAVKLFVNWLIAGGPSSGAPPPS-NH 2
化合物3.Y(aib)EGTFTSDYSIYLDEEAVKLFVQWLIAGGPSSGAPPPS-NH 2
化合物4.
Figure PCTCN2021104822-appb-000009
化合物5.Y(aib)EGTFTSDYSIYLDEEAVRLFVNWLIAGGPSSGAPPPSC-NH 2
化合物6.
Figure PCTCN2021104822-appb-000010
化合物7.Y(aib)EGTFTSDYSIYLDEEAVKLFVNWLIAG-NH 2
化合物8.Y(aib)EGTFTSDYSIYLEKEAVRLFVNWLIAGGPSSGAPPPS-NH 2
化合物9.Y(aib)EGTFTSDYSIYLEKEAVKLFVNWLIAGGPSSGAPPPS-NH 2
化合物10.Y(aib)EGTFTSDYSIYLEKEAAKLFVNWLIAGGPSSGAPPPS-NH 2
化合物11.
Figure PCTCN2021104822-appb-000011
化合物12.Y(aib)EGTFTSDYSIYLEKEAVKLFVNWLIAGGPSSGAPPPK-NH 2
化合物13.
Figure PCTCN2021104822-appb-000012
化合物14.
Figure PCTCN2021104822-appb-000013
化合物15.Y(aib)EGTFTSDYSIYLEKEAVRLFVNWLLAG-NH 2
化合物16.Y(aib)EGTFTSDYSIYLEKEAVRLFIEWLIAGGPSSGAPPPS-NH 2
化合物17.
Figure PCTCN2021104822-appb-000014
化合物18.Y(aib)EGTFTSDLSIQLEKEAARLFIEWLLAGGPSSGAPPPS-NH 2
化合物19.Y(aib)EGTFTSDLSIQLEKEAVRLFIEWLLAGGPSSGAPPPS-NH 2
化合物20.
Figure PCTCN2021104822-appb-000015
化合物21.
Figure PCTCN2021104822-appb-000016
化合物22.
Figure PCTCN2021104822-appb-000017
化合物23.
Figure PCTCN2021104822-appb-000018
化合物24.Y(aib)EGTFTSDLSIQLEKEAVKLFIEWLLAGGPSSGAPPPS-NH 2化合物25.Y(aib)EGTFTSDLSIQLEKEAVRLFIEWLLAG-NH 2
化合物26.
Figure PCTCN2021104822-appb-000019
化合物27.
Figure PCTCN2021104822-appb-000020
化合物28.
Figure PCTCN2021104822-appb-000021
化合物29
Figure PCTCN2021104822-appb-000022
化合物30
Figure PCTCN2021104822-appb-000023
化合物31.Y(aib)EGTFTSDLSIALEKEAVRLFIEWLLAGGPSSGAPPPS-NH 2
化合物32.Y(aib)EGTFTSDLSIALEKEAVRLFIEWLLAGGPSSGAPPPSC-NH 2
化合物33.Y(aib)EGTFTSDLSIALEKEAVRLFIEWLLAGGPSSGAPPPC-NH 2
化合物34.Y(aib)EGTFTSDLSIALEKEAVRLFIEWLLAGGPSSGAPPPSK-NH 2
化合物35.Y(aib)EGTFTSDLSIALEKEAVRLFIEWLLAGGPSSGAPPPK-NH 2
化合物36.Y(aib)EGTFTSDLSI(aib)LEKEAVRLFIEWLLAGGPSSGAPPPS-NH 2
化合物37.Y(aib)EGTFTSDLSI(aib)LEKEAVRLFIEWLLAGGPSSGAPPPSC-NH 2
化合物38.Y(aib)EGTFTSDLSI(aib)LEKEAVRLFIEWLLAGGPSSGAPPPC-NH 2
化合物39.Y(aib)EGTFTSDLSI(aib)LEKEAVRLFIEWLLAGGPSSGAPPPSK-NH 2
化合物40.Y(aib)EGTFTSDLSI(aib)LEKEAVRLFIEWLLAGGPSSGAPPPK-NH2
化合物41.Y(aib)EGTFTSDLSIALEKEAVRLFIEWLLAG-NH 2
化合物42.Y(aib)EGTFTSDLSI(aib)LEKEAVRLFIEWLLAG-NH 2
化合物43.Y(aib)EGTFTSDLSIALEKEAVKLFIEWLLAGGPSSGAPPPS-NH 2
化合物44.Y(aib)EGTFTSDLSIALEKEAVKLFIEWLLAGGPSSGAPPPK-NH 2
化合物45.Y(aib)EGTFTSDLSIALEKEAVKLFIEWLLAGGPSSGAPPPSK-NH 2
化合物46.Y(aib)EGTFTSDLSIALEKEAVKLFIEWLLAGGPSSGAPPPSC-NH 2
化合物47.Y(aib)EGTFTSDLSIALEKEAVKLFIEWLLAGGPSSGAPPPC-NH 2
化合物48.Y(aib)EGTFTSDLSI(aib)LEKEAVKLFIEWLLAGGPSSGAPPPS-NH 2
化合物49.Y(aib)EGTFTSDLSI(aib)LEKEAVKLFIEWLLAGGPSSGAPPPK-NH 2
化合物50.Y(aib)EGTFTSDLSI(aib)LEKEAVKLFIEWLLAGGPSSGAPPPSK-NH 2
化合物51.Y(aib)EGTFTSDLSI(aib)LEKEAVKLFIEWLLAGGPSSGAPPPC-NH 2
化合物52.Y(aib)EGTFTSDLSI(aib)LEKEAVKLFIEWLLAGGPSSGAPPPSC-NH 2
化合物53.Y(aib)EGTFTSDLSIQLEKEAVRLFVNWLLAGGPSSGAPPPS-NH 2
化合物54.Y(aib)EGTFTSDLSIALEKEAVRLFVNWLLAGGPSSGAPPPK-NH 2
化合物55.Y(aib)EGTFTSDLSI(aib)LEKEAVRLFVNWLLAGGPSSGAPPPC-NH 2
化合物56.Y(aib)EGTFTSDLSI(aib)LEKEAVRLFVNWLLAGGPSSGAPPPK-NH 2
化合物57.Y(aib)EGTFTSDYSIYLDEEAVRLFIEWLIAGGPSSGAPPPK-NH 2
化合物58.Y(aib)EGTFTSDLSIQLEKEAVRLFVNWLLAGGPSSGAPPPS-NH 2
化合物59.Y(aib)EGTFTSDLSIALEKEAVRLFVNWLLAGGPSSGAPPPS-NH 2
化合物60.Y(aib)EGTFTSDLSI(aib)LEKEAVRLFVNWLLAGGPSSGAPPPS-NH 2
化合物61.Y(aib)EGTFTSDYSIYLDEEAVRLFIEWLIAGGPSSGAPPPS-NH 2
化合物62Y(aib)EGTFTSDLSIQLEKEAVRLFIEWLLAGGPSSGAPPPSC-NH 2
化合物63Y(aib)EGTFTSDLSIQLEKEAVRLFIEWLLAGGPSSGAPPPC-NH 2
化合物64Y(aib)EGTFTSDLSIQLEKEAVRLFIEWLLAGGPSSGAPPPSK-NH 2
化合物65Y(aib)EGTFTSDLSIQLEKEAVRLFIEWLLAGGPSSGAPPPK-NH 2
化合物66Y(aib)EGTFTSDLSIQLEKEAVKLFIEWLLAGGPSSGAPPPSC-NH 2
化合物67Y(aib)EGTFTSDLSIQLEKEAVKLFIEWLLAGGPSSGAPPPC-NH 2
化合物68Y(aib)EGTFTSDLSIQLEKEAVKLFIEWLLAGGPSSGAPPPSK-NH 2
化合物69Y(aib)EGTFTSDLSIQLEKEAVKLFIEWLLAGGPSSGAPPPK-NH 2
化合物70.Y(aib)EGTFTSDYSIYLDEEAVRLFVNWLIAGGPSSGAPPPSK-NH 2
化合物71.Y(aib)EGTFTSDYSIYLDEEAVKLFVNWLIAGGPSSGAPPPSK-NH 2
化合物72.Y(aib)EGTFTSDYSIYLDEEAVRLFVNWLIAGGPSSGAPPPK-NH 2
化合物73.Y(aib)EGTFTSDYSIYLDEEAVKLFVNWLIAGGPSSGAPPPK-NH 2
化合物74.Y(aib)EGTFTSDYSIYLDEEAVKLFVNWLIAGGPSSGAPPPSC-NH 2
化合物75.Y(aib)EGTFTSDYSIYLDEEAVRLFVNWLIAGGPSSGAPPPC-NH 2
化合物76.Y(aib)EGTFTSDYSIYLDEEAVKLFVNWLIAGGPSSGAPPPC-NH 2
化合物77.Y(aib)EGTFTSDYSIYLEKEAVRLFVNWLIAGGPSSGAPPPSK-NH 2
化合物78.Y(aib)EGTFTSDYSIYLEKEAVKLFVNWLIAGGPSSGAPPPSK-NH 2
化合物79.Y(aib)EGTFTSDYSIYLEKEAVRLFVNWLIAGGPSSGAPPPK-NH 2
化合物80.Y(aib)EGTFTSDYSIYLEKEAVRLFVNWLIAGGPSSGAPPPSC-NH 2
化合物81.Y(aib)EGTFTSDYSIYLEKEAVKLFVNWLIAGGPSSGAPPPSC-NH 2
化合物82.Y(aib)EGTFTSDYSIYLEKEAVRLFVNWLIAGGPSSGAPPPC-NH 2
化合物83.Y(aib)EGTFTSDYSIYLEKEAVKLFVNWLIAGGPSSGAPPPC-NH 2
化合物84.Y(aib)EGTFTSDYSIYLEKEAVRLFIEWLIAGGPSSGAPPPSK-NH 2
化合物85.Y(aib)EGTFTSDYSIYLEKEAVRLFIEWLIAGGPSSGAPPPK-NH 2
化合物86.Y(aib)EGTFTSDYSIYLEKEAVRLFIEWLIAGGPSSGAPPPSC-NH 2
化合物87.Y(aib)EGTFTSDYSIYLEKEAVRLFIEWLIAGGPSSGAPPPC-NH 2
化合物88.Y(aib)EGTFTSDYSIYLEKEAVRLFIEWLIAG-NH 2
化合物89.Y(aib)EGTFTSDLSIQLEKEAVRLFVNWLLAG-NH 2
化合物90.Y(aib)EGTFTSDLSIALEKEAVRLFVNWLLAG-NH 2
化合物91.Y(aib)EGTFTSDLSI(aib)LEKEAVRLFVNWLLAG-NH 2
化合物92.Y(aib)EGTFTSDLSIQLEKEAVRLFIEWLLAGGPSSGA-NH 2
化合物93.Y(aib)EGTFTSDYSIYLDEEAVRLFIEWLIAGGPSSGAPPPS-NH 2
化合物94.Y(aib)EGTFTSDLSI(aib)LEKEAVRLFIEWLLAGGPSSGAP-NH 2
化合物95.Y(aib)EGTFTSDYSIYLEKEAVRLFIEWLIAGGPSSGAPP-NH 2
化合物96.Y(aib)EGTFTSDYSIYLDEEAVRLFVNWLIAGGPSSGAPP-NH 2
化合物97.Y(aib)EGTFTSDYSIYLEKEAVKLFVNWLIAGGPSSGAP-NH 2
化合物98.Y(aib)EGTFTSDYSIYLEKEAVRLFIAWLLAGGPSSGAPPPS-NH 2
化合物99.Y(aib)EGTFTSDYSIYLDEEAVRLFVNWLIAGG-NH 2
化合物100.Y(aib)EGTFTSDYSIYLEKEAVRLFIEWLIAGGPSSGAP-NH 2
化合物101.Y(aib)EGTFTSDLSKALEKEAVRLFIEWLLAGGPSSGAPPPS-NH 2
化合物102.Y(aib)EGTFTSDYSIYLEKEAVKLFIEWLIAGGPSSGAPPPS-NH 2
化合物103.Y(aib)EGTFTSDYSIYLDEEAVRLFVNWLIAGGPSSGA-NH 2
化合物104.Y(aib)EGTFTSDLSIQLEKEAVKEFIAWLIAGGPSSGAPPPS-NH 2
化合物105.Y(aib)EGTFTSDYSIYLDEEAVRLFIAWLIAGGPSSGAPPPS-NH 2
化合物106.Y(aib)EGTFTSDYSIYLEKEAVKLFVNWLIAGG-NH 2
化合物107.Y(aib)EGTFTSDLSIALEKEAVRLFVNWLIAGGPSSGAPPPS-NH 2
化合物108.Y(aib)EGTFTSDYSIYLDEEAVRLFVNWLIAGGPSSGAP-NH 2
化合物109.Y(aib)EGTFTSDYSIYLEKEAVKLFVNWLIAGGPSSG-NH 2
化合物110.Y(aib)EGTFTSDYSIYLEKEAVRLFIEWLIAGGPSSGA-NH 2
化合物111.Y(aib)EGTFTSDLSIALEKEAVRLFIEWLLAGGPSSGA-NH 2
化合物112.Y(aib)EGTFTSDYSIYLEKEAVKLFVNWLIAGGP-NH 2
化合物113.Y(aib)EGTFTSDYSIYLDEEAVRLFVNWLLAGGPSSGAPPP-NH 2
化合物114.Y(aib)EGTFTSDLSIQLEKEAVRLFVNWLIAGGPSSGAPPPS-NH 2
化合物115.Y(aib)EGTFTSDLSI(aib)LEKEAVRLFIEWLLAGGPSSGA-NH 2
化合物116.Y(aib)EGTFTSDYSIYLEKEAVRLFIEWLIAGGPSS-NH 2
化合物117.Y(aib)EGTFTSDLSIQLEKEAVRLFIAWLIAGGPSSGAPPPS-NH 2
化合物118.Y(aib)EGTFTSDYSIYLEKEAVKLFVNWLLAGGPSSGAPPP-NH 2
化合物119.Y(aib)EGTFTSDLSIALEKEAVRLFIEWLLAGGPS-NH 2
化合物120.Y(aib)EGTFTSDYSIYLDEEAVRLFVNWLIAGGPSS-NH 2
化合物121.Y(aib)EGTFTSDLSIQLEKEAVRLFIEWLIAGGPSSGAPPP-NH 2
化合物122.Y(aib)EGTFTSDYSIYLDEEAVRLFVNWLIAGGP-NH 2
化合物123.Y(aib)EGTFTSDYSIYLEKEAVRLFIEWLLAGGPSSGAPPP-NH 2
化合物124.Y(aib)EGTFTSDLSIQLEKEAVRLFIEWLLAGG-NH 2
化合物125.Y(aib)EGTFTSDLSIQLEKEAVKLFIEWLIAGGPSSGAPPP-NH 2
化合物126.Y(aib)EGTFTSDYSIYLEKEAVKLFIAWLIAGGPSSGAPPPS-NH 2
化合物127.Y(aib)EGTFTSDLSIALEKEAVRLFIAWLIAGGPSSGAPPPS-NH 2
化合物128.Y(aib)EGTFTSDLSIQLEKEAVKLFIEWLLAGGPSSGAPP-NH 2
化合物129.Y(aib)EGTFTSDYSIYLEKEAVKEFIAWLLAGGPSSGAPPP-NH 2
化合物130.Y(aib)EGTFTSDLSIQLEKEAVRLFIEWLLAGGP-NH 2
化合物131.Y(aib)EGTFTSDLSIQLEKEAVKLFIEWLLAGGPSSGAP-NH 2
化合物132.Y(aib)EGTFTSDYSIYLEKEAVKLFVNWLIAGGPSSGA-NH 2
化合物133.Y(aib)EGTFISDLSIALEKEAVRLFIEWLLAGGPSSGAPPPS-NH 2
化合物134.Y(aib)EGTFTSDYSIYLEKEAVRLFIEWLIAGGP-NH 2
化合物135.Y(aib)EGTFTSDYSIYLEKEAVKLFVNWLIAGGPSS-NH 2
化合物136.Y(aib)EGTFTSDLSI(aib)LEKEAVKEFIAWLLAGGPSSGAPPPS-NH 2
化合物137.Y(aib)EGTFTSDLSIQLEKEAVKLFIEWLLAGGPSSGA-NH 2
化合物138.Y(aib)EGTFTSDLSIALEKEAVRLFIEWLLAGGPSSG-NH 2
化合物139.Y(aib)EGTFTSDYSIYLDEEAVRLFVNWLIAGGPS-NH 2
化合物140.Y(aib)EGTFTSDLSIQLEKEAVRLFIEWLLAGGPSS-NH 2
化合物141.Y(aib)EGTFTSDYSIYLEKEAVKLFVNWLIAGGPSSGAPP-NH 2
化合物142.Y(aib)EGTFTSDLSIALEKEAVRLFIEWLLAGGPSSGAP-NH 2
化合物143.Y(aib)EGTFTSDLSIQLEKEAVKLFIEWLLAGGPSSG-NH 2
化合物144.Y(aib)EGTFTSDYSIALEKEAVRLFIEWLLAGGPSSGAPPPS-NH 2
化合物145.Y(aib)EGTFTSDLSIQLEKEAVKLFIEWLLAGGPSS-NH 2
化合物146.Y(aib)EGTFTSDLSIQLEKEAVRLFIEWLLAGGPSSG-NH 2
化合物147.Y(aib)EGTFISDLSI(aib)LEKEAVRLFIEWLLAGGPSSGAPPPS-NH 2
化合物148.Y(aib)EGTFTSDYSIYLEKEAVRLFIEWLIAGGPSSG-NH 2
化合物149.Y(aib)EGTFTSDYSIYLEKEAVKEFIAWLIAGGPSSGAPPPS-NH 2
化合物150.Y(aib)EGTFTSDLSI(aib)LEKEAVRLFIEWLLAGGPSSGAPP-NH 2
化合物151.Y(aib)EGTFTSDLSIYLDEEAVRLFVNWLLAGGPSSGAPPPS-NH 2
化合物152.Y(aib)EGTFTSDLSIALEKEAVRLFIEWLLAGGP-NH 2
化合物153.Y(aib)EGTFTSDLSIQLEKEAVKLFIEWLLAGGPS-NH 2
化合物154.Y(aib)EGTFTSDLSIQLEKEAVRLFIEWLLAGGPSSGAPP-NH 2
化合物155.Y(aib)EGTFTSDYSIYLEKEAVRLFIEWLIAGG-NH 2
化合物156.Y(aib)EGTFTSDLSIQLEKEAVKLFIEWLLAGGP-NH 2
化合物157.Y(aib)EGTFTSDLSIALEKEAVQDFVNWLIAGGPSSGAPPPS-NH 2
化合物158.Y(aib)EGTFTSDLSIQLEKEAVRLFIEWLLAGGPS-NH 2
化合物159.Y(aib)EGTFTSDLSIYLDEEAVRLFVNWLLAGGPSSGAP-NH 2
化合物160.Y(aib)EGTFTSDLSIALEKEAVRLFIEWLLAGGPSSGAPPP-NH 2
化合物161.Y(aib)EGTFTSDLSI(aib)LEKEAVRLFIAWLLAGGPSSGAPPPS-NH 2
化合物162.Y(aib)EGTFTSDYSIQLDEEAVRLFVNWLLAGGPSSGAPPPS-NH 2
化合物163.Y(aib)EGTFTSDLSIALEKEAVKEFIAWLIAGGPSSGAPPPS-NH 2
化合物164.Y(aib)EGTFTSDYSIYLEKEAVRLFIEWLIAGGPS-NH 2
化合物165.Y(aib)EGTFTSDYSIYLDEEAVRLFVNWLIAGGPSSG-NH 2
化合物166.Y(aib)EGTFTSDLSI(aib)LEKEAVQDFVNWLLAGGPSSGAPPPS-NH 2
化合物167.Y(aib)EGTFTSDLSIYLEKEAVKLFVNWLLAGGPSSGAP-NH 2
化合物168.Y(aib)EGTFTSDLSK(aib)LEKEAVRLFIEWLLAGGPSSGAPPP-NH 2
化合物169.Y(aib)EGTFTSDYSIYLDEEAVKEFIAWLIAGGPSSGAPPPS-NH 2
化合物170.Y(aib)EGTFTSDLSIYLEKEAVRLFIEWLLAGGPSSGAPP-NH 2
化合物171.Y(aib)EGTFTSDYSIALDEEAVRLFVNWLLAGGPSSGAPPPS-NH 2
化合物172.Y(aib)EGTFTSDLSIALEKEAVKLFVNWLLAGGPSSGAPPPS-NH 2
化合物173.Y(aib)EGTFTSDLSIYLEKEAVRLFIEWLLAGGPSSGAP-NH 2
化合物174.Y(aib)EGTFTSDLSI(aib)LEKEAVRLFIEWLLAGG-NH 2
化合物175.Y(aib)EGTFTSDLSIYLEKEAVKLFVNWLLAGGPSSGA-NH 2
化合物176.Y(aib)EGTFTSDLSIYLDEEAVRLFVNWLLAGGPS-NH 2
化合物177.Y(aib)EGTFTSDLSIYLDEEAVRLFVNWLLAGGPSSGAPPP-NH 2
化合物178.Y(aib)EGTFTSDLSI(aib)LEKEAVRLFIEWLLAGGPS-NH 2
化合物179.Y(aib)EGTFTSDLSIALEKEAVRLFIEWLLAGGPSSGAPP-NH 2
化合物180.Y(aib)EGTFTSDLSIYLEKEAVKLFVNWLLAGGPSSG-NH 2
化合物181.Y(aib)EGTFTSDLSI(aib)LEKEAVRLFIEWLLAGGPSSG-NH 2
化合物182.Y(aib)EGTFTSDYSIQLEKEAVRLFIEWLLAGGPSSGAPPPS-NH 2
化合物183.Y(aib)EGTFTSDLSIYLEKEAVKLFVNWLLAGGPSSGAPPP-NH 2
化合物184.Y(aib)EGTFTSDLSI(aib)LEKEAVRLFIEWLLAGGPSS-NH 2
化合物185.Y(aib)EGTFTSDLSIYLDEEAVRLFVNWLLAGGPSSGA-NH 2
化合物186.Y(aib)EGTFTSDYSI(aib)LEKEAVRLFIEWLLAGGPSSGAPPPS-NH 2
化合物187.Y(aib)EGTFTSDLSIALEKEAVRLFIEWLLAGG-NH 2
化合物188.Y(aib)EGTFTSDLSIQLEKEAVRLFIEWLLAGGPSSGAP-NH 2
化合物189.Y(aib)EGTFTSDYSIYLEKEAVKLFVNWLIAGGPS-NH 2
化合物190.Y(aib)EGTFTSDLSIYLEKEAVRLFIEWLLAGGPSSGAPPPS-NH 2
化合物191.Y(aib)EGTFTSDLSI(aib)LEKEAVRLFVNWLLAGGPSSGAPPPS-NH 2
化合物192.Y(aib)EGTFTSDLSIYLDEEAVRLFVNWLLAGGPSSG-NH 2
化合物193.Y(aib)EGTFTSDLSIYLEKEAVKLFVNWLLAGGPS-NH 2
化合物194.Y(aib)EGTFTSDLSIYLDEEAVRLFVNWLLAGGPSS-NH 2
化合物195.Y(aib)EGTFTSDLSK(aib)LEKEAVRLFIEWLLAGGPSSGAPPPS-NH 2
化合物196.Y(aib)EGTFTSDLSIYLEKEAVRLFIEWLLAGGPSSG-NH 2
化合物197.Y(aib)EGTFTSDLSIYLEKEAVKLFVNWLLAGGPSSGAPP-NH 2
化合物198.Y(aib)EGTFTSDLSIYLEKEAVRLFIEWLLAGGPS-NH 2
化合物199.Y(aib)EGTFTSDLSI(aib)LEKEAVRLFIEWLLAGGP-NH 2
化合物200.Y(aib)EGTFTSDLSIYLEKEAVRLFIEWLLAGGP-NH 2
化合物201.Y(aib)EGTFTSDLSIYLDEEAVRLFVNWLLAGG-NH 2
化合物202.Y(aib)EGTFTSDLSIYLEKEAVKLFVNWLLAGGPSSGAPPPS-NH 2
化合物203.Y(aib)EGTFTSDLSIYLEKEAVRLFIEWLLAGGPSS-NH 2
化合物204.Y(aib)EGTFTSDLSIYLDEEAVRLFVNWLLAGGP-NH 2
化合物205.Y(aib)EGTFTSDLSIYLEKEAVKLFVNWLLAGGPSS-NH 2
化合物206.Y(aib)EGTFTSDLSIQLEKEAVKLFIEWLLAGG-NH2
化合物207.Y(aib)EGTFTSDYSIYLEKEAVRLFIEWLLAGGPSSGAPPP-NH 2
化合物208.Y(aib)EGTFTSDLSIYLEKEAVKLFVNWLLAGGP-NH 2
化合物209.Y(aib)EGTFTSDLSIYLEKEAVRLFIEWLLAGGPSSGAPPP-NH 2
化合物210.Y(aib)EGTFTSDLSI(aib)LEKEAVRLFIEWLLAGGPSSGAPPP-NH 2
化合物211.Y(aib)EGTFTSDLSIYLEKEAVRLFIEWLLAGGPSSGA-NH 2
化合物212.Y(aib)EGTFTSDLSIYLEKEAVKLFVNWLLAGG-NH 2
化合物213.Y(aib)EGTFTSDYSI(aib)LDEEAVRLFVNWLLAGGPSSGAPPPS-NH 2
化合物214.Y(aib)EGTFTSDLSIALEKEAVRLFIEWLLAGGPSS-NH 2
化合物215.Y(aib)EGTFTSDLSIYLDEEAVRLFVNWLLAGGPSSGAPP-NH 2
化合物216.Y(aib)EGTFTSDLSI(aib)LEKEAVKLFVNWLLAGGPSSGAPPPS-NH 2
化合物217.Y(aib)EGTFTSDLSSALEKEAVRLFIEWLLAGGPSSGAPPPK-NH 2
化合物218.Y(aib)EGTFTSDLSIYLEKEAVRLFIEWLLAGG-NH 2
化合物219.Y(aib)EGTFTSDLSIQLEKEAVKLFVNWLLAGGPSSGAPPPS-NH 2
化合物220.
Figure PCTCN2021104822-appb-000024
化合物221
Figure PCTCN2021104822-appb-000025
根据前述任一方面的药物制剂，其中所述肽化合物只包含天然氨基酸。
药物制剂可以制成例如片剂、包衣片、糖锭剂、硬和软明胶胶囊、溶液、乳液或者混悬液，经口服给药。但是，也可以制成栓剂，通过直肠给药，或者制成注射液，通过非胃肠给药。常用的非胃肠给药方式包括皮下注射、静脉注射、透皮给药、吸入给药等。
根据前述任一方面的药物制剂，所述载体或赋形剂选自缓冲液、防腐剂、等渗剂、增溶剂、稳定剂、表面活性剂、螯合剂中的一种或多种。
根据前述任一方面的药物制剂，所述缓冲液是选自磷酸盐缓冲液、磷酸氢盐缓冲液、磷酸二氢盐缓冲液、醋酸盐缓冲液、碳酸盐缓冲液、碳酸氢盐缓冲液、硼酸盐缓冲液、马来酸盐缓冲液、富马酸盐缓冲液、乳酸盐缓冲液、柠檬酸盐缓冲液、巴比妥钠缓冲液、三羟甲基氨基甲烷(Tris)缓冲液中的一种或多种。
根据前述任一方面的药物制剂，在一些实施方案中，所述缓冲液为磷酸氢二钠、磷酸氢二钾、磷酸二氢钠、磷酸二氢钾、醋酸钠溶液中的一种或多种。
根据前述任一方面的药物制剂，在一些实施方案中，所述缓冲液为磷酸氢二钠溶液。
根据前述任一方面的药物制剂，所述防腐剂选自苯酚、间甲酚、对甲酚、邻甲酚、氯甲酚、苄醇、苯基亚硝酸汞、苯氧基乙醇、甲醛、氯丁醇、氯化镁(如六水合氯化镁)、烷基对羟基苯甲酸酯类(甲酯、乙酯、丙酯、丁酯等)、苯扎氯铵、苄索氯铵、甲醋吡喃酮钠和硫柳汞中的一种或多种。
根据前述任一方面的药物制剂，在一些实施方案中，所述防腐剂为苯酚。
根据前述任一方面的药物制剂，所述等渗剂为本领域常用的渗透压调节剂，如碳水化合物、多元醇或盐。等渗剂选自甘油、丙二醇、单糖、二糖、多糖、醛醇以及氯化钠中的一种或多种；优选地，所述单糖选自果糖、麦芽糖、半乳糖、葡萄糖、D-甘露糖、山梨糖等；优选地，所述二糖选自乳糖、蔗糖、海藻糖、纤维二糖等；优选地，所述多糖选自棉子糖、松三糖、麦芽糖糊精、右旋糖苷、淀粉等；优选地，所述醛醇选自甘露醇、木糖醇、麦芽糖醇、乳糖醇、木糖醇、山梨糖醇(葡糖醇)等。渗透压调节剂还可以选自人工合成物质，例如聚乙二醇或聚丙二醇，例如PEG200、PEG400、PEG1000、PEG4000等。
根据前述任一方面的药物制剂，在一些实施方案中，所述等渗剂为甘油。
根据前述任一方面的药物制剂，在一些实施方案中，所述等渗剂为丙二醇。
根据前述任一方面的药物制剂，在一些实施方案中，所述赋形剂是糖赋形剂；所述糖赋形剂选自：单糖、二糖、多糖以及醛醇中的一种或多种。
根据前述任一方面的药物制剂，在一些实施方案中，所述表面活性剂选自聚山梨酯(例如例如吐温
Figure PCTCN2021104822-appb-000026
(聚氧乙烯(20)山梨糖醇酐单月桂酸酯)、吐温
Figure PCTCN2021104822-appb-000027
(聚氧乙烯(20)山梨糖醇酐单棕榈酸酯)、吐温
Figure PCTCN2021104822-appb-000028
(聚氧乙烯(20)山梨糖醇酐单油酸酯))、泊洛沙姆184或188、普流罗尼F68(聚氧乙烯-聚氧丙烯嵌段共聚物)和PEG(聚乙二醇)或表面活性剂如聚山梨酯20或80或者泊洛沙姆184或188、普流罗尼、其它嵌段共聚物中的一种或多种。通常吐温
Figure PCTCN2021104822-appb-000029
或吐温
Figure PCTCN2021104822-appb-000030
的浓度在0.001-0.05％。吐温
Figure PCTCN2021104822-appb-000031
或吐温
Figure PCTCN2021104822-appb-000032
的其它优选范围在0.005％至0.05％之间、0.0075％至0.05％之间以及0.01％至0.05％之间。
前述任一方面的药物制剂，在一些实施方案中，所述肽化合物的浓度至少为0.1mg/ml，优选0.5-20mg/ml，0.5-10mg/ml，1-8mg/ml，1-6mg/ml，1-5mg/ml，1.5-4mg/ml；更优选1.5mg/ml。
根据前述任一方面的药物制剂，在一些实施方案中，磷酸氢二钠的浓度至少为0.1mg/ml，优选0.1-10mg/ml，0.3-10mg/ml，0.5-10mg/ml，0.5-5mg/ml，0.5-3mg/ml，0.7-2mg/ml。本发明制剂所用磷酸氢二钠可以是无水磷酸氢二钠或磷酸氢二钠水合物，例如磷酸氢二钠二水合物、磷酸氢二钠七水合物、磷酸氢二钠十二水合物等。优选药用辅料磷酸氢二钠十二水合物。
根据前述任一方面的药物制剂，在一些实施方案中，甘油的浓度至少为12mg/ml，优选15-25mg/ml，17-22mg/ml，17-20mg/ml。
根据前述任一方面的药物制剂，在一些实施方案中，丙二醇的浓度至少为8mg/ml，优选10-20mg/ml，10-18mg/ml，10-16mg/ml，12-16mg/ml，13-15mg/ml。
根据前述任一方面的药物制剂，在一些实施方案中，所述药物制剂的pH在3-9之间，优选4-8.8，5-8.6，6-8.5，6.5-8.5，7.0-8.5，7.2-8.5，7.2-8.0，7.4-8.0，7.5-8.0，7.4-7.6，7.5-7.6。根据前述任一方面的药物制剂，在一些实施方案中，所述防腐剂为苯酚，优选地，其浓度不大于5.5mg./ml，优选不大于5.0mg/ml。
根据前述任一方面的药物制剂，在一些实施方案中，所述药物制剂中的肽化合物为化合物27、29、220或221。
在一方面本发明涉及治疗或预防下列疾病或状况的方法：葡萄糖耐量受损(IGT)、高血糖症、1型糖尿病、2型糖尿病、肥胖症、代谢综合征和神经退行性疾病，特别是用于延缓或预防2型糖尿病中的疾病进展，延缓从葡萄糖耐量受损到2型糖尿病的进展；延缓从2型糖尿病到需要胰岛素的糖尿病的进展；治疗代谢综合征，用于调节食欲，诱发饱足感，减少食物摄入，增加能量消耗，治疗肥胖症或预防超重；预防减肥成功后的体重反弹；治疗与超重或肥胖症相关的疾病或状态；治疗贪食症；治疗暴食；治疗血脂异常、动脉粥样硬化、高血压、冠心病、β-阻断剂中毒；非酒精性脂肪性肝病(NAFLD，non-alcoholic fatty liver disease)(可分为单纯性脂肪肝(SFL)、非酒精性脂肪性肝炎(NASH)及其相关肝硬化)；用于抑制胃肠道的运动，用于与使用如X射线、CT和NMR扫描的技术的胃肠道调查联用；所述方法包括对患者施用有效量的前述任一方面的肽化合物或其药学上可接受的盐或溶剂合物或药物组合物。
在一方面本发明涉及前述任一方面的药物制剂在制备用于降血糖或治疗糖尿病的药物中的用途。
在一方面本发明涉及前述任一方面的药物制剂在制备用于减肥的药物中的用途。
在一方面本发明涉及前述任一方面的药物制剂在制备用于降血脂的药物中的用途，优选降低选自下列的血脂成分：胆固醇、甘油三酯、游离脂肪酸、低密度脂蛋白胆固醇。
在一方面本发明涉及前述任一方面的药物制剂的制备方法，其中所述制备方法包括以下步骤：
(1)将缓冲剂、等渗剂和可选的防腐剂和表面活性剂溶解于适量无菌注射用水得到溶液；
(2)加入式(VII)的肽化合物或其药学上可接受的盐或溶剂合物，调节至所需pH范围；
(3)加入适量的无菌注射用水使制剂溶液达到目标体积；
(4)用0.22微米的滤膜对制剂溶液进行除菌过滤。
优选地，所述缓冲剂是磷酸氢二钠或磷酸氢二钠水合物；
优选地，所述防腐剂是苯酚或间甲酚；更优选地，所述防腐剂是苯酚。
优选地，所述等渗剂是甘油或丙二醇；更优选地，所述等渗剂是甘油。
本发明人通过对GLP-1受体激动剂肽衍生物进行一系列结构改造，包括对特定氨基酸进行选择，或在肽的C末端引入新氨基酸，或对肽的C末端氨基酸残基进行取代，并将独特的长效基团通过多肽C末端的半胱氨酸残基侧链巯基或赖氨酸残基的侧链氨基链接到多肽上，得到了一类全新的肽化合物。取得了预料不到的技术效果。
附图说明
图1：本发明化合物1、2、8、16、18、19、24和36降低db/db小鼠的血糖的测试。
图2：本发明化合物31、35、38、44和49降低db/db小鼠的血糖的测试。
图3：本发明化合物6、13、14和26的腹腔注射葡萄糖耐受试验(IPGTT)。
图4：本发明化合物4、11、17、20和23降低体重的测试。
图5：本发明化合物4、11、17、20和23空腹血糖变化。
图6：本发明化合物4、11、17、20和23有效降低TC浓度。
图7：本发明化合物4、11、17、20和23有效降低TG浓度。
图8：本发明化合物21、22、27、28、29和30空腹血糖测试。
图9：本发明化合物42、115和178降低db/db小鼠的血糖的测试。
图10：本发明化合物27和化合物29有效降低体重。
图11：本发明化合物27和化合物29有效降低摄食量。
图12：本发明化合物27和化合物29有效降低低密度脂蛋白胆固醇(LDL-C)。
图13：本发明化合物35和化合物40有效降低脂肪组织量。
具体实施方式
除非另外说明，下述定义适用于本发明全文。未定义的术语可以根据行业内约定俗成的定义理解。
“氨基酸”指同时包含氨基和羧基官能团的分子，α-氨基酸的氨基和羧基连接在同一个碳原子(α碳)上。α碳可以另外有1-2个有机取代基。氨基酸包含L和D同分异构体和消旋混合物。如无特别说明，本发明中多肽序列中的氨基酸残基都是L同分异构体即L-氨基酸，D-氨基酸在氨基酸名称或缩写前加小写字母“d”表示，如dK。
本发明的氨基酸序列含有用于天然存在的氨基酸的常规单字母或三字母代码，以及用于其它氨基酸的普遍承认的三字母代码，如Tic(1，2，3，4-四氢异喹啉-3-羧酸)、Aib(α-氨基异丁酸)或GABA(γ-氨基丁酸)。常用分子结构的缩写代码包括：
hGlu为高谷氨酸；
α-hGlu为-HNCH(CO-)CH 2CH 2CH 2COOH的L同分异构体；
δ-hGlu为-HNCH(COOH)CH 2CH 2CH 2CO-的L同分异构体；
α-Glu为-HNCH(CO-)CH 2CH 2COOH的L同分异构体；
γ-Glu或gGlu为-HNCH(COOH)CH 2CH 2CO-的L同分异构体；
α-Asp为-HNCH(CO-)CH 2COOH的L同分异构体；
β-Asp为-HNCH(COOH)CH 2CO-的L同分异构体；
β-Ala为-HN-CH 2-CH 2-COOH；
PEG2为2-(2-(2-氨基乙氧基)乙氧基)乙酸(CAS No.134978-97-5)。
本发明中多肽的氨基酸组成可以改变而基本不影响其生物活性。例如，一个多肽序列可以包含一个或多个保守氨基酸取代。保守氨基酸取代是一个氨基酸残基被另一个有相似侧链的氨基酸残基取代。文献中根据氨基酸残基侧链的性质对氨基酸残基进行分类。含有碱性侧链氨基酸残基包括赖氨酸、精氨酸、组氨酸；包含酸性侧链及其酰胺侧链氨基酸残基包括天冬氨酸、谷氨酸、天冬酰胺、谷氨酰胺；小脂肪族、非极性或弱极性侧链氨基酸残基包括甘氨酸、丙氨 酸、苏氨酸、丝氨酸、脯氨酸；大脂肪族、非极性侧链氨基酸残基包括亮氨酸、异亮氨酸、缬氨酸；芳香族氨基酸残基包括苯丙氨酸、色氨酸、酪氨酸；含硫侧链氨基酸残基包括半胱氨酸、甲硫氨酸。
在一些实施方案中，所述衍生物包含含有亲脂性部分和可选的带1-3个负电荷的部分的取代基，其中所述带负电荷的部分中的一个在亲脂性部分的远端。在一些实施方案中，所述取代基连接在序列C末端的氨基酸的侧链上。如果序列C末端是赖氨酸，就是连接在赖氨酸残基的ε氨基上。
如本文所用，术语“治疗”包括抑制、减缓、停止或逆转现有症状或病患的进展或严重程度。因此，治疗包括预防、治疗和/或治愈。预防指防止潜在疾病和/或防止症状恶化或疾病发展。
如本文所用，“疗效”表示由个体的治疗所导致的效果，其改变、通常改良或改善疾病或疾病状况的症状，或者治愈疾病或疾病状况。
如本文所用，“治疗有效量”或“治疗有效剂量”指施用于对象之后至少足以产生疗效的物质、化合物、材料或包含化合物的组合物的量。因此，其为防止、治愈、改善、阻滞或部分阻滞疾病或病症的症状所必需的量。
如本文所用，“预防有效量”或“预防有效剂量”指在施用于对象时会具有预期的预防效果的物质、化合物、材料或包含化合物的组合物的量，例如，防止或延迟疾病或症状的发生或复发，减少疾病或症状发生或复发的可能性。完全预防有效剂量不必通过施用一个剂量发生，并且可以仅在施用一系列剂量之后发生。因此，预防有效量可以在一次或多次施用中施用。
如本文中所使用的，术语“患者”是指哺乳动物，例如人。
Holst(Holst，J.J.Physiol.Rev.2007，87，1409)和Meier(Meier，J.J.Nat.Rev.Endocrinol.2012，8，728)描述了GLP-1受体激动剂，如GLP-1、利拉鲁肽和毒蜥外泌肽-4。
本发明的某些化合物通常在宽剂量范围内有效。例如，每周一次给药的剂量可以在每人每周约0.05至约30mg的范围内。本发明的某些化合物可以每天给药。另外，本发明的某些化合物可以每周一次给药。
应当理解，根据所述实施方案的治疗剂将与药学上可接受的合适的载体、赋形剂、以及其它被掺入制剂中以提供改善的转移、递送、耐受性等的试剂一同施用。大量适当的制剂可见于所有药物化学工作者已知的药典中：Remington′s Pharmaceutical Sciences(第15版，Mack Publishing Company，Easton，Pa.(1975))，特别是其中Blaug、Seymour的第87章。这些制剂包括例如粉末、糊剂、膏剂、凝胶剂、蜡、油、脂质、含脂质(阳离子或阴离子)载体(例如LipofectinTM)、DNA缀合物、无水吸浆、水包油和油包水乳液、乳液聚乙二醇(各种分子量的聚乙二醇)、半固态凝胶以及含有聚乙二醇的半固态混合物。任何前述混合物均可适用于根据本发明的治疗或疗法，条件是制剂中的活性成分不被制剂灭活并且制剂在生理学上是相容的并耐受给药途径。
如本文所用，术语“药学上可接受的载体”旨在包括与药物给药相容的任何和所有溶剂、分散介质、包衣、抗细菌剂和抗真菌剂、等渗剂和吸收延缓剂等。合适载体描述于最新版的Remington′s Pharmaceutical Sciences中，这是本领域的标准参考书目，其以引用方式并入本文。此类载体或稀释剂的优选示例包括但不限于水、盐水、林格氏溶液、葡萄糖溶液和5％的人血清白蛋白。也可以使用脂质体和非水性载体，例如固定化油。将此类介质和试剂用于药物活性物质是本领域熟知的。
待用于临床体内施用的制剂必须为无菌的。这可容易地通过无菌滤膜过滤实现。
本发明的化合物可以与多种无机酸或有机酸中的任意反应形成药学上可接受的酸加成盐。药学上可接受的盐和制备它们的常用方法是本领域公知的。参见例如Handbook of Pharmaceutical Salts：Properties，Selection and Use.第二修订版(Wiley-VCH，2011)；S.M.Berge等人“Pharmaceutical Salts”，Journal of Pharmaceutical Sciences，Vol.66，No.1，1977年1月。常用的药学上可接受的盐包括三氟乙酸盐、醋酸盐、柠檬酸盐、盐酸盐、磷酸盐等。
本发明的化合物可以与一种或者多种无机碱或有机碱反应形成药学上可接受的盐，常用的药学上可接受的盐包括钠盐、钾盐、铵盐等。
将所述实施方案的药物组合物配制成与其预期施用途径相容。给药途径的示例包括肠胃外，例如静脉内、皮内、皮下、经口(例如吸入)、经皮(P局部的)、经粘膜和直肠给药。用于肠胃外、皮内或皮下施用的溶液或悬浮液可包括以下组分：注射用无菌稀释剂例如水、盐溶液、固定油、聚乙二醇类、甘油、丙二醇或其它合成溶剂；抗细菌剂，例如苄醇、对羟基苯甲酸甲酯、苯酚或间甲酚；抗氧化剂，例如抗坏血酸或亚硫酸氢钠；螯合剂，例如乙二胺四乙酸(EDTA)；缓冲剂，例如乙酸盐、柠檬酸盐或磷酸盐、以及调节渗透压的试剂，例如氯化钠或右旋糖。pH可用酸或碱进行调节，例如盐酸或氢氧化钠。可将肠胃外制剂包装在安瓿瓶、西林瓶、一次性注射器、玻璃或塑料制多剂量小瓶或注射笔内。注射笔主要有两种类型，一种是一次性的预填充式笔，内装有药物，无需更换药物笔芯，用完后即可扔掉；另一种是更为常用的耐用型注射笔，由注射笔和药物笔芯构成，用完后更换笔芯即可继续使用。
适于注射用途的药物组合物包括无菌水性溶液(在此是水溶性的)或分散体以及用于即时制备无菌注射液或分散体的无菌粉末。对于静脉内施用，合适的载体包括生理盐水、抑菌水、Cremophor ELTM(BASF，Parsippany，N.J.)或磷酸盐缓冲盐水(PBS)。在所有情况下，组合物必须是无菌的并且流动性应当达到易于注射的程度。其在制造和储存条件下必须是稳定的并且必须能防止微生物例如细菌和真菌的污染作用。载体可以是含有例如水、乙醇、多元醇(例如，甘油、丙二醇和液体聚乙二醇等)的溶剂或分散介质，及其适宜的混合物。例如通过利用涂层例如卵磷脂，在分散体情况下维持所需颗粒尺寸，以及利用表面活性剂，可以保持适宜的流动性。对微生物作用的防止可以通过各种抗细菌剂和抗真菌剂例如对羟基苯甲酸酯、氯代丁醇、苯酚、间甲酚、抗坏血酸、硫柳汞等来实现。在许多情况下，将优选在组合物中包含等渗剂，例如糖、多元醇(诸如甘露糖醇、山梨醇)、氯化钠。注射用组合物的延长吸收可通过在所述组合物中包含延缓吸收的试剂例如单硬脂酸铝和明胶来达到。根据需要，可以通过将本发明化合物以所需量掺入具有上文所列成分中的一种或组合(按需要)的合适溶剂中来制备无菌注射溶液，然后过滤消毒。一般来讲，通过将本发明化合物掺入含有分散介质和上文所列那些所需其它成分的无菌载体中来制备分散体。就用于制备无菌注射溶液的无菌粉末而言，制备方法是获得粉末的真空干燥和冷冻干燥，该粉末包含活性成分和任何另外的期望成分，它们来自前述的这些成分的无菌过滤溶液。
对于吸入给药，从包含合适推进剂如二氧化碳等气体的加压容器或分配器或者喷雾器以气溶胶喷雾形式递送化合物。
还可以通过经粘膜或透皮方式全身给药。对于经粘膜或透皮给药，在制剂中使用适于渗透屏障的渗透剂。此类渗透剂通常在本领域是通常所知的，并且包括如用于经粘膜给药的去污剂、胆盐和夫西地酸衍生物。经粘膜给药可以通过使用喷鼻剂或栓剂来实现。对于透皮给药，可将一种或多种所述本发明化合物配制成如本领域通常所知的膏剂、软膏、凝胶、或霜膏。
还可将化合物以栓剂(例如，具有常规栓剂基质，如可可脂或其它甘油酯)或滞留性灌肠剂形式进行制备以用于经直肠递送。
在一个实施方案中，所述本发明化合物可用防止其被身体迅速消除的载体制备，例如缓释/控释制剂，包括植入体和微胶囊化递送体系。可使用可生物降解、可生物相容的聚合物，例如乙烯-乙酸乙烯酯、聚酐、聚乙醇酸、胶原、聚原酸酯和聚乳酸。用于制备此类制剂的方法对于本领域技术人员而言是显而易见的。
例如，这些活性成分可胶囊包封于例如通过凝聚技术或通过界面聚合法制备的微胶囊中，例如分别在胶体给药系统(例如，脂质体、白蛋白微球、微乳液、纳米颗粒和纳米胶囊剂)或大乳液中的羟甲基纤维素或明胶微胶囊和聚(甲基丙烯酸甲酯)微胶囊。
可制备缓释制剂。适宜的缓释制剂的示例包括含有本发明化合物的固体疏水聚合物的半透性基质，该基质是成型制品形式例如膜或微胶囊。缓释基质的示例包括聚脂、水凝胶(例如，聚(2-羟乙基-甲基丙酸酯)、或聚(乙烯醇))、聚交酯(美国专利No.3,773,919)、L-谷氨酸和γ乙基-L-谷氨酸盐的共聚物、不可降解的乙烯-乙酸乙烯酯、可降解乳酸-乙醇酸共聚物例如LUPRON DEPOTTM(由乳酸-乙醇酸共聚物和醋酸亮丙瑞林构成的注射用微球)、和聚-D-(-)-3-羟基丁酸。虽然聚合物例如乙烯-乙酸乙烯酯和乳酸-乙醇酸能够释放分子100天以上，但是一些水凝胶释 放蛋白质的时间却较短。聚乳酸(PLA)和聚乳酸乙醇酸共聚物(PLGA)是近年来研究的热点。此外，还有清蛋白微球、壳聚糖微球、明胶微球等。
脂质体混悬剂也可以用作药学上可接受的载体。这些可根据本领域技术人员已知的方法制备，例如在美国专利No.4,522,811中有所描述。
尤其有利的是以剂量单位形式配制肠胃外组合物以易于施用和剂量的一致性。如本文所用，剂量单位形式是指用于待治疗的受试者，适合作为单位剂量的物理上可分离的单位；每个单位含有经计算与所需药物载体结合产生期望治疗效果的预定量的一种或多种所述本发明化合物。所述实施方案的剂量单位形式的规格由以下指示并直接取决于：本发明化合物的独特特征和待实现的具体治疗效果，和用于治疗个体的此类本发明化合物的调配领域中固有的局限性。
所述药物组合物可与给药说明书一起放于容器、包装、或分配器中。
本发明提供了一种用于治疗患者中2型糖尿病的方法，包括向需要这种治疗的患者施用有效量的本发明化合物或其药学上可接受的盐。本发明还提供了一种用于治疗患者中2型糖尿病的方法，包括向需要这种治疗的患者施用有效量的本发明化合物或其药学上可接受的盐，其中所述施用是皮下的。本发明还提供了一种治疗患者中2型糖尿病的方法，包括向需要这种治疗的患者施用有效量的本发明化合物或其药学上可接受的盐，以及同时、分开，或相继施用有效量的一种或多种其他活性成分。在一个实施方案中，其他一种或多种活性成分是目前可获得的口服降低葡萄糖的药物，所述药物来自在施用前被视为护理标准的一类药物(由诸如美国糖尿病协会(American Diabetes Association)的行业指南确定)。
本发明还提供了治疗或预防下列疾病或状况的方法：葡萄糖耐量受损(IGT)、高血糖症、1型糖尿病、2型糖尿病、肥胖症、代谢综合征和神经退行性疾病，特别是用于延缓或预防2型糖尿病中的疾病进展，延缓从葡萄糖耐量受损到2型糖尿病的进展；延缓从2型糖尿病到需要胰岛素的糖尿病的进展；治疗代谢综合征，用于调节食欲，诱发饱足感，减少食物摄入，增加能量消耗，治疗肥胖症或预防超重；预防减肥成功后的体重反弹；治疗与超重或肥胖症相关的疾病或状态；治疗贪食症；治疗暴食；治疗血脂异常、动脉粥样硬化、高血压、冠心病、β-阻断剂中毒；非酒精性脂肪性肝病(NAFLD，non-alcoholic fatty liver disease)(可分为单纯性脂肪肝(SFL)、非酒精性脂肪性肝炎(NASH)及其相关肝硬化)；用于抑制胃肠道的运动，用于与使用如X射线、CT和NMR扫描的技术的胃肠道调查联用。所述方法包括向需要这种治疗的患者施用有效量的本发明化合物或其药学上可接受的盐或其溶剂化物，以及同时、分开，或相继施用有效量的一种或多种其他活性成分。
进一步优选的医药用途包括治疗或预防退行性疾病，特别是神经退行性疾病如阿兹海默病(Alzheimer′s disease)、帕金森氏病(Parkinson′s disease)、亨廷顿氏舞蹈病(Huntington′s disease)、共济失调(例如脊髓小脑性共济失调)、肯尼迪病(Kennedy disease)、肌强直性营养不良、路易体痴呆症(Lewy body dementia)、多系统萎缩(multi-systemic atrophy)、肌萎缩性脊髓侧索硬化、原发性脊髓侧索硬化、脊髓性肌萎缩、朊病毒相关疾病(例如克雅氏病(Creutzfeldt-Jacob disease))、多发性硬化、毛细血管扩增、贝敦氏症(Batten disease)、皮层基底节变性(corticobasal degeneration)、脊髓亚急性联合变性、脊髓痨、泰-萨二氏病(Tay-Sachs disease)、中毒性脑病、婴儿雷夫叙姆病(infantile Refsum disease)、雷夫叙姆病、神经棘红细胞增多症、尼曼匹克症(Niemann-Pick disease)、莱姆病(Lyme disease)、马查多·约瑟夫病(Machado-Joseph disease)、桑德霍夫病(Sandhoff disease)、雪-杜二氏综合征(Shy-Drager syndrome)、刺猬摇摆综合征(wobbly hedgehog syndrome)、原发病(proteopathy)、脑β-淀粉样脑血管病、青光眼中的视网膜神经节细胞变性、核蛋白病(synucleinopathies)、滔蛋白病(tauopathies)、额颞叶变性(FTLD)、痴呆症、Cadasil综合征、具有淀粉样变性的遗传性脑溢血、亚历山大病(Alexander disease)、seipinopathies、家族性淀粉样变性神经病变、老年系统性淀粉样变性(senile systemic amyloidosis)、serpinopathies、AL(轻链)淀粉样变性(原发性全身淀粉样变性)、AH(重链)淀粉样变性、AA(继发性)淀粉样变性、主动脉内淀粉样变性(aorticmedial amyloidosis)、ApoAI淀粉样变性、ApoAII淀粉样变性、ApoAIV淀粉样变性、芬兰型家族性淀粉样变性(FAF)、溶菌酶淀粉样变性、纤维蛋白原淀粉样变性、透析淀粉样变性、包涵体肌炎/肌病、白内障、具有视紫 红质突变的视网膜色素变性、甲状腺髓样癌、心脏心房淀粉样变性、垂体催乳素瘤、遗传性网格状角膜营养不良(Hereditary lattice corneal dystrophy)、皮肤性苔藓状淀粉样变性、马洛里小体(Mallory bodies)、角膜乳铁蛋白淀粉样变性、肺泡蛋白沉着症(pulmonary alveolar proteinosis)、牙原性(Pindborg)肿瘤淀粉体、囊性纤维化病、镰状细胞疾病或危重病性肌病(CIM)。进一步的医药用途包括治疗骨骼相关的病症，如骨质疏松症或骨关节炎等，其中骨形成的增加和骨吸收(bone resorption)的减少可能是有益的。
缩略语
保护基：
Aloc或AOC，allyloxycarbonyl：烯丙氧羰基；Bom，benzyloxymethyl：苄氧甲基；2-Br-Z，2-bromobenzyloxycarbonyl：2-溴苄氧羰基；tBu，t-butyl：叔丁基；Bz，benzoy l：苯甲酰基；Bzl，benzyl：苄基；Boc，tert-butoxycarbonyl：叔丁氧羰基；CHO，formyl：甲酰基；cHx，cyclohexyl：环己基；Cbz或z，benzyloxycarbonyl：苄氧羰基；2-Cl-Z，2-chlorobenzyloxycarbonyl：2-氯苄氧羰基；Fm，9-fluorenylmethyl：9-芴基甲基；Fmoc，9-fluorenylmethoxycarbonyl：9-芴甲氧羰基；Mtt，4-methyltrityl：4-甲基三苯甲基；Pmc，(2，2，5，7，8-pentamethylchroman-6-sulphonyl：2，2，5，7，8-五甲基-6-羟基色满；Tos，4-toluenesulphonyl：对甲苯磺酰；Trt，triphenylmethyl：三苯甲基；Xan，xanthyl：吨基、氧(杂)蒽基。
试剂和溶剂：
ACN，acetonitrile：乙腈；BOP，benzotriazol-1-yloxytris(dimethylamino)phosphonium hexafluorophosphate：苯并三唑-1-三(三甲氨基)-六氟磷酸酯(卡特缩合剂)；DCC，N，N′-Dicyclohexylcarbodiimide：二环己基碳化二亚胺；DCM：二氯甲烷；DEPBT，3-(Diethoxyphosphoryloxy)-1，2，3-benzotriazin-4(3H)-one：3-(二乙氧基邻酰氧基)-1，2，3-苯并三嗪-4-酮；DIC，N，N′-Diisopropylcarbodiimide：N，N′-二异丙基碳二亚胺；DIPEA(或DIEA)，diisopropylethylamine：二异丙基乙胺；DMF：N，N-二甲基甲酰胺；DMSO：二甲亚砜；EDC或EDCI，1-ethyl-3-(3-dimethylaminopropyl)carbodiimide：1-乙基-(3-二甲基氨基丙基)碳酰二亚胺盐酸盐；EtOAc：乙酸乙酯；HATU，1-[Bis(dimethylamino)methylene]-1H-1，2，3-triazolo[4，5-b]pyridinium 3-oxide hexafluorophosphate：1-[二(二甲基氨基)亚甲基]-1H-1，2，3-三唑并[4，5-b]吡啶鎓3-氧化物六氟磷酸盐；HBTU，O-(1H-benzotriazole-1-yl)-N，N，N′，N′-tetramethyluronium hexafluorophosphate：苯并三氮唑-N，N，N′，N′-四甲基脲六氟磷酸盐；HOAT，1-Hydroxy-7-azabenzotriazole：1-羟基-7-氮杂苯并三唑；HOBT，1-hydroxybenzotriazole：1-羟基-苯并-三氮唑；Cl-HOBT：6-氯-1-羟基-苯并-三氮唑；NMM，N-Methylmorpholine：N-甲基吗啉；NMP，N-methylpyrrolidinone：N-甲基吡咯烷酮；Su，succinimide：琥珀酰亚胺；TEA，triethylamine：三乙胺；TFA，trifluoroacetic acid三氟乙酸；TIS，triisopropylsilane：三异丙基硅烷。
多肽化学合成方法
多肽固相化学合成方法是一种发展完善的方法学，可参文献例如R.C.Sheppard，Solid Phase Peptide Synthesis.A Practical Approach，Oxford-IRL Press，New York，1989。
线性多肽使用Boc固相多肽合成法或Fmoc固相多肽合成法。如果使用Fmoc化学合成C-末端是羧基的多肽，通常选用Wang树脂；C-末端是酰胺的多肽通常选用Rink amide树脂(本文中Rink amide树脂包括Rink Amide-AM树脂、Rink Amide-MBHA树脂等同类树脂)。如果使用Boc化学合成C-末端是羧基的多肽，通常选用Pam树脂；C-末端是酰胺的多肽通常选用MBHA树脂。常用的缩合剂和活化剂是DIC和HOBT，其他可选肽键缩合剂包括BOP、HBTU、DEPBT等。氨基酸5倍过量。缩合时间为1小时。多肽可以手工合成，也可以使用多肽固相合成仪合成。
Fmoc保护基用20％哌啶/DMF脱除。Boc保护基用TFA脱除。肽键缩合反应用茚三酮(Ninhydrin，2，2-Dihydroxyindane-1，3-dione)试剂监测。
固相合成可以选用已预装载C末端氨基酸的树脂，或者选用未装载氨基酸的树脂。
在RinkAmide树脂上装载第一个氨基酸的方法可参考业内通常做法。一种常用方法简述如下：称量适量的树脂，在固相合成管中用20％哌啶/DMF脱除Fmoc保护基(15mL/g树脂，30分 钟X2)，用DMF洗涤树脂。称量相当于树脂氨基5倍当量的Fmoc氨基酸、HATU、HOAT和10倍当量的NMM，加入DMF混匀后转入固相合成管。反应过夜后，用DMF洗涤树脂。向固相合成管加入1∶1 醋酸酐/吡啶(v/v)，30分钟后排空，用DMF洗涤树脂。第一个氨基酸装载完毕。
使用Fmoc固相多肽合成法时，常用的氨基酸及保护基如下：
Fmoc-Cys(Trt)-OH、Fmoc-Asp(OtBu)-OH、Fmoc-Glu(OtBu)-OH、Fmoc-His(Trt)-OH、Fmoc-Lys(Boc)-OH、Fmoc-Asn(Trt)-OH、Fmoc-Gln(Trt)-OH、Fmoc-Arg(Pmc)-OH、Fmoc-Ser(tBu)-OH、Fmoc-Thr(tBu)-OH、Fmoc-Trp(Boc)-OH、Fmoc-Tyr(tBu)-OH
合成过程中采用有适当保护的结构单元，如上述标准氨基酸、Fmoc-8-氨基-3，6-二氧杂辛酸(CAS No.166108-71-0)、Fmoc-Glu-OtBu(CAS No.84793-07-7)。脂肪酸部分的引入可以使用结构单元来实现，例如但不限于二十烷二酸单叔丁酯。在每个偶联步骤之后，未反应的肽中间体可以用乙酸酐(10当量)和过量可力丁(20当量)封端。
固相Fmoc化学合成多肽后，常用的切割试剂是TFA。将干树脂放在一个摇瓶中，加入适当量含有90∶4∶2∶2∶2(v/v)三氟乙酸∶三异丙基硅烷∶1，2-乙二硫醇∶水∶苯甲硫醚切割液(10-25mL/g树脂)，盖上盖子，在室温下进行间歇式旋转震荡。2小时后抽滤树脂，以新的TFA清洗树脂2-3次，合并滤液，滴加8-10倍体积的冰乙醚。最后，离心收集沉淀出来的多肽粗品。
使用Boc固相多肽合成法时，常用氨基酸和保护基如下：Boc-Cys(4-MeBzl)-OH、Boc-Asp(OcHx)-OH、Boc-Glu(OcHx)-OH、Boc-His(Bom)-OH、Boc-Lys(2-Cl-Z)-OH，Boc-Asn(Xan)-OH、Boc-Arg(Tos)-OH、Boc-Ser(Bzl)-OH、Boc-Thr(Bzl)-OH、Boc-Trp(CHO)-OH和Boc-Tyr(2-Br-Z)-OH
如果赖氨酸的侧链氨基用于合成内酰胺或酰化反应，赖氨酸的侧链氨基可以使用烯丙氧羰基(aloc)保护或Fmoc保护。如果天冬氨酸或谷氨酸的侧链羧基用于内酰胺合成或酰化反应，羧基应该转化为烯丙酯或9-芴基甲基保护，例如Boc-Glu(OAllyl)-OH、Boc-Glu(Ofm)-OH。
固相Boc化学合成多肽后，对于PAM、MBHA树脂，通常采用HF切割，每0.1毫摩尔树脂加5毫升HF，同时加入对甲苯酚、对巯基苯酚或苯甲醚等试剂，混合物在冰浴条件下搅拌1小时。真空抽干HF后，多肽用冰乙醚沉淀，离心收集沉淀，经过HPLC分离纯化，冷冻干燥得到最后产品。
纯化
将粗肽溶于水和乙腈(例如水/乙腈(3∶1))的合适混合物中，并通过反相制备型HPLC(例如AKTA purifier、岛津LC-20AR等)纯化，根据装载的粗肽量和极性大小选用不同填料和大小的柱子，例如C8或C18半制备柱或制备柱。缓冲液A为0.1％TFA水溶液，缓冲液B为0.1％TFA的乙腈。缓冲液B梯度上升进行洗脱，通过分析型HPLC检查相关级分(fraction)。使用ZORBAX 300 SB-C18(4.6X250mm，5μM)柱，缓冲液A为0.1％TFA水溶液，缓冲液B为0.1％TFA的乙腈。流速1ml/min，在210nm波长检测。将含有纯的目标肽的级分混合并冷冻干燥，得到肽产品分装于玻璃小瓶中保存。
制备方法
本发明的化合物是直链肽。可以按照多肽序列自C末端至N末端的顺序逐步偶联每一个氨基酸，从而得到多肽主链。过程为：首先将一个氨基被封闭基团保护的氨基酸共价连接在固相载体上，脱掉第一个氨基酸的氨基保护基，这样第一个氨基酸就接到固相载体上。然后氨基被封闭的第二个氨基酸的羧基经过活化后，与己接在固相载体的第一个氨基酸的氨基反应形成肽键，这样在固相载体上就生成了一个带有保护基的二肽。重复上述肽键形成反应，使肽链从C端向N端延长，直至生成所需要的肽链。最后脱去保护基，水解肽链和固相载体之间的共价键，就得到了合成好的肽。
本发明部分化合物通过侧链含有氨基或者巯基的氨基酸的侧链氨基或者巯基缀合长效基团或者修饰基团。以化合物27为例说明合成路线和方法。
化合物27的合成包括如下步骤：
步骤A：将Lys(PG)和树脂偶联得到Lys(PG)-树脂，PG为赖氨酸侧链氨基的保护基团；
步骤B：Lys(PG)-树脂经第一逐步偶联氨基酸或氨基酸衍生物，得到序列如化合物27主肽链所示的第一肽树脂；
步骤C：脱除序列如化合物27主肽链所示的第一肽树脂中Lys的侧链保护基团PG，经第二逐步偶联2-(2-(2-氨乙氧基)乙氧基)乙酸、2-(2-(2-氨乙氧基)乙氧基)乙酸、γ-Glu和十八烷二酸，获得第二肽树脂；
步骤D：取第二肽树脂经裂解、纯化，得到化合物27。
优选地，步骤A中树脂为Rink Amide树脂，或者Rink Amide-AM树脂、Rink Amide-MBHA树脂等同类树脂。优选地，步骤A中偶联采用的活化剂选自DIC和HOBt，或者HATU和HOAT，或者BOP、PyBOP、PyAOP、HBTU、TBTU、DEPBT等。优选地，Lys的侧链保护基为aloc、Dde或者ivDde。
步骤B中第一逐步偶联时，根据化合物27序列，逐步偶联Fmoc-Pro-OH、Fmoc-Pro-OH、Fmoc-Pro-OH、Fmoc-Ala-OH、Fmoc-Gly-OH、Fmoc-Ser(tBu)-OH、Fmoc-Ser(tBu)-OH、Fmoc-Pro-OH、Fmoc-Gly-OH、Fmoc-Gly-OH、Fmoc-Ala-OH、Fmoc-Leu-OH、Fmoc-Leu-OH、Fmoc-Trp(Boc)-OH、Fmoc-Glu(OtBu)-OH、Fmoc-Ile-OH、Fmoc-Phe-OH、Fmoc-Leu-OH、Fmoc-Arg(Pbf)-OH、Fmoc-Val-OH、Fmoc-Ala-OH、Fmoc-Glu(OtBu)-OH、Fmoc-Lys(Boc)-OH、Fmoc-Glu(OtBu)-OH、Fmoc-Leu-OH、Fmoc-Ala-OH、Fmoc-Ile-OH、Fmoc-Ser(tBu)-OH、Fmoc-Leu-OH、Fmoc-Asp(OtBu)-OH、Fmoc-Ser(tBu)-OH、Fmoc-Thr(tBu)-OH、Fmoc-Phe-OH、Fmoc-Thr(tBu)-OH、Fmoc-Gly-OH、Fmoc-Glu(OtBu)-OH、Fmoc-Aib-OH和Boc-Tyr(tBu)-OH。
步骤B中第一逐步偶联和步骤C中第二逐步偶联采用的偶联剂包括缩合剂和反应溶剂，缩合剂可以是DIC和HOBt的混合液，PyBOP、HOBt和DIEA的混合液，或HATU、HOAt和DIEA的混合液，或DEPBT和DIEA的混合液，或HBTU和DIEA的混合液，反应溶剂为DMF、DCM、NMP或DMSO中的一种或两者以上的混合液。
当PG是aloc时，步骤C中脱除采用的试剂为1-20当量吗啡啉(或者1-20当量的苯硅烷替代吗啡啉)与0.05-3当量Pd(PPh 3) 4脱除。优选地，aloc保护基用5-10当量吗啡啉(或者5-10当量的苯硅烷替代吗啡啉)与0.1-0.3当量Pd(PPh 3) 4脱除。保护基脱除反应可以进行两次，每次10-30分钟，优先选用CH 2Cl 2为溶剂。
脱除Aloc保护基的另一个方法是用催化量的四(三苯基膦)钯(0)和37∶2∶1比例的DCM、冰醋酸和NMM(15mL/g树脂)在氩气环境、室温条件下搅拌2小时。反应后每克树脂用0.5％DIPEA/DMF(10mL)，0.5％二乙基二硫代氨基甲酸钠/DMF(3X 10mL)，1∶1 DCM∶DMF(5X10mL)清洗。
当PG是Dde或ivDde时，步骤C中脱除保护基采用的试剂为水合肼/DMF混合液。配制2％(w/v)水合肼的DMF溶液(25mL/g树脂)，加入树脂，5分钟后抽干，用DMF洗树脂。用2％水合肼/DMF脱保护基及DMF洗涤的过程重复3次。
步骤C中第二逐步偶联时，根据化合物27序列，逐步偶联Fmoc-8-氨基-3，6-二氧杂辛酸(CAS No.166108-71-0)、Fmoc-Glu-OtBu(CAS No.84793-07-7)和十八烷二酸单叔丁酯HOOC-(CH2)16-COOtBu。
步骤D中裂解采用的试剂包括TFA及PhSMe、PhOMe、EDT、H 2O、TIS、PhOH中的一种、两种或者两种以上的化合物。例如，裂解采用的试剂为TFA、苯甲硫醚、甲硫醚和EDT的混合液，TFA、苯甲硫醚、甲硫醚和EDT的体积比为90∶5∶3∶2。优选地，裂解采用的试剂为TFA、H 2O和TIS混合液，体积比为95∶2.5∶2.5。
本发明还包括可用于合成本发明化合物或其药学上可接受盐的新的中间体和方法。本发明的中间体和化合物可以通过本领域已知的多种方法制备。特别地，在下面的实施例中举例说明了使用化学合成的方法。所描述的每一途径的具体合成步骤可以以不同的方式组合，以制备本发明的化合物或其盐。试剂和原料是本领域普通技术人员容易获得的。
实施例
参照实施例进一步阐释本发明。这些实施例绝非旨在限制所请求保护的本发明的范围。本领域技术人员可以借鉴本发明的内容，适当改进工艺参数，对本发明所述方法和应用进行改动或适当变更与组合，来实现和应用本发明技术。所有类似的替换和改动对本领域技术人员是显而易见的，它们都被视为包括在本发明中。
氨基酸原料、缩合试剂等购自吉尔生化(上海)有限公司。Rink Amide树脂购自上虞普尔公司和天津南开和成科技有限公司。
实施例1 多肽2的合成
选取预装载的中低载量Fmoc-Ser(tBu)-Rink Amide树脂(例如0.4mmole/g)，用30％哌啶/DMF脱除Fmoc保护基(2X10分钟)，用DMF洗涤树脂3遍。使用Fmoc固相多肽合成法。将氨基酸(相对于树脂氨基酸载量10当量)溶于DMF，配成0.3M溶液。向溶液加入HOBT和DIC(相对于树脂氨基酸载量10当量)，混合溶液震荡混匀后加入树脂，在室温偶联60分钟。排空固相反应管中的溶液，用DMF洗涤树脂3遍。至此完成一个合成单元的偶联。多肽自C末端至N末端的每个合成单元都采用同样的偶联方法，氨基酸残基使用“多肽固相化学合成方法”部分列举的Fmoc固相合成常用的保护基或其它适合本序列的保护基。
肽链合成后树脂用DCM洗涤，加入含有90∶4∶2∶2∶2(v/v)三氟乙酸∶三异丙基硅烷∶1，2-乙二硫醇∶水∶苯甲硫醚切割液(10-25mL/g树脂)，在室温震荡2小时，用冰乙醚沉淀。粗肽溶于0.1％TFA，30％乙腈水溶液，通过制备型RP-HPLC，C8，5μM反相柱。缓冲液A为0.1％TFA水溶液，缓冲液B为0.1％TFA的乙腈。缓冲液B梯度逐步上升进行洗脱，合并正确的级分(fraction)并低温冷冻干燥，得到白色固体。通过质谱分析和氨基酸测序确定多肽的结构。本发明中C末端是丝氨酸的化合物都可以按照实施例1的方法合成。
实施例2 多肽7合成
选取预装载的Fmoc-Gly-Rink Amide树脂。其余合成方法和步骤与实施例1类似。本发明中C末端是甘氨酸的化合物都可以按照实施例2的方法合成。
实施例3 化合物23的合成
选取预装载的低载量Fmoc-Lys(Aloc)-Rink Amide树脂(例如0.29mmole/g)。多肽自C末端至N末端的每个合成单元都采用实施例1的偶联方法，除C末端赖氨酸以外的氨基酸残基使用“多肽固相化学合成方法”部分列举的Fmoc固相合成常用的保护基。肽链合成后，脱除C末端赖氨酸侧链烯丙氧羰基可以用四(三苯基膦)钯(0)和37∶2∶1比例的DCM、冰醋酸和NMM(15mL/g树脂)在氩气环境、室温条件下搅拌2小时。四(三苯基膦)钯(0)可以使用催化量至1当量。反应后每克树脂用0.5％DIPEA/DMF(10mL)，0.5％二乙基二硫代氨基甲酸钠/DMF(3X 10mL)，1∶1 DCM∶DMF(5X10mL)清洗。Aloc保护基也可以用5-10当量吗啡啉(或者5-10当量的苯硅烷)与0.1-0.3当量Pd(PPh 3) 4脱除。保护基脱除反应可以进行两次，每次30分钟，选用CH 2Cl 2为溶剂。脱除侧链Aloc保护基后，此赖氨酸侧链取代基的合成使用结构单元Fmoc-8-氨基-3，6-二氧杂辛酸(CAS No.166108-71-0)、Fmoc-Glu-OtBu(CAS No.84793-07-7)和十八烷二酸单叔丁酯HOOC-(CH 2) 16-COOtBu。侧链取代基每个结构单元的用量是树脂氨基酸载量10当量，每步偶联时间为4小时。其余合成方法和步骤与实施例1类似。
另外一种方法是选取预装载的低载量Fmoc-Lys(ivDde)-Rink Amide树脂。主肽链的合成方法与上一段使用Fmoc-Lys(Aloc)-RinkAmide树脂的方法相同。主肽链合成后，C末端赖氨酸侧链ivDde保护基用2％水合肼/DMF脱除。配制2％(w/v)水合肼的DMF溶液(25mL/g树脂)，加入树脂，5分钟后抽干，用DMF洗树脂。用2％水合肼/DMF脱保护基及DMF洗涤的过程重复3次。此赖氨酸侧链取代基的合成方法与上一段Fmoc-Lys(Aloc)-Rink Amide树脂的侧链链接方法一样。
本发明中C末端是赖氨酸而且侧链氨基连接长效基团的化合物，例如化合物4、6、11、13、14、17、21-23、27-30、220和221也可以用实施例3的方法合成，或者采用“制备方法”部分化合物27的合成方法。
实施例4 多肽33合成
选取预装载的Fmoc-Cys(Trt)-Rink Amide树脂。其余合成方法和步骤与实施例1类似。本发明中C末端是半胱氨酸的化合物都可以按照实施例4的方法合成。
实施例5 多肽95合成
选取预装载的Fmoc-Pro-Rink Amide树脂。其余合成方法和步骤与实施例1类似。本发明中C末端是脯氨酸的化合物都可以按照实施例5的方法合成。
实施例6 多肽110合成
选取预装载的Fmoc-Ala-Rink Amide树脂。其余合成方法和步骤与实施例1类似。本发明中C末端是丙氨酸的化合物都可以按照实施例6的方法合成。
表1列出了本发明中部分化合物的计算分子量和实测分子量。
表1
化合物 计算分子量 实测分子量 化合物 计算分子量 实测分子量
化合物1 4191.6 4191.2 化合物2 4163.6 4163.1
化合物3 4177.6 4177.0 化合物4 5035.6 5035.4
化合物5 4294.7 4293.9 化合物6 4948.5 4947.6
化合物7 3328.7 3327.7 化合物8 4204.7 4203.1
化合物9 4176.6 4176.2 化合物10 4148.6 4148.0
化合物11 5048.7 5047.5 化合物12 4217.7 4217.1
化合物13 4933.6 4933.5 化合物14 4961.6 4960.4
化合物15 3369.8 3368.7 化合物16 4233.7 4232.8
化合物17 5077.7 5076.3 化合物18 4120.6 4119.5
化合物19 4148.6 4147.1 化合物20 5010.7 5009.3
化合物21 4992.7 4992.5 化合物22 4905.6 4904.4
化合物23 4964.7 4963.9 化合物24 4120.6 4120.1
化合物25 3313.8 3312.6 化合物26 4923.6 4922.5
化合物27 4848.5 4847.8 化合物28 4935.6 4935.5
化合物28 4935.6 4935.5 化合物29 4862.6 4862.4
化合物30 4949.6 4948.7 化合物31 4091.6 4090.3
化合物32 4194.7 4193.1 化合物33 4107.6 4107.2
化合物34 4219.8 4219.3 化合物35 4132.7 4131.9
化合物36 4105.6 4105.1 化合物37 4208.7 4208.3
化合物38 4121.7 4121.0 化合物39 4233.8 4232.6
化合物40 4146.7 4145.2 化合物41 3256.7 3256.1
化合物42 3270.7 3269.8 化合物43 4063.6 4063.1
化合物44 4104.7 4104.2 化合物45 4191.7 4190.4
化合物46 4166.7 4166.2 化合物47 4079.6 4078.0
化合物48 4077.6 4076.8 化合物49 4118.7 4118.1
化合物50 4205.8 4205.2 化合物51 4093.7 4093.0
化合物52 4180.7 4179.3 化合物53 4119.6 4119.7
化合物54 4103.6 4103.1 化合物55 4092.6 4092.0
化合物115 3727.3 3726.8 化合物178 3512.0 3511.6
化合物220 4876.7 4875.9 化合物221 4890.7 4889.8
质谱分子量和氨基酸测序结果证明多肽结构正确。
多肽溶于生理盐水(pH 7.4)，制成原液(stock solution)。原液中多肽浓度通过Bradford法、紫外分光度检测法等常规方法定量。动物药效试验前根据给药量取含有所需剂量的多肽原液，用缓冲生理盐水(PBS，pH 7.4)稀释配成注射液。每只动物比较合适的注射液体积是5ml/kg体重。可以此计算需要配置的注射液的体积。
动物实验所有的数据将被录入到Excel文档中，并以mean±S.E.M的方式表示，多组间差异采用graphpad Prism 6软件比较采用单因素方差分析(One-way analysis ofvariance(ANOVA))Dunnett’s方法，两组间差异采用非配对T-Test方法，P值小于0.05时被认为有显著性差异。
实施例7
本发明的多肽体内药效可以在本领域已知的任何合适的动物模型中以及在临床试验中测定。例如db/db小鼠是一种比较合适的糖尿病动物模型。
db/db小鼠饲养于严格控制环境条件的动物饲养间中，饲养间的温度维持在20～24℃，湿度维持在40～70％。通过温湿度计对饲养间的温度和湿度进行实时监控，并且每天对温度和湿度记录两次(上午和下午各1次)。动物饲养间的采光由一个电子定时开灯系统来控制，每天开灯12小时关灯12小时(上午7：00开，下午19：00关)。实验过程中，动物单笼饲养，并给每个笼中的小鼠提供玩具。实验过程中，动物自由饮水。db/db雄性小鼠(6周龄)适应试验环境一周。试验前三天(-3天
Figure PCTCN2021104822-appb-000033
-1天)记录基线血糖和体重。基于三日血糖和体重将小鼠随机分组，每组6只。小鼠在上午10：00皮下注射生理盐水(5ml/kg，对照组)或多肽化合物1、2、8、16、18、19、24和36(30nmol/kg)，在给药前0小时及给药后1、2、4、6、8和10小时采血，使用美国强生公司稳豪型血糖仪及配套试纸检测血糖。以时间为横坐标，不同时间点的血糖值为纵坐标，绘制血糖曲线，计算曲线下面积(AUC)，比较多肽化合物降血糖作用的时间和效果。
结果如图1所示，表明，化合物1、2、8、16、18、19、24和36均可以大幅度降低2型糖尿病小鼠的血糖，与对照组有统计学的显著差异。这些化合物有潜力作为糖尿病治疗药物。
实施例8
db/db小鼠饲养条件与实施例7相同。db/db雄性小鼠(8周龄)适应试验环境一周。试验前三天(-3天
Figure PCTCN2021104822-appb-000034
-1天)记录基线血糖和体重。基于三日血糖和体重将小鼠随机分组，每组6只。小鼠在上午10：00皮下注射生理盐水(5ml/kg，对照组)或多肽化合物31、35、38、44和49(30nmol/kg)，在给药前0小时及给药后1、2、4、6、8和10小时采血，使用美国强生公司稳豪型血糖仪及配套试纸检测血糖。以时间为横坐标，不同时间点的血糖值为纵坐标，建立降血糖作用的时效曲线，计算降糖作用曲线下面积(AUC)。
结果如图2所示，表明，化合物31、35、38、44和49均可以大幅度降低2型糖尿病小鼠的血糖，与对照组有统计学的显著差异。这些化合物有潜力作为糖尿病治疗药物。
实施例9
db/db小鼠饲养条件与实施例7相同。试验前三天(-3天
Figure PCTCN2021104822-appb-000035
-1天)记录db/db雄性小鼠(6周龄)基线血糖和体重。基于三日血糖和体重将小鼠随机分组，每组6只。试验前一天(-1天)18：00试验动物皮下注射生理盐水(5ml/kg，对照组)或化合物6、13、14和26(3nmol/kg)。试验当天动物禁食6小时(8：00-14：00)，进行腹腔注射葡萄糖耐受试验(IPGTT)。动物于14：00单次腹腔注射葡萄糖(1.5克/公斤)水溶液，并将给糖时间记为0点。在给糖前0分钟，给糖后15、30、60、120和180分钟对动物进行血糖检测，以时间为横坐标，不同时间点的血糖值为纵坐标，绘制血糖曲线。
结果如图3所示，表明，化合物6、13、14和26均可以大幅度降低2型糖尿病小鼠的血糖，而且显示出延长的体内作用时间，有潜力作为长效糖尿病治疗药物。
实施例10
本发明的多肽体内药效可以在本领域已知的任何合适的动物模型中以及在临床试验中测定。饮食诱导的肥胖(DIO)小鼠是肥胖症、胰岛素抵抗和高血脂动物模型。
5周龄雄性C57BL/6小鼠饲养于严格控制环境条件的动物饲养间中，饲养间的温度维持在20～24℃，湿度维持在30～70％。通过温湿度计对饲养间的温度和湿度进行实时监控，并且每天对温度和湿度记录两次(上午和下午各1次)。动物饲养间的采光由一个电子定时开灯系统来控制，每天开灯12小时关灯12小时(上午6：00开，下午18：00关)。实验过程中，动物单笼饲养，并给每个笼中的小鼠提供玩具。动物从6周龄开始用高脂饲料饲养(各营养成分重量比为蛋白26.2％，碳水化合物26.3％，脂肪36.9％，提供热量百分比分别为20％、20％和60％)。饲养过程中，动物自由饮水。选取25周龄、平均体重49克左右雄性DIO小鼠进行试验。动物进行抓取适应、皮下注射适应1周。并在实验前连续3天称量体重和摄食量，实验前1天测量动物血糖，并按照动物的血糖与体重分组，每组6只。
实验期间，对照组和利拉鲁肽组动物每天皮下注射一次生理盐水或利拉鲁肽(100nmol/kg)。另外5组动物在1、3、5、7、9、11、13天皮下分别注射一次多肽4、11、17、20和23(25nmol/kg)，注射。14天实验期间，每天称量动物的体重及摄食量。体重变化百分比是[(最终体重-起始体重)/起始体重]*100％。
实验开始前一天及第15天用血糖仪检测动物的空腹血糖水平。空腹血糖检测时，动物禁食时间为早9：00至下午15：00，检测时间为下午15：00。
第16天，动物禁食6小时(8：00-14：00)，实施安乐死术，解剖动物，心脏采血，并离心分装为血浆，用于生化水平检测，主要项目包括甘油三酯(TG)和胆固醇(TC)。生化指标分析使用日立系列全自动生化分析仪(HITACHI 7180)。另外收集动物肝脏，检测肝脏甘油三酯和胆固醇。
动物14天体重变化结果如图4所示。与对照组相比，给药组的体重显著下降，第14天体重与对照组有统计学的显著差异，而且多肽4、11、17、20和23降体重的能力显著优于减肥药利拉鲁肽。
空腹血糖(试验开始前和完成后空腹血糖对比)变化如图5所示，表明与对照组相比，给药组的空腹血糖显著下降，而且多肽4、11、17、20和23组优于利拉鲁肽组。空腹血糖下降标志给药组动物对血糖的调控能力改善。
如图6和7所示，与对照组相比，给药组动物的胆固醇和甘油三酯都显著下降，多肽4、11、17、20和23组的下降幅度都显著大于利拉鲁肽组。
实施例11
db/db雄性小鼠(江苏集萃药康生物，6周龄)到达设施后饲养于严格控制环境条件的动物饲养间中，饲养间的温度维持在20～24℃，湿度维持在40～70％。通过温湿度计对饲养间的温度和湿度进行实时监控，并且每天对温度和湿度记录两次(上午和下午各1次)。动物饲养间的采光由一个电子定时开灯系统来控制，每天开灯12小时关灯12小时(上午7：00开，下午19：00关)。实验过程中，动物单笼饲养，并给每个笼中的小鼠提供玩具。实验过程中，动物自由饮水。动物适应环境两周。试验前三天(-3天
Figure PCTCN2021104822-appb-000036
-1天)动物早9：00禁食6小时后，15：00测量空腹血糖。基于三日空腹血糖和体重将小鼠随机分组，每组6只。试验目标是测量化合物降低小鼠空腹血糖的能力。试验期间动物的禁食时间为早9：00至晚21：00。试验第一天，小鼠预先空腹6小时((9：00-15：00)，然后皮下注射生理盐水(5ml/kg)或化合物21、22、27、28、29和30(5nmol/kg)，在给药前0小时及给药后1、3、6、24、30和48小时采血，使用美国强生公司稳豪型血糖仪及配套试纸检测血糖。以时间为横坐标，不同时间点的血糖值为纵坐标，建立降血糖作用的时效曲线。
结果如图8所示，化合物21、22、27、28、29和30均可以大幅度降低db/db小鼠的血糖，与对照组有统计学的显著差异。这些化合物有潜力作为长效糖尿病治疗药物。另外，三对化合物21和22、27和28、29和30显示，当化合物C末端赖氨酸侧链连接长效基团时，其邻位的丝氨酸缺失显著提升化合物的疗效，产生意想不到的效果。
实施例12
db/db小鼠饲养条件与实施例7相同。db/db雄性小鼠(江苏集萃药康生物，7周龄)适应试验环境一周。试验前三天(-3天
Figure PCTCN2021104822-appb-000037
-1天)记录基线血糖和体重。基于三日血糖和体重将小鼠随机分组，每组6只。小鼠在上午10：00皮下注射生理盐水(5ml/kg，对照组)或多肽化合物42、115、178(35nmol/kg)，在给药前0小时及给药后1.5，4，7，10小时采血，使用美国强生公司稳豪型血糖仪及配套试纸检测血糖。以时间为横坐标，不同时间点的血糖值为纵坐标，绘制血糖曲线，计算曲线下面积(AUC)，比较多肽化合物降血糖作用的时间和效果。
结果如图9所示，化合物42、115、178均可以显著降低2型糖尿病小鼠的血糖。这些化合物有潜力作为糖尿病治疗药物。
实施例13
DIO肥胖小鼠试验由上海药明康德新药开发有限公司完成。雄性C57BL/6小鼠自5周龄起用高脂饲料(货号：D12492i，Research Diets，Inc)饲养25周。动物30周龄时进行抓取适应和皮下注射适应1周。实验前连续3天称量体重和摄食量，实验前1天测量动物空腹血糖，去掉血糖过高的动物，并按照动物的随机血糖与体重(以体重为主要参考指标)分组，每组5只。实验期间，动物按组别每天皮下注射一次生理盐水、化合物27和化合物29(3nmol/kg)，给药周期为10天。实验期间，每天测量动物的体重及摄食量。实验结束后，动物禁食6h，实施安乐死术，解剖动物，心脏采血，并离心分装为血浆，用于生化水平检测。
如图10所示，与对照组相比，给药组动物的体重显著下降。第11天，给药组动物的体重与同组动物的起始体重有统计学的显著差异，与对照组动物的体重也有统计学的显著差异(P＜0.0001)。
如图11所示，与对照组相比，给药组动物的摄食量显著下降。动物10天累计进食量与对照组有统计学的显著差异(P＜0.0001)，说明化合物27和化合物29有抑制食欲的作用。
如图12所示，化合物27和化合物29大幅度降低实验动物的低密度脂蛋白胆固醇(LDL-C)，与对照组有统计学的显著差异(P＜0.0001)。由于LDL-C水平与心血管疾病密切相关，化合物27和化合物29有潜力用于高脂血症治疗，降低心血管疾病风险。
实施例14
DIO肥胖小鼠试验由上海药明康德新药开发有限公司完成。动物饲养情况与实施例13相同。动物40周龄时进行抓取适应和皮下注射适应1周。实验前连续3天称量体重和摄食量，实验前1天测量动物空腹血糖，去掉血糖过高的动物，并按照动物的随机血糖与体重(以体重为主要参考指标)分组，平均体重47克，每组6只。实验期间，动物按组别每天皮下注射一次生理盐水或者每只动物皮下注射1.5nmole化合物35或化合物40，给药周期为14天。实验开始前及实验结束后用EchoMRI体脂仪检测动物的体脂含量。
DIO肥胖小鼠实验开始前(第0天)及实验结束后(第15天)脂肪组织量和瘦肉组织量变化结果如图13所示。与对照组相比，给药组动物的脂肪组织量显著下降，与对照组有统计学的显著差异，但瘦肉组织量基本不变，说明化合物35和化合物40能够以比较理想的方式减肥。
实施例15 化合物27制剂的盐体系的筛选及其溶解度考察
1.磷酸氢二钠体系
磷酸氢二钠体系：配制pH值范围为6.2-8.5的磷酸盐溶液，加入原料药进行溶解度考察，不同pH值溶液中的试验结果显示：随着pH值升高，化合物27溶解度明显增加，当pH≤6.5 时，溶解度低于1mg/ml，当pH＞6.5时，溶解度和溶解速度大大提高，可以达到2mg/ml的浓度，甚至更高。所以pH＞6.5的磷酸氢二钠体系适合配制成原料药的目标浓度水针。
2.醋酸盐体系
醋酸盐体系：当pH＞6.5时，原料药溶解度和溶解速度都比较低，按照1mg/ml的浓度配制原料药溶液，溶解时间大于30分钟，不适合放大生产，且将其放置于冷藏条件下考察物理稳定性时发现药物析出。pH＜6.5时，溶解困难。
结论：选择pH＞6.5的磷酸氢二钠体系进行后续研究。
实施例16 化合物27制剂的稳定性研究
配制化合物27原料药的磷酸盐溶液，化合物27浓度1mg/ml，每毫升包含：甘油20mg、苯酚5.5mg、磷酸氢二钠(十二水合物)2.86mg及注射用水。pH用1N盐酸或氢氧化钠水溶液调节。在室温(25～30℃)和冷藏(2～8℃)条件下分别放置不同的时间进行考察，具体结果见表2。
表2 稳定性考察表
Figure PCTCN2021104822-appb-000038
结果显示：化合物27在pH＜7.3时，物理稳定性较差，化合物27发生了多肽变性和沉淀。当pH＞7.4时，溶液澄清，稳定性良好。同时，对化合物27进行了HPLC检测，结果显示，pH＜7.32时，化合物27的含量发生明显的降低，与其状态变化现象相一致，说明当pH＜7.4时，化合物27会发生多肽变性导致含量降低。
由于强碱性制剂不适合临床应用，所以注射液的pH值一般不高于8.5，最好不高于8.2。化合物27选择使用pH＝7.5的磷酸盐体系。
实施例17 化合物27的制剂辅料用量选择
1.磷酸氢二钠用量考察
按照化合物27原料药1.5mg/ml规格配制不同的磷酸盐溶液，以含药溶液pH值为7.5为目标来确定磷酸氢二钠用量。具体结果见表3。
表3 盐用量考察
磷酸氢二钠(十二水合物)用量 空白溶液pH值 含药溶液pH值
2.86mg/ml 8.01 7.64
2.0mg/ml 7.97 7.49
结论：磷酸氢二钠(十二水合物)用量为2.0mg/ml。
2.甘油用量考察
按照化合物27原料药1.5mg/ml、磷酸氢二钠(十二水合物)2.0mg/ml、苯酚5.0mg/ml，配制不同甘油用量的磷酸盐溶液，以渗透压为主要评价指标，具体结果见表4。
表4 不同甘油用量的渗透压测定结果
Figure PCTCN2021104822-appb-000039
结果显示，甘油用量为19.7mg/ml的溶液渗透压厚尔浓度最接近于正常人体的渗透压厚尔浓度值285-310mOsmol/kg，选择甘油用量为19.7mg/ml。
3.制剂配制
根据制剂处方，先将制剂所需数量的磷酸氢二钠、苯酚、甘油和适量的注射用无菌水配制成溶液，再将原料药加入到溶液中，搅拌溶解，然后加入适量的注射用无菌水使制剂溶液达到目标体积。制剂溶液pH可以通过1N HCl和1N NaOH溶液调节。最后用0.22微米的滤膜对制剂溶液进行除菌过滤。此配制方法适用于本发明所有化合物的制剂处方。
4.制剂处方
化合物27制剂处方见表5和表6。
表5 制剂处方一
组分 每毫升用量(mg)
化合物27 1.5
磷酸氢二钠(十二水合物) 2.0
丙二醇 14.0
苯酚 5.0
注射用水 977.24
pH值 7.5
表6 制剂处方二
组分 每毫升用量(mg)
化合物27 1.5
磷酸氢二钠(十二水合物) 2.0
甘油 19.7
苯酚 5.0
注射用水 971.54
pH值 7.5
实施例18 化合物220制剂配方
化合物220制剂处方见表7-9。
表7 制剂处方三
名称 每毫升用量(mg)
化合物220 1.5
磷酸氢二钠(十二水合物) 2.00
甘油 18.00
苯酚 5.00
注射用水 974.40
pH值 7.5
表8 制剂处方四
名称 每毫升用量(mg)
化合物220 1.5
磷酸氢二钠(十二水合物) 2.84
丙二醇 14.00
苯酚 5.0
注射用水 978.00
pH值 7.5
表9 制剂处方五
组分 每毫升用量(mg)
化合物220 1.5
磷酸氢二钠(十二水合物) 2.84
丙二醇 14.00
苯酚 5.0
注射用水 978.00
pH值 8.0
实施例19 化合物221制剂配方
化合物221制剂处方见表10和表11。
表10 制剂处方六
名称 每毫升用量(mg)
化合物221 1.5
磷酸氢二钠(十二水合物) 2.00
甘油 18.00
苯酚 5.00
注射用水 974.40
pH值 7.5
表11 制剂处方七
名称 每毫升用量(mg)
化合物221 1.5
磷酸氢二钠(十二水合物) 2.84
丙二醇 14.00
苯酚 5.0
注射用水 978.00
pH值 7.5
实施例20 制剂稳定性研究
RP-HPLC检测方法：流动相A：50mM KH 2PO 4/K 2HPO 4水溶液(每升含K 2HPO 4 1.203g，KH 2PO 4 5.865g)，pH＝6.0B：100％乙腈；梯度：38-55％，0-50min；色谱柱：Luna C18，3μm 4.6 X 150mm；流速：0.8mL/min；检测波长：214nm
含量测定：将标准品用注射用水稀释成不同浓度的溶液，用上述高效液相的操作方法进行检测，不同浓度的标准品得到不同的峰面积，然后用Excel软件做标准曲线，得到计算公式。
样品含量计算：取样品用上述高效液相的操作方法进行检测，将得到的峰面积代入到标准曲线的计算公式，就可得到样品的含量值。
有关物质含量：以杂质峰面积占总积分面积的比例计算。
将制剂样品置于长期条件(温度5℃±3℃)下放置6个月，分别于第1、2、3、6月末取样检查(表12)。
表12
Figure PCTCN2021104822-appb-000040
Figure PCTCN2021104822-appb-000041
将制剂样品置于加速条件(25℃±2℃，60％±5％)放置6个月，分别于第1、3、6月末取样检查(表13)。
表13
Figure PCTCN2021104822-appb-000042
以上处方一至处方七的注射液在长期条件下6个月内各项考察指标均在合规范围内，处方一的注射液在25℃加速条件下6个月内各项考察指标均在合规范围内。
实施例21
db/db小鼠饲养条件与实施例7相同。db/db雄性小鼠(8周龄)适应试验环境一周。试验前三天记录基线血糖和体重，基于三日血糖和体重将小鼠随机分4组，每组8只。小鼠每72小时皮下注射空白注射液(每毫升包含：磷酸氢二钠(十二水合物)2.0mg，甘油18.0mg，苯酚5.0mg，无菌注射用水974.4mg；对照组)或多肽化合物27、220、221(8nmol/kg，分别按照处方二、处方三和处方六配制制剂)，重复给药10次。第31天采取血样，测量HbA1c(％)。结果：对照组6.9±0.5，化合物27组5.6±0.4，化合物220组5.3±0.2，化合物221组5.1±0.1。给药组与对照组有统计学的显著差异。因此，化合物27、220和221的制剂有希望成为糖尿病治疗药物。

Claims (13)

  1. 一种药物制剂，所述药物制剂包含式(VII)的肽化合物或其药学上可接受的盐或溶剂合物，
    Y-aib-E-G-T-F-X11-S-D-X1-S-X12-X2-L-X3-X4-E-A-X5-X6-X13-F-X7-X8-W-L-X9-A-G-X10(VII)
    其中，X1代表选自L或Y的氨基酸，X2代表选自Q、A、aib或Y的氨基酸，X3代表选自D或E的氨基酸，X4代表选自E或K的氨基酸，X5代表选自V或A的氨基酸，X6代表选自K、R或Q的氨基酸，X7代表选自I或V的氨基酸，X8代表选自E、Q、N或A的氨基酸，X9代表选自I或L的氨基酸，X10代表不存在或GPSSGAPPP，GPPSGAPPP，GPSSGKPPP，GPSSGEPPP，GPSSaibAPPP，GPSSGAPP，GPSSGAP，GPSSGA，GPSSG，GPSS，GPS，GP，G；X11代表T或I的氨基酸；X12代表I、S或K的氨基酸；X13代表L、E或D的氨基酸；
    任选地，在X10的C端添加一个或两个选自S或者侧链含有氨基或者巯基的氨基酸，并且C末端氨基酸的羧基任选地被酰胺化为C末端酰胺，所述氨基酸具有式
    Figure PCTCN2021104822-appb-100001
    其中波浪线代表连接至相邻基团的连接点，n1为1-7的整数，当II或III为C末端氨基酸时，其羧基部分是COOH或CONH 2，优选地，含有侧链氨基的氨基酸是赖氨酸，含有侧链巯基的氨基酸是半胱氨酸，
    任选地，X10的C端添加的含有侧链氨基的氨基酸在其侧链氨基被长效基团修饰，优选地，所述长效基团具有式(IV)的结构：
    O1-O2-O3-O4-O5-O6-O7-O8-(IV)，
    其中O1代表式(V)或(VI)的结构：
    Figure PCTCN2021104822-appb-100002
    其中n2为6-24的整数，优选10-24，进一步优选16-22；
    其中波浪线代表连接至相邻基团的氨基的连接点，O2-O3-O4-O5-O6-O7-O8-代表连接体，其中O2至O8中的每一个独立地由以下氨基酸残基或长链结构中的任一个表示：α-Glu、γ-Glu、α-Asp、β-Asp、α-hGlu、δ-hGlu、Gly、Ala、β-Ala、GABA或PEG2，或者O2至O8中的一个或多个不存在，条件是O2至O8中至少有两个存在，优选地，O2至O8中含有至少一个带负电荷的部分。
  2. 根据权利要求1的药物制剂，其中所述肽化合物具有式(I)的结构，
    Y-aib-E-G-T-F-T-S-D-X1-S-I-X2-L-X3-X4-E-A-X5-X6-L-F-X7-X8-W-L-X9-A-G-X10(I)
    其中，X1代表选自L或Y的氨基酸，X2代表选自Q、A、aib或Y的氨基酸，X3代表选自D或E的氨基酸，X4代表选自E或K的氨基酸，X5代表选自V或A的氨基酸，X6代表选自K或R的氨基酸，X7代表选自I或V的氨基酸，X8代表选自E、Q或N的氨基酸，X9代表选自I或L的氨基酸，X10代表不存在或GPSSGAPPP，
    任选地，在X10的C端添加一个或两个选自S或者侧链含有氨基或者巯基的氨基酸，并且C末端氨基酸的羧基任选地被酰胺化为C末端酰胺，所述氨基酸具有式
    Figure PCTCN2021104822-appb-100003
    其中波浪线代表连接至相邻基团的连接点，n1为1-7的整数，优选地，含有侧链氨基的氨基酸是赖氨酸，含有侧链巯基的氨基酸是半胱氨酸，
    任选地，X10的C末端添加的含有侧链氨基的氨基酸在其侧链氨基被长效基团修饰，优选地，所述链接赖氨酸侧链氨基的长效基团具有式(IV)的结构：
    O1-O2-O3-O4-O5-O6-O7-O8-(IV)，
    其中O1代表式(V)或(VI)的结构：
    Figure PCTCN2021104822-appb-100004
    其中n2为6-24的整数，优选10-24，进一步优选16-22；
    其中波浪线代表连接至相邻基团的氨基的连接点，O2-O3-O4-O5-O6-O7-O8-代表连接体，其中O2至O8中的每一个独立地由以下氨基酸残基或长链结构中的任一个表示：α-Glu、γ-Glu、α-Asp、β-Asp、α-hGlu、δ-hGlu、Gly、Ala、β-Ala、GABA或PEG2，或者O2至O8中的一个或多个不存在，条件是O2至O8中至少有两个存在，优选地，O2至O8中含有至少一个带负电荷的部分。
  3. 根据权利要求1或2的药物制剂，其中O2-O3-O4-O5-O6-O7-O8-代表选自下组的连接体γGlu-PEG2-γGlu-、γGlu-PEG2-2×γGlu-、γGlu-PEG2-、γGlu-2×PEG2-、γGlu-3×PEG2-、γGlu-PEG2-γGlu-PEG2、γGlu-2×PEG2-γGlu-、γGlu-2×PEG2-2×γGlu-、2×γGlu-、2×γGlu-PEG2-、2×γGlu-PEG2-γGlu-、2×γGlu-PEG2-γGlu-PEG2-、2×γGlu-2×PEG2-、2×γGlu-2×PEG2-γGlu、2×γGlu-2×PEG2-2×γGlu-；
    任选地，根据前述任一方面的药物制剂，其中赖氨酸侧链氨基缀合长效基团，具有式(VIII)或式(IX)的结构：
    Figure PCTCN2021104822-appb-100005
    其中波浪线代表连接至相邻氨基酸残基的连接点。
  4. 根据前述权利要求任一项的药物制剂，其中X10的C末端添加的含有侧链巯基的氨基酸在其侧链巯基被式(IV)的长效基团修饰，所述含有侧链巯基的氨基酸的侧链巯基通过迈克尔反应受体或硫醇反应性基团与连接基团L一端连接，优选地，所述连接基团L另一端进一步通 过氨基或羧基与式(IV)的长效基团形成共价键连接，优选地，所述连接基团L选自：-NH-(CH 2) n5-(CH 2CH 2O) n6-(CH 2) n7-，-NH-(CH 2) n5-(CH 2CH 2O) n6-(CH 2) n7-NH-，-NH-(CH 2) n5-(CH 2CH 2O) n6-(CH 2) n7-CO-，-NH-(CH 2) n5-(CH 2CH 2O) n6-(CH 2) n7-NHCO-(CH 2) n8-，-NH-(CH 2) n5-(CH 2CH 2O) n6-(CH 2) n7-NHCO-(CH 2) n8-NH-或其任意组合，其中n3、n4、n5、n6、n7、n8各自是0至10的整数，更优选地，L是-NH-CH 2-(CH 2CH 2O) 3-(CH 2) 3-NH-或-NH-(CH 2) n5-(CH 2CH 2O) n6-(CH 2) n7-NHCO-(CH 2) n8-。
  5. 根据前述权利要求任一项的药物制剂，其中X5是V；或者其中X2是A；或者其中X2是Aib；或者其中X2是A，X5是V；或者其中X2是Aib，X5是V；
    优选地，X1是L，X3是E，X4是K，X5是V，X6是R,X7是I，X8是E，X9是L，X10是GPSSGAPPPK；
    优选地，X1是L，X2是A或aib，X3是E，X4是K，X5是V，X6是R,X7是I，X8是E，X9是L，X10是GPSSGAPPPK；优选地，X10的C末端赖氨酸侧链氨基缀合长效基团；更优选地，X10的C末端赖氨酸侧链氨基缀合长效基团具有式(VIII)或式(IX)的结构。
  6. 根据前述权利要求任一项的药物制剂，其中所述肽化合物选自：
    化合物1.Y(aib)EGTFTSDYSIYLDEEAVRLFVNWLIAGGPSSGAPPPS-NH 2
    化合物2.Y(aib)EGTFTSDYSIYLDEEAVKLFVNWLIAGGPSSGAPPPS-NH 2
    化合物3.Y(aib)EGTFTSDYSIYLDEEAVKLFVQWLIAGGPSSGAPPPS-NH 2
    化合物4.
    Figure PCTCN2021104822-appb-100006
    化合物5.Y(aib)EGTFTSDYSIYLDEEAVRLFVNWLIAGGPSSGAPPPSC-NH 2
    化合物6.
    Figure PCTCN2021104822-appb-100007
    化合物7.Y(aib)EGTFTSDYSIYLDEEAVKLFVNWLIAG-NH 2
    化合物8.Y(aib)EGTFTSDYSIYLEKEAVRLFVNWLIAGGPSSGAPPPS-NH 2
    化合物9.Y(aib)EGTFTSDYSIYLEKEAVKLFVNWLIAGGPSSGAPPPS-NH 2
    化合物10.Y(aib)EGTFTSDYSIYLEKEAAKLFVNWLIAGGPSSGAPPPS-NH 2
    化合物11.
    Figure PCTCN2021104822-appb-100008
    化合物12.Y(aib)EGTFTSDYSIYLEKEAVKLFVNWLIAGGPSSGAPPPK-NH 2
    化合物13.
    Figure PCTCN2021104822-appb-100009
    化合物14.
    Figure PCTCN2021104822-appb-100010
    化合物15.Y(aib)EGTFTSDYSIYLEKEAVRLFVNWLLAG-NH 2
    化合物16.Y(aib)EGTFTSDYSIYLEKEAVRLFIEWLIAGGPSSGAPPPS-NH 2
    化合物17.
    Figure PCTCN2021104822-appb-100011
    化合物18.Y(aib)EGTFTSDLSIQLEKEAARLFIEWLLAGGPSSGAPPPS-NH 2
    化合物19.Y(aib)EGTFTSDLSIQLEKEAVRLFIEWLLAGGPSSGAPPPS-NH 2
    化合物20.
    Figure PCTCN2021104822-appb-100012
    化合物21.
    Figure PCTCN2021104822-appb-100013
    化合物22.
    Figure PCTCN2021104822-appb-100014
    化合物23.
    Figure PCTCN2021104822-appb-100015
    化合物24.Y(aib)EGTFTSDLSIQLEKEAVKLFIEWLLAGGPSSGAPPPS-NH 2
    化合物25.Y(aib)EGTFTSDLSIQLEKEAVRLFIEWLLAG-NH 2
    化合物26.
    Figure PCTCN2021104822-appb-100016
    化合物27.
    Figure PCTCN2021104822-appb-100017
    化合物28.
    Figure PCTCN2021104822-appb-100018
    化合物29.
    Figure PCTCN2021104822-appb-100019
    化合物30.
    Figure PCTCN2021104822-appb-100020
    化合物31.Y(aib)EGTFTSDLSIALEKEAVRLFIEWLLAGGPSSGAPPPS-NH 2
    化合物32.Y(aib)EGTFTSDLSIALEKEAVRLFIEWLLAGGPSSGAPPPSC-NH 2
    化合物33.Y(aib)EGTFTSDLSIALEKEAVRLFIEWLLAGGPSSGAPPPC-NH 2
    化合物34.Y(aib)EGTFTSDLSIALEKEAVRLFIEWLLAGGPSSGAPPPSK-NH 2
    化合物35.Y(aib)EGTFTSDLSIALEKEAVRLFIEWLLAGGPSSGAPPPK-NH 2
    化合物36.Y(aib)EGTFTSDLSI(aib)LEKEAVRLFIEWLLAGGPSSGAPPPS-NH 2
    化合物37.Y(aib)EGTFTSDLSI(aib)LEKEAVRLFIEWLLAGGPSSGAPPPSC-NH 2
    化合物38.Y(aib)EGTFTSDLSI(aib)LEKEAVRLFIEWLLAGGPSSGAPPPC-NH 2
    化合物39.Y(aib)EGTFTSDLSI(aib)LEKEAVRLFIEWLLAGGPSSGAPPPSK-NH 2
    化合物40.Y(aib)EGTFTSDLSI(aib)LEKEAVRLFIEWLLAGGPSSGAPPPK-NH 2
    化合物41.Y(aib)EGTFTSDLSIALEKEAVRLFIEWLLAG-NH 2
    化合物42.Y(aib)EGTFTSDLSI(aib)LEKEAVRLFIEWLLAG-NH 2
    化合物43.Y(aib)EGTFTSDLSIALEKEAVKLFIEWLLAGGPSSGAPPPS-NH 2
    化合物44.Y(aib)EGTFTSDLSIALEKEAVKLFIEWLLAGGPSSGAPPPK-NH 2
    化合物45.Y(aib)EGTFTSDLSIALEKEAVKLFIEWLLAGGPSSGAPPPSK-NH 2
    化合物46.Y(aib)EGTFTSDLSIALEKEAVKLFIEWLLAGGPSSGAPPPSC-NH 2
    化合物47.Y(aib)EGTFTSDLSIALEKEAVKLFIEWLLAGGPSSGAPPPC-NH 2
    化合物48.Y(aib)EGTFTSDLSI(aib)LEKEAVKLFIEWLLAGGPSSGAPPPS-NH 2
    化合物49.Y(aib)EGTFTSDLSI(aib)LEKEAVKLFIEWLLAGGPSSGAPPPK-NH 2
    化合物50.Y(aib)EGTFTSDLSI(aib)LEKEAVKLFIEWLLAGGPSSGAPPPSK-NH 2
    化合物51.Y(aib)EGTFTSDLSI(aib)LEKEAVKLFIEWLLAGGPSSGAPPPC-NH 2
    化合物52.Y(aib)EGTFTSDLSI(aib)LEKEAVKLFIEWLLAGGPSSGAPPPSC-NH 2
    化合物53.Y(aib)EGTFTSDLSIQLEKEAVRLFVNWLLAGGPSSGAPPPS-NH 2
    化合物54.Y(aib)EGTFTSDLSIALEKEAVRLFVNWLLAGGPSSGAPPPK-NH 2
    化合物55.Y(aib)EGTFTSDLSI(aib)LEKEAVRLFVNWLLAGGPSSGAPPPC-NH 2
    化合物56.Y(aib)EGTFTSDLSI(aib)LEKEAVRLFVNWLLAGGPSSGAPPPK-NH 2
    化合物57.Y(aib)EGTFTSDYSIYLDEEAVRLFIEWLIAGGPSSGAPPPK-NH 2
    化合物58.Y(aib)EGTFTSDLSIQLEKEAVRLFVNWLLAGGPSSGAPPPS-NH 2
    化合物59.Y(aib)EGTFTSDLSIALEKEAVRLFVNWLLAGGPSSGAPPPS-NH 2
    化合物60.Y(aib)EGTFTSDLSI(aib)LEKEAVRLFVNWLLAGGPSSGAPPPS-NH 2
    化合物61.Y(aib)EGTFTSDYSIYLDEEAVRLFIEWLIAGGPSSGAPPPS-NH 2
    化合物62.Y(aib)EGTFTSDLSIQLEKEAVRLFIEWLLAGGPSSGAPPPSC-NH 2
    化合物63.Y(aib)EGTFTSDLSIQLEKEAVRLFIEWLLAGGPSSGAPPPC-NH 2
    化合物64.Y(aib)EGTFTSDLSIQLEKEAVRLFIEWLLAGGPSSGAPPPSK-NH 2
    化合物65.Y(aib)EGTFTSDLSIQLEKEAVRLFIEWLLAGGPSSGAPPPK-NH 2
    化合物66.Y(aib)EGTFTSDLSIQLEKEAVKLFIEWLLAGGPSSGAPPPSC-NH 2
    化合物67.Y(aib)EGTFTSDLSIQLEKEAVKLFIEWLLAGGPSSGAPPPC-NH 2
    化合物68.Y(aib)EGTFTSDLSIQLEKEAVKLFIEWLLAGGPSSGAPPPSK-NH 2
    化合物69.Y(aib)EGTFTSDLSIQLEKEAVKLFIEWLLAGGPSSGAPPPK-NH 2
    化合物70.Y(aib)EGTFTSDYSIYLDEEAVRLFVNWLIAGGPSSGAPPPSK-NH 2
    化合物71.Y(aib)EGTFTSDYSIYLDEEAVKLFVNWLIAGGPSSGAPPPSK-NH 2
    化合物72.Y(aib)EGTFTSDYSIYLDEEAVRLFVNWLIAGGPSSGAPPPK-NH 2
    化合物73.Y(aib)EGTFTSDYSIYLDEEAVKLFVNWLIAGGPSSGAPPPK-NH 2
    化合物74.Y(aib)EGTFTSDYSIYLDEEAVKLFVNWLIAGGPSSGAPPPSC-NH 2
    化合物75.Y(aib)EGTFTSDYSIYLDEEAVRLFVNWLIAGGPSSGAPPPC-NH 2
    化合物76.Y(aib)EGTFTSDYSIYLDEEAVKLFVNWLIAGGPSSGAPPPC-NH 2
    化合物77.Y(aib)EGTFTSDYSIYLEKEAVRLFVNWLIAGGPSSGAPPPSK-NH 2
    化合物78.Y(aib)EGTFTSDYSIYLEKEAVKLFVNWLIAGGPSSGAPPPSK-NH 2
    化合物79.Y(aib)EGTFTSDYSIYLEKEAVRLFVNWLIAGGPSSGAPPPK-NH 2
    化合物80.Y(aib)EGTFTSDYSIYLEKEAVRLFVNWLIAGGPSSGAPPPSC-NH 2
    化合物81.Y(aib)EGTFTSDYSIYLEKEAVKLFVNWLIAGGPSSGAPPPSC-NH 2
    化合物82.Y(aib)EGTFTSDYSIYLEKEAVRLFVNWLIAGGPSSGAPPPC-NH 2
    化合物83.Y(aib)EGTFTSDYSIYLEKEAVKLFVNWLIAGGPSSGAPPPC-NH 2
    化合物84.Y(aib)EGTFTSDYSIYLEKEAVRLFIEWLIAGGPSSGAPPPSK-NH 2
    化合物85.Y(aib)EGTFTSDYSIYLEKEAVRLFIEWLIAGGPSSGAPPPK-NH 2
    化合物86.Y(aib)EGTFTSDYSIYLEKEAVRLFIEWLIAGGPSSGAPPPSC-NH 2
    化合物87.Y(aib)EGTFTSDYSIYLEKEAVRLFIEWLIAGGPSSGAPPPC-NH 2
    化合物88.Y(aib)EGTFTSDYSIYLEKEAVRLFIEWLIAG-NH 2
    化合物89.Y(aib)EGTFTSDLSIQLEKEAVRLFVNWLLAG-NH 2
    化合物90.Y(aib)EGTFTSDLSIALEKEAVRLFVNWLLAG-NH 2
    化合物91.Y(aib)EGTFTSDLSI(aib)LEKEAVRLFVNWLLAG-NH 2
    化合物92.Y(aib)EGTFTSDLSIQLEKEAVRLFIEWLLAGGPSSGA-NH 2
    化合物93.Y(aib)EGTFTSDYSIYLDEEAVRLFIEWLIAGGPSSGAPPPS-NH 2
    化合物94.Y(aib)EGTFTSDLSI(aib)LEKEAVRLFIEWLLAGGPSSGAP-NH 2
    化合物95.Y(aib)EGTFTSDYSIYLEKEAVRLFIEWLIAGGPSSGAPP-NH 2
    化合物96.Y(aib)EGTFTSDYSIYLDEEAVRLFVNWLIAGGPSSGAPP-NH 2
    化合物97.Y(aib)EGTFTSDYSIYLEKEAVKLFVNWLIAGGPSSGAP-NH 2
    化合物98.Y(aib)EGTFTSDYSIYLEKEAVRLFIAWLLAGGPSSGAPPPS-NH 2
    化合物99.Y(aib)EGTFTSDYSIYLDEEAVRLFVNWLIAGG-NH 2
    化合物100.Y(aib)EGTFTSDYSIYLEKEAVRLFIEWLIAGGPSSGAP-NH 2
    化合物101.Y(aib)EGTFTSDLSKALEKEAVRLFIEWLLAGGPSSGAPPPS-NH 2
    化合物102.Y(aib)EGTFTSDYSIYLEKEAVKLFIEWLIAGGPSSGAPPPS-NH 2
    化合物103.Y(aib)EGTFTSDYSIYLDEEAVRLFVNWLIAGGPSSGA-NH 2
    化合物104.Y(aib)EGTFTSDLSIQLEKEAVKEFIAWLIAGGPSSGAPPPS-NH 2
    化合物105.Y(aib)EGTFTSDYSIYLDEEAVRLFIAWLIAGGPSSGAPPPS-NH 2
    化合物106.Y(aib)EGTFTSDYSIYLEKEAVKLFVNWLIAGG-NH 2
    化合物107.Y(aib)EGTFTSDLSIALEKEAVRLFVNWLIAGGPSSGAPPPS-NH 2
    化合物108.Y(aib)EGTFTSDYSIYLDEEAVRLFVNWLIAGGPSSGAP-NH 2
    化合物109.Y(aib)EGTFTSDYSIYLEKEAVKLFVNWLIAGGPSSG-NH 2
    化合物110.Y(aib)EGTFTSDYSIYLEKEAVRLFIEWLIAGGPSSGA-NH 2
    化合物111.Y(aib)EGTFTSDLSIALEKEAVRLFIEWLLAGGPSSGA-NH 2
    化合物112.Y(aib)EGTFTSDYSIYLEKEAVKLFVNWLIAGGP-NH 2
    化合物113.Y(aib)EGTFTSDYSIYLDEEAVRLFVNWLLAGGPSSGAPPP-NH 2
    化合物114.Y(aib)EGTFTSDLSIQLEKEAVRLFVNWLIAGGPSSGAPPPS-NH 2
    化合物115.Y(aib)EGTFTSDLSI(aib)LEKEAVRLFIEWLLAGGPSSGA-NH 2
    化合物116.Y(aib)EGTFTSDYSIYLEKEAVRLFIEWLIAGGPSS-NH 2
    化合物117.Y(aib)EGTFTSDLSIQLEKEAVRLFIAWLIAGGPSSGAPPPS-NH 2
    化合物118.Y(aib)EGTFTSDYSIYLEKEAVKLFVNWLLAGGPSSGAPPP-NH 2
    化合物119.Y(aib)EGTFTSDLSIALEKEAVRLFIEWLLAGGPS-NH 2
    化合物120.Y(aib)EGTFTSDYSIYLDEEAVRLFVNWLIAGGPSS-NH 2
    化合物121.Y(aib)EGTFTSDLSIQLEKEAVRLFIEWLIAGGPSSGAPPP-NH 2
    化合物122.Y(aib)EGTFTSDYSIYLDEEAVRLFVNWLIAGGP-NH 2
    化合物123.Y(aib)EGTFTSDYSIYLEKEAVRLFIEWLLAGGPSSGAPPP-NH 2
    化合物124.Y(aib)EGTFTSDLSIQLEKEAVRLFIEWLLAGG-NH 2
    化合物125.Y(aib)EGTFTSDLSIQLEKEAVKLFIEWLIAGGPSSGAPPP-NH 2
    化合物126.Y(aib)EGTFTSDYSIYLEKEAVKLFIAWLIAGGPSSGAPPPS-NH 2
    化合物127.Y(aib)EGTFTSDLSIALEKEAVRLFIAWLIAGGPSSGAPPPS-NH 2
    化合物128.Y(aib)EGTFTSDLSIQLEKEAVKLFIEWLLAGGPSSGAPP-NH 2
    化合物129.Y(aib)EGTFTSDYSIYLEKEAVKEFIAWLLAGGPSSGAPPP-NH 2
    化合物130.Y(aib)EGTFTSDLSIQLEKEAVRLFIEWLLAGGP-NH 2
    化合物131.Y(aib)EGTFTSDLSIQLEKEAVKLFIEWLLAGGPSSGAP-NH 2
    化合物132.Y(aib)EGTFTSDYSIYLEKEAVKLFVNWLIAGGPSSGA-NH 2
    化合物133.Y(aib)EGTFISDLSIALEKEAVRLFIEWLLAGGPSSGAPPPS-NH 2
    化合物134.Y(aib)EGTFTSDYSIYLEKEAVRLFIEWLIAGGP-NH 2
    化合物135.Y(aib)EGTFTSDYSIYLEKEAVKLFVNWLIAGGPSS-NH 2
    化合物136.Y(aib)EGTFTSDLSI(aib)LEKEAVKEFIAWLLAGGPSSGAPPPS-NH 2
    化合物137.Y(aib)EGTFTSDLSIQLEKEAVKLFIEWLLAGGPSSGA-NH 2
    化合物138.Y(aib)EGTFTSDLSIALEKEAVRLFIEWLLAGGPSSG-NH 2
    化合物139.Y(aib)EGTFTSDYSIYLDEEAVRLFVNWLIAGGPS-NH 2
    化合物140.Y(aib)EGTFTSDLSIQLEKEAVRLFIEWLLAGGPSS-NH 2
    化合物141.Y(aib)EGTFTSDYSIYLEKEAVKLFVNWLIAGGPSSGAPP-NH 2
    化合物142.Y(aib)EGTFTSDLSIALEKEAVRLFIEWLLAGGPSSGAP-NH 2
    化合物143.Y(aib)EGTFTSDLSIQLEKEAVKLFIEWLLAGGPSSG-NH 2
    化合物144.Y(aib)EGTFTSDYSIALEKEAVRLFIEWLLAGGPSSGAPPPS-NH 2
    化合物145.Y(aib)EGTFTSDLSIQLEKEAVKLFIEWLLAGGPSS-NH 2
    化合物146.Y(aib)EGTFTSDLSIQLEKEAVRLFIEWLLAGGPSSG-NH 2
    化合物147.Y(aib)EGTFISDLSI(aib)LEKEAVRLFIEWLLAGGPSSGAPPPS-NH 2
    化合物148.Y(aib)EGTFTSDYSIYLEKEAVRLFIEWLIAGGPSSG-NH 2
    化合物149.Y(aib)EGTFTSDYSIYLEKEAVKEFIAWLIAGGPSSGAPPPS-NH 2
    化合物150.Y(aib)EGTFTSDLSI(aib)LEKEAVRLFIEWLLAGGPSSGAPP-NH 2
    化合物151.Y(aib)EGTFTSDLSIYLDEEAVRLFVNWLLAGGPSSGAPPPS-NH 2
    化合物152.Y(aib)EGTFTSDLSIALEKEAVRLFIEWLLAGGP-NH 2
    化合物153.Y(aib)EGTFTSDLSIQLEKEAVKLFIEWLLAGGPS-NH 2
    化合物154.Y(aib)EGTFTSDLSIQLEKEAVRLFIEWLLAGGPSSGAPP-NH 2
    化合物155.Y(aib)EGTFTSDYSIYLEKEAVRLFIEWLIAGG-NH 2
    化合物156.Y(aib)EGTFTSDLSIQLEKEAVKLFIEWLLAGGP-NH 2
    化合物157.Y(aib)EGTFTSDLSIALEKEAVQDFVNWLIAGGPSSGAPPPS-NH 2
    化合物158.Y(aib)EGTFTSDLSIQLEKEAVRLFIEWLLAGGPS-NH 2
    化合物159.Y(aib)EGTFTSDLSIYLDEEAVRLFVNWLLAGGPSSGAP-NH 2
    化合物160.Y(aib)EGTFTSDLSIALEKEAVRLFIEWLLAGGPSSGAPPP-NH 2
    化合物161.Y(aib)EGTFTSDLSI(aib)LEKEAVRLFIAWLLAGGPSSGAPPPS-NH 2
    化合物162.Y(aib)EGTFTSDYSIQLDEEAVRLFVNWLLAGGPSSGAPPPS-NH 2
    化合物163.Y(aib)EGTFTSDLSIALEKEAVKEFIAWLIAGGPSSGAPPPS-NH 2
    化合物164.Y(aib)EGTFTSDYSIYLEKEAVRLFIEWLIAGGPS-NH 2
    化合物165.Y(aib)EGTFTSDYSIYLDEEAVRLFVNWLIAGGPSSG-NH 2
    化合物166.Y(aib)EGTFTSDLSI(aib)LEKEAVQDFVNWLLAGGPSSGAPPPS-NH 2
    化合物167.Y(aib)EGTFTSDLSIYLEKEAVKLFVNWLLAGGPSSGAP-NH 2
    化合物168.Y(aib)EGTFTSDLSK(aib)LEKEAVRLFIEWLLAGGPSSGAPPP-NH 2
    化合物169.Y(aib)EGTFTSDYSIYLDEEAVKEFIAWLIAGGPSSGAPPPS-NH 2
    化合物170.Y(aib)EGTFTSDLSIYLEKEAVRLFIEWLLAGGPSSGAPP-NH 2
    化合物171.Y(aib)EGTFTSDYSIALDEEAVRLFVNWLLAGGPSSGAPPPS-NH 2
    化合物172.Y(aib)EGTFTSDLSIALEKEAVKLFVNWLLAGGPSSGAPPPS-NH 2
    化合物173.Y(aib)EGTFTSDLSIYLEKEAVRLFIEWLLAGGPSSGAP-NH 2
    化合物174.Y(aib)EGTFTSDLSI(aib)LEKEAVRLFIEWLLAGG-NH 2
    化合物175.Y(aib)EGTFTSDLSIYLEKEAVKLFVNWLLAGGPSSGA-NH 2
    化合物176.Y(aib)EGTFTSDLSIYLDEEAVRLFVNWLLAGGPS-NH 2
    化合物177.Y(aib)EGTFTSDLSIYLDEEAVRLFVNWLLAGGPSSGAPPP-NH 2
    化合物178.Y(aib)EGTFTSDLSI(aib)LEKEAVRLFIEWLLAGGPS-NH 2YS-32
    化合物179.Y(aib)EGTFTSDLSIALEKEAVRLFIEWLLAGGPSSGAPP-NH 2
    化合物180.Y(aib)EGTFTSDLSIYLEKEAVKLFVNWLLAGGPSSG-NH 2
    化合物181.Y(aib)EGTFTSDLSI(aib)LEKEAVRLFIEWLLAGGPSSG-NH 2
    化合物182.Y(aib)EGTFTSDYSIQLEKEAVRLFIEWLLAGGPSSGAPPPS-NH 2
    化合物183.Y(aib)EGTFTSDLSIYLEKEAVKLFVNWLLAGGPSSGAPPP-NH 2
    化合物184.Y(aib)EGTFTSDLSI(aib)LEKEAVRLFIEWLLAGGPSS-NH 2
    化合物185.Y(aib)EGTFTSDLSIYLDEEAVRLFVNWLLAGGPSSGA-NH 2
    化合物186.Y(aib)EGTFTSDYSI(aib)LEKEAVRLFIEWLLAGGPSSGAPPPS-NH 2
    化合物187.Y(aib)EGTFTSDLSIALEKEAVRLFIEWLLAGG-NH 2
    化合物188.Y(aib)EGTFTSDLSIQLEKEAVRLFIEWLLAGGPSSGAP-NH 2
    化合物189.Y(aib)EGTFTSDYSIYLEKEAVKLFVNWLIAGGPS-NH 2
    化合物190.Y(aib)EGTFTSDLSIYLEKEAVRLFIEWLLAGGPSSGAPPPS-NH 2
    化合物191.Y(aib)EGTFTSDLSI(aib)LEKEAVRLFVNWLLAGGPSSGAPPPS-NH 2
    化合物192.Y(aib)EGTFTSDLSIYLDEEAVRLFVNWLLAGGPSSG-NH 2
    化合物193.Y(aib)EGTFTSDLSIYLEKEAVKLFVNWLLAGGPS-NH 2
    化合物194.Y(aib)EGTFTSDLSIYLDEEAVRLFVNWLLAGGPSS-NH 2
    化合物195.Y(aib)EGTFTSDLSK(aib)LEKEAVRLFIEWLLAGGPSSGAPPPS-NH 2
    化合物196.Y(aib)EGTFTSDLSIYLEKEAVRLFIEWLLAGGPSSG-NH 2
    化合物197.Y(aib)EGTFTSDLSIYLEKEAVKLFVNWLLAGGPSSGAPP-NH 2
    化合物198.Y(aib)EGTFTSDLSIYLEKEAVRLFIEWLLAGGPS-NH 2
    化合物199.Y(aib)EGTFTSDLSI(aib)LEKEAVRLFIEWLLAGGP-NH 2
    化合物200.Y(aib)EGTFTSDLSIYLEKEAVRLFIEWLLAGGP-NH 2
    化合物201.Y(aib)EGTFTSDLSIYLDEEAVRLFVNWLLAGG-NH 2
    化合物202.Y(aib)EGTFTSDLSIYLEKEAVKLFVNWLLAGGPSSGAPPPS-NH 2
    化合物203.Y(aib)EGTFTSDLSIYLEKEAVRLFIEWLLAGGPSS-NH 2
    化合物204.Y(aib)EGTFTSDLSIYLDEEAVRLFVNWLLAGGP-NH 2
    化合物205.Y(aib)EGTFTSDLSIYLEKEAVKLFVNWLLAGGPSS-NH 2
    化合物206.Y(aib)EGTFTSDLSIQLEKEAVKLFIEWLLAGG-NH 2
    化合物207.Y(aib)EGTFTSDYSIYLEKEAVRLFIEWLLAGGPSSGAPPP-NH 2
    化合物208.Y(aib)EGTFTSDLSIYLEKEAVKLFVNWLLAGGP-NH 2
    化合物209.Y(aib)EGTFTSDLSIYLEKEAVRLFIEWLLAGGPSSGAPPP-NH 2
    化合物210.Y(aib)EGTFTSDLSI(aib)LEKEAVRLFIEWLLAGGPSSGAPPP-NH 2
    化合物211.Y(aib)EGTFTSDLSIYLEKEAVRLFIEWLLAGGPSSGA-NH 2
    化合物212.Y(aib)EGTFTSDLSIYLEKEAVKLFVNWLLAGG-NH 2
    化合物213.Y(aib)EGTFTSDYSI(aib)LDEEAVRLFVNWLLAGGPSSGAPPPS-NH 2
    化合物214.Y(aib)EGTFTSDLSIALEKEAVRLFIEWLLAGGPSS-NH 2
    化合物215.Y(aib)EGTFTSDLSIYLDEEAVRLFVNWLLAGGPSSGAPP-NH 2
    化合物216.Y(aib)EGTFTSDLSI(aib)LEKEAVKLFVNWLLAGGPSSGAPPPS-NH 2
    化合物217.Y(aib)EGTFTSDLSSALEKEAVRLFIEWLLAGGPSSGAPPPK-NH 2
    化合物218.Y(aib)EGTFTSDLSIYLEKEAVRLFIEWLLAGG-NH 2
    化合物219.Y(aib)EGTFTSDLSIQLEKEAVKLFVNWLLAGGPSSGAPPPS-NH 2
    化合物220.
    Figure PCTCN2021104822-appb-100021
    化合物221.
    Figure PCTCN2021104822-appb-100022
  7. 前述权利要求1-6任一项的药物制剂，所述载体或赋形剂选自缓冲液、防腐剂、等渗剂、增溶剂、稳定剂、表面活性剂、螯合剂中的一种或多种；
    优选地，所述缓冲液是选自磷酸盐缓冲液、磷酸氢盐缓冲液、磷酸二氢盐缓冲液、醋酸盐缓冲液、碳酸盐缓冲液、碳酸氢盐缓冲液、硼酸盐缓冲液、马来酸盐缓冲液、富马酸盐缓冲液、乳酸盐缓冲液、柠檬酸盐缓冲液、巴比妥钠缓冲液、三羟甲基氨基甲烷(Tris)缓冲液中的一种或多种；
    优选地，所述缓冲液为磷酸氢二钠、磷酸氢二钾、磷酸二氢钠、磷酸二氢钾、醋酸钠溶液中的一种或多种；优选地，所述缓冲液为磷酸氢二钠溶液；
    优选地，所述可选的防腐剂选自苯酚、间甲酚、对甲酚、邻甲酚、氯甲酚、苄醇、苯基亚硝酸汞、苯氧基乙醇、甲醛、氯丁醇、氯化镁(如六水合氯化镁)、烷基对羟基苯甲酸酯类(甲酯、乙酯、丙酯、丁酯等)、苯扎氯铵、苄索氯铵、甲醋吡喃酮钠和硫柳汞中的一种或多种；
    优选地，所述防腐剂为苯酚或间甲酚；优选地，所述防腐剂为苯酚；
    优选地，所述等渗剂选自甘油、丙二醇、单糖、二糖、多糖、醛醇以及氯化钠中的一种或多种；优选地，所述单糖选自果糖、麦芽糖、半乳糖、葡萄糖、D-甘露糖、山梨糖等；优选地，所述二糖选自乳糖、蔗糖、海藻糖、纤维二糖等；优选地，所述多糖选自棉子糖、松三糖、麦芽糖糊精、右旋糖苷、淀粉等；优选地，所述醛醇选自甘露醇、木糖醇、麦芽糖醇、乳糖醇、木糖醇、山梨糖醇(葡糖醇)等；优选地，所述等渗剂为甘油；优选地，所述等渗剂为丙二醇；
    优选地，所述赋形剂是糖赋形剂；所述糖赋形剂选自：单糖、二糖、多糖以及醛醇中的一种或多种；
    优选地，所述表面活性剂选自聚山梨酯、吐温20(聚氧乙烯(20)脱水山梨醇单月桂酸酯)、吐温40(聚氧乙烯(20)脱水山梨醇单月桂酸酯)、吐温80(聚氧乙烯(20)脱水山梨醇单油酸酯)、普流罗尼F68(聚氧乙烯聚氧丙烯嵌段共聚物)和PEG(聚乙二醇)或表面活性剂如聚山梨酯20或80或者泊洛沙姆184或188、普流罗尼、其它嵌段共聚物中的一种或多种；
    优选地，所述药物制剂的pH在3-9之间；优选地，所述药物制剂的pH在4-9之间；优选地，所述药物制剂具有pH＞6.5的pH值，优选pH≥7.4；优选地，所述pH值范围在6.5-8.5之 间；优选地，所述pH值范围在6.6-8.0之间；优选地，所述pH值范围在7.2-8.0之间；进一步优选地，所述pH值范围在7.4-8.0之间；更优选，所述pH值范围在在7.5-7.6之间；
    优选地，所述药物制剂的剂型选自片剂、包衣片、糖锭剂、硬和软明胶胶囊、溶液、乳液、混悬液、栓剂、注射液。
  8. 前述权利要求1-7任一项的药物制剂第一医药用途。
  9. 前述权利要求1-7任一项的肽药物制剂在制备用于治疗或预防下列疾病或状况的药物中的用途：葡萄糖耐量受损(IGT)、高血糖症、1型糖尿病、2型糖尿病、肥胖症、代谢综合征和神经退行性疾病，特别是用于延缓或预防2型糖尿病中的疾病进展，延缓从葡萄糖耐量受损到2型糖尿病的进展；延缓从2型糖尿病到需要胰岛素的糖尿病的进展，治疗代谢综合征，用于调节食欲，诱发饱足感，减少食物摄入，增加能量消耗，治疗肥胖症或预防超重；预防减肥成功后的体重反弹；治疗与超重或肥胖症相关的疾病或状态；治疗贪食症；治疗暴食；治疗血脂异常、动脉粥样硬化、高血压、冠心病、β-阻断剂中毒；非酒精性脂肪性肝病(NAFLD,non-alcoholic fatty liver disease)(可分为单纯性脂肪肝(SFL)、非酒精性脂肪性肝炎(NASH)及其相关肝硬化)；用于抑制胃肠道的运动；神经退行性疾病如阿兹海默病(Alzheimer's disease)、帕金森氏病(Parkinson's disease)、亨廷顿氏舞蹈病(Huntington's disease)、共济失调(例如脊髓小脑性共济失调)、肯尼迪病(Kennedy disease)、肌强直性营养不良、路易体痴呆症(Lewy body dementia)、多系统萎缩(multi-systemic atrophy)、肌萎缩性脊髓侧索硬化、原发性脊髓侧索硬化、脊髓性肌萎缩、朊病毒相关疾病(例如克雅氏病(Creutzfeldt-Jacob disease))、多发性硬化、毛细血管扩增、贝敦氏症(Batten disease)、皮层基底节变性(corticobasal degeneration)、脊髓亚急性联合变性、脊髓痨、泰-萨二氏病(Tay-Sachs disease)、中毒性脑病、婴儿雷夫叙姆病(infantile Refsum disease)、雷夫叙姆病、神经棘红细胞增多症、尼曼匹克症(Niemann-Pick disease)、莱姆病(Lyme disease)、马查多·约瑟夫病(Machado-Joseph disease)、桑德霍夫病(Sandhoff disease)、雪-杜二氏综合征(Shy-Drager syndrome)、刺猬摇摆综合征(wobbly hedgehog syndrome)、原发病(proteopathy)、脑β-淀粉样脑血管病、青光眼中的视网膜神经节细胞变性、核蛋白病(synucleinopathies)、滔蛋白病(tauopathies)、额颞叶变性(FTLD)、痴呆症、Cadasil综合征、具有淀粉样变性的遗传性脑溢血、亚历山大病(Alexander disease)、seipinopathies、家族性淀粉样变性神经病变、老年系统性淀粉样变性(senile systemic amyloidosis)、serpinopathies、AL(轻链)淀粉样变性(原发性全身淀粉样变性)、AH(重链)淀粉样变性、AA(继发性)淀粉样变性、主动脉内淀粉样变性(aortic medial amyloidosis)、ApoAI淀粉样变性、ApoAII淀粉样变性、ApoAIV淀粉样变性、芬兰型家族性淀粉样变性(FAF)、溶菌酶淀粉样变性、纤维蛋白原淀粉样变性、透析淀粉样变性、包涵体肌炎/肌病、白内障、具有视紫红质突变的视网膜色素变性、甲状腺髓样癌、心脏心房淀粉样变性、垂体催乳素瘤、遗传性网格状角膜营养不良(Hereditary lattice corneal dystrophy)、皮肤性苔藓状淀粉样变性、马洛里小体(Mallory bodies)、角膜乳铁蛋白淀粉样变性、肺泡蛋白沉着症(pulmonary alveolar proteinosis)、牙原性(Pindborg)肿瘤淀粉体、囊性纤维化病、镰状细胞疾病或危重病性肌病(CIM)、骨骼相关的病症。
  10. 根据权利要求9的用途，其中所述用途是制备用于减肥的药物。
  11. 前述权利要求1-7任一项的药物制剂在制备用于降血脂的药物中的用途，优选降低选自下列的血脂成分：胆固醇、甘油三酯、游离脂肪酸、低密度脂蛋白胆固醇。
  12. 前述权利要求1-7任一项的药物制剂在制备用于降血糖或治疗糖尿病的药物中的用途。
  13. 权利要求1-7任一项的药物制剂的制备方法，其中所述制备方法包括以下步骤：
    (1)将缓冲剂、等渗剂和可选的防腐剂和表面活性剂溶解于适量无菌注射用水得到溶液；
    (2)加入式(VII)的肽化合物或其药学上可接受的盐或溶剂合物，调节至所需pH范围；
    (3)加入适量的无菌注射用水使制剂溶液达到目标体积；
    (4)用0.22微米的滤膜对制剂溶液进行除菌过滤；
    优选地，所述缓冲剂是磷酸氢二钠或磷酸氢二钠水合物；
    优选地，所述防腐剂是苯酚或间甲酚；更优选地，所述防腐剂是苯酚；
    优选地，所述等渗剂是甘油或丙二醇；更优选地，所述等渗剂是甘油。
PCT/CN2021/104822 2020-07-06 2021-07-06 新型多肽制剂及其治疗用途 WO2022007809A1 (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202180048688.9A CN116133677A (zh) 2020-07-06 2021-07-06 新型多肽制剂及其治疗用途

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN202010643548.3 2020-07-06
CN202010643548 2020-07-06

Publications (1)

Publication Number Publication Date
WO2022007809A1 true WO2022007809A1 (zh) 2022-01-13

Family

ID=79552785

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CN2021/104822 WO2022007809A1 (zh) 2020-07-06 2021-07-06 新型多肽制剂及其治疗用途

Country Status (2)

Country Link
CN (1) CN116133677A (zh)
WO (1) WO2022007809A1 (zh)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11744873B2 (en) 2021-01-20 2023-09-05 Viking Therapeutics, Inc. Compositions and methods for the treatment of metabolic and liver disorders
WO2024001877A1 (zh) * 2022-06-30 2024-01-04 深圳翰宇药业股份有限公司 一种多肽药物溶液制剂及其制备方法

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103458920A (zh) * 2010-12-22 2013-12-18 印第安那大学科技研究公司 表现出gip受体活性的胰高血糖素类似物
WO2015086728A1 (en) * 2013-12-13 2015-06-18 Sanofi Exendin-4 peptide analogues as dual glp-1/gip receptor agonists
WO2015086730A1 (en) * 2013-12-13 2015-06-18 Sanofi Non-acylated exendin-4 peptide analogues
WO2015086729A1 (en) * 2013-12-13 2015-06-18 Sanofi Dual glp-1/gip receptor agonists
CN104902919B (zh) * 2012-12-21 2018-11-20 赛诺菲 Glp1/gip双重激动剂或glp1/gip/胰高血糖素三重激动剂
WO2020115048A1 (en) * 2018-12-03 2020-06-11 Antag Therapeutics Aps Modified gip peptide analogues
WO2020143625A1 (zh) * 2019-01-07 2020-07-16 鸿绪生物医药科技（北京）有限公司 新型多肽及其治疗用途

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103458920A (zh) * 2010-12-22 2013-12-18 印第安那大学科技研究公司 表现出gip受体活性的胰高血糖素类似物
CN104902919B (zh) * 2012-12-21 2018-11-20 赛诺菲 Glp1/gip双重激动剂或glp1/gip/胰高血糖素三重激动剂
WO2015086728A1 (en) * 2013-12-13 2015-06-18 Sanofi Exendin-4 peptide analogues as dual glp-1/gip receptor agonists
WO2015086730A1 (en) * 2013-12-13 2015-06-18 Sanofi Non-acylated exendin-4 peptide analogues
WO2015086729A1 (en) * 2013-12-13 2015-06-18 Sanofi Dual glp-1/gip receptor agonists
WO2020115048A1 (en) * 2018-12-03 2020-06-11 Antag Therapeutics Aps Modified gip peptide analogues
WO2020143625A1 (zh) * 2019-01-07 2020-07-16 鸿绪生物医药科技（北京）有限公司 新型多肽及其治疗用途

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11744873B2 (en) 2021-01-20 2023-09-05 Viking Therapeutics, Inc. Compositions and methods for the treatment of metabolic and liver disorders
WO2024001877A1 (zh) * 2022-06-30 2024-01-04 深圳翰宇药业股份有限公司 一种多肽药物溶液制剂及其制备方法

Also Published As

Publication number Publication date
CN116133677A (zh) 2023-05-16

Similar Documents

Publication Publication Date Title
US10604555B2 (en) GIP derivatives and uses thereof
US9938335B2 (en) Glucagon and GLP-1 co-agonist compounds
WO2020143625A1 (zh) 新型多肽及其治疗用途
JP5890085B2 (ja) 生理学的ｐＨの緩衝液中で向上した溶解度を示すグルカゴン類縁体
EP1934245B1 (en) Y2 selective receptor agonists for therapeutic interventions
US7595294B2 (en) Vasoactive intestinal polypeptide pharmaceuticals
WO2012031518A1 (zh) Exendin-4类似物的定位聚乙二醇化修饰物及其用途
WO2022007809A1 (zh) 新型多肽制剂及其治疗用途
JP2017514801A (ja) 二重アシル化ｇｌｐ−１化合物
EP1786458A2 (en) Y2/y4 selective receptor agonists for therapeutic interventions
EP3630806B1 (en) Long-acting gip peptide analogues
US20080214440A1 (en) Vasoactive intestinal polypeptide compositions
US20100160226A1 (en) Y-receptor agonists
JP2022551233A (ja) 異なる構造のｇｌｐ－１アナログペプチド修飾二量体およびその調製方法のｉｉ型糖尿病の治療における用途
WO2013037267A1 (zh) 利拉鲁肽变构体及其缀合物
WO2022007805A1 (zh) 新型多肽及其治疗用途
WO2008043102A2 (en) Vasoactive intestinal polypeptide compositions
JP2011525895A (ja) アミリン及びサケカルシトニンの誘導体化ハイブリッドペプチド
US20090170775A1 (en) Vasoactive intestinal polypeptide compositions
CN116650424A (zh) 新型多肽制剂及其治疗用途
CN114891071A (zh) 新型多肽及其治疗用途
US20230183310A1 (en) Polypeptide Compounds and Use Thereof in the Prevention or Treatment of Diabetes or Diabetic Complications
JP2008545644A (ja) 新規ポリ（エチレングリコール）誘導体とタンパク質へのそのカップリング方法
CN117756913A (zh) 一种新型长效多肽化合物、组合物及其应用

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 21838810

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 21838810

Country of ref document: EP

Kind code of ref document: A1